<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002845.pub2" GROUP_ID="STD" ID="459499111610212699" MERGED_FROM="" MODIFIED="2008-11-11 21:02:58 +0100" MODIFIED_BY="Rebecca Gray" REVIEW_NO="MW01" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2008-11-11 15:01:28 -0500" MODIFIED_BY="Rebecca Gray">
<TITLE>Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush)</TITLE>
<CONTACT>
<PERSON ID="A76471B282E26AA2002589C35D4B2319" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Munira</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Nurbhai</LAST_NAME>
<SUFFIX/>
<POSITION>Research Coordinator</POSITION>
<EMAIL_1>mnurbhia@ohri.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Clinical Epidemiology Program</DEPARTMENT>
<ORGANISATION>Ottawa Health Research Institute</ORGANISATION>
<ADDRESS_1>ASB Box 693</ADDRESS_1>
<ADDRESS_2>Rm 2-006, 1053 Carling avenue</ADDRESS_2>
<CITY>Ottawa</CITY>
<ZIP>K1Y 4 E9</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2008-11-11 14:56:13 -0500" MODIFIED_BY="Rebecca Gray">
<PERSON ID="A76471B282E26AA2002589C35D4B2319" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Munira</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Nurbhai</LAST_NAME>
<SUFFIX/>
<POSITION>Research Coordinator</POSITION>
<EMAIL_1>mnurbhia@ohri.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Clinical Epidemiology Program</DEPARTMENT>
<ORGANISATION>Ottawa Health Research Institute</ORGANISATION>
<ADDRESS_1>ASB Box 693</ADDRESS_1>
<ADDRESS_2>Rm 2-006, 1053 Carling avenue</ADDRESS_2>
<CITY>Ottawa</CITY>
<ZIP>K1Y 4 E9</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="7557" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Jeremy</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Grimshaw</LAST_NAME>
<SUFFIX/>
<POSITION>Co-ordinating Editor, Cochrane Effective Practice and Organisation of Care Group</POSITION>
<EMAIL_1>jgrimshaw@ohri.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Director, Clinical Epidemiology Programme</DEPARTMENT>
<ORGANISATION>Ottawa Health Research Institute</ORGANISATION>
<ADDRESS_1>1053 Carling Avenue</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ottawa</CITY>
<ZIP>K1Y 4E9</ZIP>
<REGION>ON</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 613 798 5555 ext: 15231</PHONE_1>
<PHONE_2/>
<FAX_1>+1 613 761 5492</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="15015" ROLE="AUTHOR">
<PREFIX>Mrs</PREFIX>
<FIRST_NAME>Margaret</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Watson</LAST_NAME>
<SUFFIX/>
<POSITION>Research and Development Training Fellow</POSITION>
<EMAIL_1>m.c.watson@abdn.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of General Practice and Primary Care</DEPARTMENT>
<ORGANISATION>University of Aberdeen</ORGANISATION>
<ADDRESS_1>Westburn Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Aberdeen</CITY>
<ZIP>AB25 2AY</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1224 553785</PHONE_1>
<PHONE_2/>
<FAX_1>+44 1224 840683</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="7210" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Christine</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Bond</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Primary Care (Pharmacy)</POSITION>
<EMAIL_1>c.m.bond@abdn.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of General Practice and Primary Care</DEPARTMENT>
<ORGANISATION>University of Aberdeen</ORGANISATION>
<ADDRESS_1>Foresterhill Health Centre</ADDRESS_1>
<ADDRESS_2>Westburn Road</ADDRESS_2>
<CITY>Aberdeen</CITY>
<ZIP>AB25 2AY</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1224 553973</PHONE_1>
<PHONE_2>+44 1224 558466</PHONE_2>
<FAX_1>+44 1224 550683</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14598" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Jill</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Mollison</LAST_NAME>
<SUFFIX/>
<POSITION>Lecturer</POSITION>
<EMAIL_1>jill.mollison@virgin.net</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Public Health, Medical School</DEPARTMENT>
<ORGANISATION>University of Aberdeen</ORGANISATION>
<ADDRESS_1>Forresterhill</ADDRESS_1>
<ADDRESS_2/>
<CITY>Aberdeen</CITY>
<ZIP>AB25 2ZD</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1224 554089</PHONE_1>
<PHONE_2/>
<FAX_1>+44 1224 662994</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="8D1EF7C182E26AA201830EC78D275BE5" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Anne</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Ludbrook</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Health Economics Research Unit</DEPARTMENT>
<ORGANISATION>University of Aberdeen</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Aberdeen</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-11-11 14:57:41 -0500" MODIFIED_BY="Rebecca Gray">
<UP_TO_DATE>
<DATE DAY="20" MONTH="8" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="8" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="20" MONTH="8" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2008-11-11 15:01:28 -0500" MODIFIED_BY="Rebecca Gray">
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="29" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-11-11 15:01:28 -0500" MODIFIED_BY="Rebecca Gray">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2008-11-11 15:01:28 -0500" MODIFIED_BY="Rebecca Gray">
<DATE DAY="22" MONTH="8" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive update</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Clinical Epidemiology Program, Ottawa Health Research Institute</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Department of General Practice and Primary Care, University of Aberdeen</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Health Services Research Unit, University of Aberdeen</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>JG holds a Tier 1 Canadian Research Chair in Knowledge Transfer and Uptake</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>MW's post is funded by the University of Aberdeen</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>The Health Services Research Unit is funded by the Chief Scientist Office, Scottish Executive Health Department</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>The Health Economic Research Unit is funded by the Chief Scientist Office, Scottish Executive Health Department</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-11 14:58:36 -0500" MODIFIED_BY="Rebecca Gray">
<SUMMARY MODIFIED="2008-11-11 14:58:36 -0500" MODIFIED_BY="Rebecca Gray">
<TITLE MODIFIED="2008-11-11 14:58:36 -0500" MODIFIED_BY="Rebecca Gray">Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush)</TITLE>
<SUMMARY_BODY MODIFIED="2008-11-11 14:58:10 -0500" MODIFIED_BY="Rebecca Gray">
<P>Anti-fungals are available for oral and intra-vaginal treatment of uncomplicated vulvovaginal candidiasis (thrush). The primary objective of this review was to assess the relative effectiveness of oral versus intra-vaginal anti-fungals for the treatment of uncomplicated vulvovaginal candidiasis. The secondary objectives of the review were to assess the cost-effectiveness, safety and patient preference of oral versus intra-vaginal anti-fungals. No statistically significant differences were observed in clinical cure rates of anti-fungals administered by the oral and intra-vaginal routes for the treatment of uncomplicated vaginal candidiasis. No definitive conclusion can be made regarding the relative safety of oral and intra-vaginal anti-fungals for uncomplicated vaginal candidiasis. The decision to prescribe or recommend the purchase of an anti-fungal for oral or intra-vaginal administration should take into consideration: safety, cost and treatment preference. Unless there is a previous history of adverse reaction to one route of administration or contraindications, women who are purchasing their own treatment should be given full information about the characteristics and costs of treatment to make their own decision. If health services are paying the treatment cost, decision-makers should consider whether the higher cost of some oral anti-fungals is worth the gain in convenience, if this is the patient's preference.<BR/>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Anti-fungals are available for oral and intra-vaginal treatment of uncomplicated vulvovaginal candidiasis (thrush). </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>The primary objective of this review was to assess the relative effectiveness of oral versus intra-vaginal anti-fungals for the treatment of uncomplicated vulvovaginal candidiasis.<BR/>The secondary objectives of the review were to assess the cost-effectiveness, safety and patient preference of oral versus intra-vaginal anti-fungals.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>The following sources were searched for the original review: The Cochrane Library (Issue 4, 1999), MEDLINE (January 1985 to May 2000), EMBASE (January 1980 to January 2000) and the Cochrane Sexually Transmitted Disease (STD) Group Specialised Register of Controlled Trials. The manufacturers of anti-fungals available in the UK were contacted. For the update, CENTRAL (January 2000 to August 2006), PUBMED (January 2000 to August 2006), EMBASE (January 2000 to August 2006) and the Cochrane STD Group Specialised Register were searched in August 2006. The reference lists of retrieved articles were reviewed manually.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised controlled trials published in any language. <BR/>Trials had to compare at least one oral anti-fungal with one intra-vaginal anti-fungal. <BR/>Women (aged 16 years or over) with uncomplicated vulvovaginal candidiasis. <BR/>The diagnosis of vulvovaginal candidiasis to be made mycologically (i.e. a positive culture and / or microscopy for yeast). <BR/>Trials were excluded if they solely involved subjects who were HIV positive, immunocompromised, pregnant, breast feeding or diabetic. <BR/>The primary outcome measure was clinical cure. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two reviewers screened titles and abstracts of the electronic search results and full text of potentially relevant papers. Independent duplicate abstraction was performed by two reviewers. Disagreements regarding trial inclusion or data abstraction were resolved by discussion between the reviewers. Odds ratios were pooled using the fixed effects models (except for two analyses when random effects models were used because of potentially important heterogeneity). </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Two new trials reporting three comparisons were found in the update. Nineteen trials are included in the review, reporting 22 oral versus intra-vaginal anti-fungal comparisons. No statistically significant differences were shown between oral and intra-vaginal anti-fungal treatment for clinical cure at short term (OR 0.94, 95% CI, 0.75 to 1.17) and long term (OR 1.07, 95% CI, 0.82 to 1.41) follow-up. No statistically significant differences for mycological cure were observed between oral and intra-vaginal treatment at short term (OR 1.15, 95% CI, 0.94 to 1.42). There was a statistically significant difference for long term follow-up (OR 1.29, 95% CI, 1.05 to 1.60) in favour of oral treatment, however the clinical significance of this result is uncertain. Two trials each reported one withdrawal from treatment due to an adverse reaction. Treatment preference data were poorly reported.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>No statistically significant differences were observed in clinical cure rates of anti-fungals administered by the oral and intra-vaginal routes for the treatment of uncomplicated vaginal candidiasis. No definitive conclusion can be made regarding the relative safety of oral and intra-vaginal anti-fungals for uncomplicated vaginal candidiasis.</P>
<P>The decision to prescribe or recommend the purchase of an anti-fungal for oral or intra-vaginal administration should take into consideration: safety, cost and treatment preference. Unless there is a previous history of adverse reaction to one route of administration or contraindications, women who are purchasing their own treatment should be given full information about the characteristics and costs of treatment to make their own decision. If health services are paying the treatment cost, decision-makers should consider whether the higher cost of some oral anti-fungals is worth the gain in convenience, if this is the patient's preference.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>Seventy-five percent of women experience at least one episode of vulvovaginal candidiasis (thrush) before the menopause (<LINK REF="REF-Sobel-1993" TYPE="REFERENCE">Sobel 1993</LINK>). Candidiasis is the term that is used generically for vaginal infections produced by Candida species. Candida albicans (C. albicans) is the species most often associated with candidiasis, however, other yeasts (e.g. C.glabrata, C. krusei) can also cause this infection. Vulvovaginal candidiasis is treated with a variety of anti-fungal drugs (<LINK REF="REF-Martindale-1999" TYPE="REFERENCE">Martindale 1999</LINK>) that are administered by the oral or local (intra-vaginal) route. The decision to use a specific anti-fungal depends upon its safety, effectiveness, cost and patient preference. This review compared the relative effectiveness, cost-effectiveness and safety of oral and intra-vaginal imidazole and triazole anti-fungals for the treatment of uncomplicated vaginal candidiasis. Patient preference for route of administration was assessed.</P>
</BACKGROUND>
<OBJECTIVES>
<P>The primary objective of this review was to assess the relative effectiveness of oral versus intra-vaginal anti-fungals for the treatment of uncomplicated vulvovaginal candidiasis.<BR/>The secondary objectives of the review were to assess the cost-effectiveness, safety and patient preference of oral versus intra-vaginal anti-fungals.</P>
<P>The following comparison was made: <BR/>Any orally administered imidazole or triazole anti-fungal compared with any imidazole or triazole anti-fungal administered by the intra-vaginal route. </P>
<P>Sub-group analyses were performed comparing:<BR/>
</P>
<UL>
<LI>Individual oral anti-fungals with intra-vaginal anti-fungals.</LI>
<LI>Single dose oral anti-fungals with single dose intra-vaginal anti-fungals.</LI>
<LI>Single dose oral anti-fungals with multiple dose intra-vaginal anti-fungals.</LI>
</UL>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Randomised controlled trials published in any language. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Women (aged 16 years or over) with uncomplicated vulvovaginal candidiasis. For the purpose of this review, uncomplicated vaginal candidiasis refers to acute episodes of this infection (i.e. less than four episodes in 12 months). The diagnosis of vulvovaginal candidiasis was confirmed mycologically (i.e. a positive culture and/or microscopy for yeast). Studies were excluded if they solely involved subjects who were HIV positive, immunocompromised, pregnant, breast feeding or diabetic. Trials that randomised subjects with acute and chronic infections were included if the results for the subjects with acute infection were presented separately, or, if less than 20% of subjects had chronic vaginal candidiasis.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<UL>
<LI>Trials that compared any of the imidazole or triazole anti-fungal drugs administered by the intra-vaginal route (butoconazole, clotrimazole, econazole, fenticonazole, isoconazole, miconazole, omoconazole, oxiconazole, terconazole and tioconazole) with orally administered imidazole or triazole anti-fungals (fluconazole, itraconazole). </LI>
<LI>Trials that compared more than two anti-fungals were included if they compared oral and intra-vaginal routes of administration, with each two-way comparison (i.e. oral vs intra-vaginal) being treated separately. </LI>
</UL>
<P>
<BR/>(Trials that involved ketoconazole were excluded due to its association with serious adverse reactions and its limited licence; it is licensed for the treatment of acute vulvovaginal candidiasis only in Costa Rica, El Salvador, Honduras and Panama in cream and tablet form, and in Guatemala, in cream form only (Personal Communication - Medical Information Department, Janssen-Cilag Ltd)). </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>PRIMARY OUTCOME MEASURE</P>
<P>Clinical cure (short and long term)</P>
<P>SECONDARY OUTCOME MEASURES</P>
<UL>
<LI>Mycological: Eradication of organism (negative vaginal yeast culture)* </LI>
</UL>
<P>
<BR/>
</P>
<UL>
<LI>Safety: Number of patient withdrawals due to adverse reactions; Incidence of adverse reactions (reported as side-effects).</LI>
</UL>
<P>
<BR/>
</P>
<UL>
<LI>Patient preference (for route of administration)</LI>
</UL>
<P>
<BR/>
</P>
<UL>
<LI>Cost-effectiveness </LI>
</UL>
<P>
<BR/>*Candida albicans is found routinely in asymptomatic women, therefore, it would have been inappropriate to use mycological eradication as the primary outcome measure for this review. </P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>See: Collaborative Review Group search strategy </P>
<P>For the original review the Cochrane Controlled Trials Register (CENTRAL/CCTR) was searched by MCW using the Medical Subject Heading (MeSH) "candidiasis-vulvovaginal" and the following text words: butoconazole, clotrimazole, econazole, fenticonazole, fluconazole, isoconazole, itraconazole, miconazole, omoconazole, oxiconazole, terconazole and tioconazole. The Cochrane Sexually Transmitted Disease (STD) Group Specialised Register of Controlled Trials was also searched using each anti-fungal name and associated terms as keywords. EMBASE was searched from January 1980 to January 2000 inclusive, using the names of all anti-fungals combined with vulvovaginal candidiasis, vaginal candidiasis and vaginal thrush. MEDLINE was searched from January 1985 to May 2000 inclusive, using the names of all anti-fungals combined with vulvovaginal candidiasis. The reference list of each trial was examined (MCW) to identify additional relevant references. The manufacturers of anti-fungals in the UK were asked to provide information regarding trials fulfilling the inclusion criteria. The same search strategy was used for the update search. CENTRAL January 2000 to August 2006, PUBMED January 2000 to August 2006, EMBASE January 2000 to August 2006 and the Cochrane STD Group Specialised Register were searched. The reference list of each trial was examined (JG, AA) to identify additional relevant references.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>DATA ABSTRACTION</P>
<P>The titles and abstracts of the electronic search results were examined independently by two reviewers (MCW and JN for the original and JG and AA for the update) to avoid selection bias. The full article formats of all selected abstracts were retrieved and assessed independently by MCW with duplicate assessment by JM, JG, or CB for the original review and by JG and AA for the update. The data from relevant trials were abstracted by MCW, with independent duplicate abstraction by JG, CB or JM for the original review and by JG and MN for the update. Disagreements regarding the inclusion of studies in the review or with data abstraction were resolved by discussion between the reviewers. </P>
<P>Methodological quality was assessed using the following criteria:<BR/>
</P>
<UL>
<LI>Random allocation of treatment was considered as "done" if a random process was used (e.g. random numbers), or if the authors stated explicitly that the trial groups were generated by random allocation.</LI>
<LI>Allocation concealment was "done" if the unit of randomisation was by patient or episode of care, and some form of centralised randomisation scheme was used (e.g. sealed opaque envelopes).</LI>
<LI>Follow-up was greater than 80% of subjects who were culture positive for yeast </LI>
<LI>Whether outcome assessors were blinded to subjects' assignment status; this was regarded as "done" if the authors stated explicitly that the outcome measures were assessed blindly. </LI>
</UL>
<P>
<BR/>The characteristics and outcomes of each trial that were abstracted included:<BR/>
</P>
<UL>
<LI>the anti-fungal used, dose, frequency and duration of administration;</LI>
<LI>type of setting;</LI>
<LI>subjects;</LI>
<LI>outcome measures;</LI>
<LI>methodological quality (described above).</LI>
</UL>
<P>
<BR/>ANALYSES</P>
<P>The main objective of the review was to compare the relative effectiveness of oral and intra-vaginal anti-fungals. In all studies, women were randomised to treatment group (by the investigators) on the basis of their clinical symptoms. At the point of randomisation, a swab was taken for mycological culture. Following randomisation some subjects were excluded because they tested negative for candida. To have used the number of subjects randomised as the denominator would have underestimated the efficacy of the individual anti-fungals. Therefore, the denominator used was the number of randomised subjects who were culture-positive for yeast prior to receiving an anti-fungal. A sensitivity analysis was performed using the number of subjects randomised as the denominator. </P>
<P>The relative safety of both routes of administration was assessed using the number of withdrawals due to adverse drug reactions, as well as the number of reported side-effects. Meta-analyses were undertaken of trials that were homogenous in terms of the outcome measures that were used or that could be calculated. Patient preference (for route of administration) was assessed where possible. The results were derived from dichotomous data, therefore, odds ratios were calculated for the purpose of the meta-analyses. Trials that were excluded from the meta-analyses because of inappropriate or insufficient data, are described within the text. Fixed effect models to pool the odds ratios for all outcome measures were generally used. Random effects models were used if there was potentially important heterogeneity judged by a Chi-squared tests with a p-value of less than 0.1. </P>
<P>Several sub-group analyses were performed. Individual drug comparisons were analysed when there were sufficient trials to do so. Comparisons included fluconazole versus clotrimazole, itraconazole versus clotrimazole, and fluconazole versus miconazole. Single dose anti-fungal regimens were compared as well as single versus multiple dose treatment. Sensitivity analyses were also performed using the methodological quality criteria (see above) and are described in the text. </P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>See: Table of Included Studies</P>
<P>Of the 833 "hits" in the original review, 17 randomised controlled trials were included in the review reporting 19 comparisons of oral versus intra-vaginal preparations. Two new trials reporting three comparisons (<LINK REF="STD-Mendling-_x0028_1_x0029_-2004" TYPE="STUDY">Mendling (1) 2004</LINK>, <LINK REF="STD-Mendling-_x0028_2_x0029_-2004" TYPE="STUDY">Mendling (2) 2004</LINK>, <LINK REF="STD-Seidman-2005" TYPE="STUDY">Seidman 2005</LINK>), giving the total of 19 randomised controlled trials reporting 22 comparisons are included in the update of this review. Seven anti-fungals were represented in the 22 comparisons - fluconazole and itraconazole (oral), and butoconazole, clotrimazole, econazole, miconazole and terconazole (intra-vaginal). Fluconazole was compared with clotrimazole in 13 comparisons (<LINK REF="STD-Adetoro-1990" TYPE="STUDY">Adetoro 1990</LINK>, <LINK REF="STD-Anonymous-1989" TYPE="STUDY">Anonymous 1989</LINK>, <LINK REF="STD-Boag-1991" TYPE="STUDY">Boag 1991</LINK>, <LINK REF="STD-Goode-1992" TYPE="STUDY">Goode 1992</LINK>, <LINK REF="STD-Mendling-_x0028_1_x0029_-2004" TYPE="STUDY">Mendling (1) 2004</LINK>, <LINK REF="STD-Mendling-_x0028_2_x0029_-2004" TYPE="STUDY">Mendling (2) 2004</LINK>, <LINK REF="STD-Mikamo-_x0028_1_x0029_-1995" TYPE="STUDY">Mikamo (1) 1995</LINK>, <LINK REF="STD-Mikamo-_x0028_2_x0029_-1995" TYPE="STUDY">Mikamo (2) 1995</LINK>, <LINK REF="STD-O_x002d_Prasertsawat-1995" TYPE="STUDY">O-Prasertsawat 1995</LINK>, <LINK REF="STD-Sobel-1995" TYPE="STUDY">Sobel 1995</LINK>, <LINK REF="STD-Stein-1991" TYPE="STUDY">Stein 1991</LINK>,<LINK REF="STD-Van-Heusden-1994" TYPE="STUDY">Van Heusden 1994</LINK>, <LINK REF="STD-Woolley-_x0028_1_x0029_-1995" TYPE="STUDY">Woolley (1) 1995</LINK>), miconazole in two studies (<LINK REF="STD-Timonen-_x0028_1_x0029_-1992" TYPE="STUDY">Timonen (1) 1992</LINK>, <LINK REF="STD-Van-Heusden-1990" TYPE="STUDY">Van Heusden 1990</LINK>), and terconazole (<LINK REF="STD-Slavin-1992" TYPE="STUDY">Slavin 1992</LINK>), econazole (<LINK REF="STD-Osser-1991" TYPE="STUDY">Osser 1991</LINK>) and butoconazole (<LINK REF="STD-Seidman-2005" TYPE="STUDY">Seidman 2005</LINK>) in one trial each. Itraconazole was compared with clotrimazole in three studies (<LINK REF="STD-Stein-1993" TYPE="STUDY">Stein 1993</LINK>, <LINK REF="STD-Tobin-1992" TYPE="STUDY">Tobin 1992</LINK>, <LINK REF="STD-Woolley-_x0028_2_x0029_-1995" TYPE="STUDY">Woolley (2) 1995</LINK>) and econazole in one trial (<LINK REF="STD-Timonen-_x0028_2_x0029_-1992" TYPE="STUDY">Timonen (2) 1992</LINK>). </P>
<P>Three trials included subjects with chronic vulvovaginal candidiasis (<LINK REF="STD-Osser-1991" TYPE="STUDY">Osser 1991</LINK>, <LINK REF="STD-Sobel-1995" TYPE="STUDY">Sobel 1995</LINK>, <LINK REF="STD-Timonen-_x0028_2_x0029_-1992" TYPE="STUDY">Timonen (2) 1992</LINK>). In one trial (<LINK REF="STD-Sobel-1995" TYPE="STUDY">Sobel 1995</LINK>), the results for acute vulvovaginal candidiasis were presented separately from subjects with chronic infection, therefore, the results for this trial were generated from the acute subjects only. Of the 258 subjects randomised in the trial by Osser (<LINK REF="STD-Osser-1991" TYPE="STUDY">Osser 1991</LINK>), 33 (13%) had chronic vulvovaginal candidiasis, and in the trial by Timonen (<LINK REF="STD-Timonen-_x0028_2_x0029_-1992" TYPE="STUDY">Timonen (2) 1992</LINK>), 13 (16%) of the subjects had chronic yeast infections. <BR/> <BR/>Ten trials (representing 12 comparisons) were conducted in Europe (<LINK REF="STD-Anonymous-1989" TYPE="STUDY">Anonymous 1989</LINK>, <LINK REF="STD-Boag-1991" TYPE="STUDY">Boag 1991</LINK>, <LINK REF="STD-Mendling-_x0028_1_x0029_-2004" TYPE="STUDY">Mendling (1) 2004</LINK>, <LINK REF="STD-Mendling-_x0028_2_x0029_-2004" TYPE="STUDY">Mendling (2) 2004</LINK>, <LINK REF="STD-Osser-1991" TYPE="STUDY">Osser 1991</LINK>, <LINK REF="STD-Timonen-_x0028_2_x0029_-1992" TYPE="STUDY">Timonen (2) 1992</LINK>, <LINK REF="STD-Timonen-_x0028_1_x0029_-1992" TYPE="STUDY">Timonen (1) 1992</LINK>, <LINK REF="STD-Tobin-1992" TYPE="STUDY">Tobin 1992</LINK>, <LINK REF="STD-Van-Heusden-1990" TYPE="STUDY">Van Heusden 1990</LINK>, <LINK REF="STD-Van-Heusden-1994" TYPE="STUDY">Van Heusden 1994</LINK>, <LINK REF="STD-Woolley-_x0028_1_x0029_-1995" TYPE="STUDY">Woolley (1) 1995</LINK>, <LINK REF="STD-Woolley-_x0028_2_x0029_-1995" TYPE="STUDY">Woolley (2) 1995</LINK>), six were conducted in the USA (<LINK REF="STD-Goode-1992" TYPE="STUDY">Goode 1992</LINK>, <LINK REF="STD-Seidman-2005" TYPE="STUDY">Seidman 2005</LINK>, <LINK REF="STD-Slavin-1992" TYPE="STUDY">Slavin 1992</LINK>, <LINK REF="STD-Sobel-1995" TYPE="STUDY">Sobel 1995</LINK>, <LINK REF="STD-Stein-1991" TYPE="STUDY">Stein 1991</LINK>, <LINK REF="STD-Stein-1993" TYPE="STUDY">Stein 1993</LINK>), one in Japan (representing 2 comparisons) (<LINK REF="STD-Mikamo-_x0028_1_x0029_-1995" TYPE="STUDY">Mikamo (1) 1995</LINK>, <LINK REF="STD-Mikamo-_x0028_2_x0029_-1995" TYPE="STUDY">Mikamo (2) 1995</LINK>), and one each in Thailand (<LINK REF="STD-O_x002d_Prasertsawat-1995" TYPE="STUDY">O-Prasertsawat 1995</LINK>) and Africa (<LINK REF="STD-Adetoro-1990" TYPE="STUDY">Adetoro 1990</LINK>). Ethnicity of the trial populations was not reported in any trial. </P>
<P>The duration of follow-up varied between trials (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). For the purpose of this review, the outcome measures that were presented at between five and 15 days were included in the short-term follow-up comparisons, and the outcome measures that were presented at between two and 12 weeks were included in the long-term follow-up comparisons. Outcome measures that were presented at time points outside these follow-up periods were excluded. There is slight overlap between the duration of short- and long-term follow-up as a result of the trial by Timonen (<LINK REF="STD-Timonen-_x0028_2_x0029_-1992" TYPE="STUDY">Timonen (2) 1992</LINK>). The <LINK REF="STD-Seidman-2005" TYPE="STUDY">Seidman 2005</LINK> trial reported first time to symptomatic relief measured by patient report (patient diary); the reported outcome of complete relief of symptoms at 72 hours was included in the short-term clinical cure analyses.</P>
<P>Compliance checks were reported in six trials (<LINK REF="STD-Boag-1991" TYPE="STUDY">Boag 1991</LINK>, <LINK REF="STD-O_x002d_Prasertsawat-1995" TYPE="STUDY">O-Prasertsawat 1995</LINK>, <LINK REF="STD-Osser-1991" TYPE="STUDY">Osser 1991</LINK>, <LINK REF="STD-Seidman-2005" TYPE="STUDY">Seidman 2005</LINK>, <LINK REF="STD-Slavin-1992" TYPE="STUDY">Slavin 1992</LINK>, <LINK REF="STD-Sobel-1995" TYPE="STUDY">Sobel 1995</LINK>). Pharmaceutical industry support was reported in seven trials (<LINK REF="STD-Anonymous-1989" TYPE="STUDY">Anonymous 1989</LINK>, <LINK REF="STD-Osser-1991" TYPE="STUDY">Osser 1991</LINK>, <LINK REF="STD-Sobel-1995" TYPE="STUDY">Sobel 1995</LINK>, <LINK REF="STD-Stein-1991" TYPE="STUDY">Stein 1991</LINK>, <LINK REF="STD-Stein-1993" TYPE="STUDY">Stein 1993</LINK>, <LINK REF="STD-Timonen-_x0028_2_x0029_-1992" TYPE="STUDY">Timonen (2) 1992</LINK>, <LINK REF="STD-Tobin-1992" TYPE="STUDY">Tobin 1992</LINK>).</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>See: Table of Included Studies</P>
<P>Allocation concealment was considered "done" for only one trial (<LINK REF="STD-O_x002d_Prasertsawat-1995" TYPE="STUDY">O-Prasertsawat 1995</LINK>), therefore, a sensitivity analysis was not performed for this quality measure. </P>
<P>Five trials had a follow-up rate of less than 80% (Mendling 2004, <LINK REF="STD-Osser-1991" TYPE="STUDY">Osser 1991</LINK>, <LINK REF="STD-Seidman-2005" TYPE="STUDY">Seidman 2005</LINK>, <LINK REF="STD-Stein-1993" TYPE="STUDY">Stein 1993</LINK>, <LINK REF="STD-Tobin-1992" TYPE="STUDY">Tobin 1992</LINK>). The percentage follow-up could not be calculated for three additional trials (<LINK REF="STD-Timonen-_x0028_1_x0029_-1992" TYPE="STUDY">Timonen (1) 1992</LINK>, <LINK REF="STD-Timonen-_x0028_2_x0029_-1992" TYPE="STUDY">Timonen (2) 1992</LINK>, <LINK REF="STD-Van-Heusden-1994" TYPE="STUDY">Van Heusden 1994</LINK>).</P>
<P>Nine trials (10 comparisons) used either double or single blind* conditions (*where the investigator was blind to treatment allocation) (<LINK REF="STD-Anonymous-1989" TYPE="STUDY">Anonymous 1989</LINK>, <LINK REF="STD-O_x002d_Prasertsawat-1995" TYPE="STUDY">O-Prasertsawat 1995</LINK>, <LINK REF="STD-Osser-1991" TYPE="STUDY">Osser 1991</LINK>, <LINK REF="STD-Slavin-1992" TYPE="STUDY">Slavin 1992</LINK>, <LINK REF="STD-Sobel-1995" TYPE="STUDY">Sobel 1995</LINK>, <LINK REF="STD-Timonen-_x0028_2_x0029_-1992" TYPE="STUDY">Timonen (2) 1992</LINK>, <LINK REF="STD-Tobin-1992" TYPE="STUDY">Tobin 1992</LINK>, <LINK REF="STD-Van-Heusden-1990" TYPE="STUDY">Van Heusden 1990</LINK>, <LINK REF="STD-Woolley-_x0028_1_x0029_-1995" TYPE="STUDY">Woolley (1) 1995</LINK>, <LINK REF="STD-Woolley-_x0028_2_x0029_-1995" TYPE="STUDY">Woolley (2) 1995</LINK>). </P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>CLINICAL CURE<BR/>No statistically significant difference was shown between oral and intra-vaginal anti-fungals for clinical cure at either time point (short OR 0.94, 95% CI, 0.75 to 1.17 and long OR 1.07, 95% CI, 0.82 to 1.41). No statistically significant differences were shown for any of the sub-group analyses. Short-term clinical cure was evaluated in ten trials and long-term clinical cure was evaluated in eight trials. At short-term follow-up, 74% cure was achieved with oral and 73% intra-vaginal treatment. At long term follow-up, cure was achieved in 80% of women receiving oral treatment and in 76% of women receiving intra-vaginal treatment. No statistically significant difference was shown between oral and intra-vaginal anti-fungals administered as single dose treatments. </P>
<P>MYCOLOGICAL CURE<BR/>All 19 studies confirmed the clinical diagnosis of vaginal candidiasis using mycological culture and / or microscopy. One study (<LINK REF="STD-Slavin-1992" TYPE="STUDY">Slavin 1992</LINK>) used microscopy only to provide mycological confirmation of the diagnosis. There was variation amongst the 18 remaining studies regarding the definition used to confirm the mycological diagnosis. Some studies reported positive "yeast culture" (<LINK REF="STD-Boag-1991" TYPE="STUDY">Boag 1991</LINK>, <LINK REF="STD-Mendling-_x0028_1_x0029_-2004" TYPE="STUDY">Mendling (1) 2004</LINK>, <LINK REF="STD-Mendling-_x0028_2_x0029_-2004" TYPE="STUDY">Mendling (2) 2004</LINK>, <LINK REF="STD-Osser-1991" TYPE="STUDY">Osser 1991</LINK>, <LINK REF="STD-Timonen-_x0028_2_x0029_-1992" TYPE="STUDY">Timonen (2) 1992</LINK>, <LINK REF="STD-Timonen-_x0028_1_x0029_-1992" TYPE="STUDY">Timonen (1) 1992</LINK>), whilst others reported positive "culture of Candida species" (<LINK REF="STD-Adetoro-1990" TYPE="STUDY">Adetoro 1990</LINK>, <LINK REF="STD-Anonymous-1989" TYPE="STUDY">Anonymous 1989</LINK>, <LINK REF="STD-Mikamo-_x0028_1_x0029_-1995" TYPE="STUDY">Mikamo (1) 1995</LINK>, <LINK REF="STD-Mikamo-_x0028_2_x0029_-1995" TYPE="STUDY">Mikamo (2) 1995</LINK>, <LINK REF="STD-O_x002d_Prasertsawat-1995" TYPE="STUDY">O-Prasertsawat 1995</LINK>, <LINK REF="STD-Sobel-1995" TYPE="STUDY">Sobel 1995</LINK>, <LINK REF="STD-Stein-1991" TYPE="STUDY">Stein 1991</LINK>, <LINK REF="STD-Stein-1993" TYPE="STUDY">Stein 1993</LINK>, <LINK REF="STD-Tobin-1992" TYPE="STUDY">Tobin 1992</LINK>, <LINK REF="STD-Van-Heusden-1990" TYPE="STUDY">Van Heusden 1990</LINK>, <LINK REF="STD-Van-Heusden-1994" TYPE="STUDY">Van Heusden 1994</LINK>, <LINK REF="STD-Woolley-_x0028_1_x0029_-1995" TYPE="STUDY">Woolley (1) 1995</LINK>, <LINK REF="STD-Woolley-_x0028_2_x0029_-1995" TYPE="STUDY">Woolley (2) 1995</LINK>). Two studies (<LINK REF="STD-Goode-1992" TYPE="STUDY">Goode 1992</LINK>, <LINK REF="STD-Seidman-2005" TYPE="STUDY">Seidman 2005</LINK>) reported mycological confirmation of "Candidiasis" but did not mention a specific species. The <LINK REF="STD-Seidman-2005" TYPE="STUDY">Seidman 2005</LINK> study did not perform yeast cultures as therapeutic efficacy was not an outcomee of interest. In only one study (<LINK REF="STD-Adetoro-1990" TYPE="STUDY">Adetoro 1990</LINK>) was mycological cure defined as the absence of Candida albicans. The terminology most often used in reporting mycological cure was the absence of growth of Candida species.</P>
<P>Nineteen of the 22 comparisons reported short term mycological cure and 14 reported long term mycological cure. No statistically significant difference was shown between oral and intra-vaginal treatment at short term (OR 1.15, 95% CI, 0.94 to 1.42). A statistically significant difference in favour of oral treatment was shown for long term follow-up (OR 1.29, 95% CI, 1.05 to 1.60). The clinical significance of this finding is uncertain given that Candida albicans is found routinely in asymptomatic women. At short term follow-up, similar proportions of women achieved mycological cure for oral (83%) and intra-vaginal (80%) treatment. However, at long-term follow-up, the proportion of women achieving mycological cure decreased to 72% for oral treatment and 66% for intra-vaginal treatment. </P>
<P>No statistically significant difference was shown between oral and intra-vaginal anti-fungals administered as single dose treatments. No statistically significant difference was shown between single dose anti-fungals compared with multiple dose anti-fungals. <BR/> <BR/>SENSITIVITY ANALYSES</P>
<P>Sensitivity analyses exploring the effects of using the number of subjects randomised, blinding of treatment allocation, and the proportion of patients followed up, did not reveal clinically or statistically significant differences in the observed effect sizes for any outcome (see <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). </P>
<P>SAFETY</P>
<P>Withdrawals due to adverse drug effects, and the number of reported side-effects, were used as a measure of anti-fungal safety. One trial (<LINK REF="STD-Timonen-_x0028_1_x0029_-1992" TYPE="STUDY">Timonen (1) 1992</LINK>) reported that one subject had her miconazole treatment "interrupted" due to an adverse reaction and another trial (<LINK REF="STD-Stein-1991" TYPE="STUDY">Stein 1991</LINK>) reported one withdrawal from fluconazole due to diarrhoea. No withdrawals due to adverse drug reactions were reported in any other trial. Thirteen trials reported side-effects (<LINK REF="STD-Adetoro-1990" TYPE="STUDY">Adetoro 1990</LINK>, <LINK REF="STD-Anonymous-1989" TYPE="STUDY">Anonymous 1989</LINK>, <LINK REF="STD-Mendling-_x0028_1_x0029_-2004" TYPE="STUDY">Mendling (1) 2004</LINK>, <LINK REF="STD-Mendling-_x0028_2_x0029_-2004" TYPE="STUDY">Mendling (2) 2004</LINK>, <LINK REF="STD-O_x002d_Prasertsawat-1995" TYPE="STUDY">O-Prasertsawat 1995</LINK>, <LINK REF="STD-Osser-1991" TYPE="STUDY">Osser 1991</LINK>, <LINK REF="STD-Seidman-2005" TYPE="STUDY">Seidman 2005</LINK>, <LINK REF="STD-Sobel-1995" TYPE="STUDY">Sobel 1995</LINK>, <LINK REF="STD-Stein-1993" TYPE="STUDY">Stein 1993</LINK>, <LINK REF="STD-Stein-1991" TYPE="STUDY">Stein 1991</LINK>, <LINK REF="STD-Timonen-_x0028_2_x0029_-1992" TYPE="STUDY">Timonen (2) 1992</LINK>, <LINK REF="STD-Timonen-_x0028_1_x0029_-1992" TYPE="STUDY">Timonen (1) 1992</LINK>, <LINK REF="STD-Van-Heusden-1990" TYPE="STUDY">Van Heusden 1990</LINK>, <LINK REF="STD-Van-Heusden-1994" TYPE="STUDY">Van Heusden 1994</LINK>). Anti-fungals administered intra-vaginally were more often associated with local reactions (e.g. irritation, "burning", pruritus) than with those administered by the oral route, but systemic effects were also reported (i.e. headache). The oral route of administration was associated with a wide range of systemic effects including gastro-intestinal side-effects and headache. The number of reported side-effects should not be used to derive conclusions about the relative safety of the anti-fungals in this review except in the broadest terms. The rate* of reported side-effects per 100 patients for each anti-fungal was 21 for fluconazole, 22 for clotrimazole, 23 for itraconazole, 38 for butoconazole and 12 each for econazole and miconazole. (*This rate was calculated using the number of reported side-effects divided by the number of subjects randomised, or the number of subjects randomised that were positive for yeast culture, depending on which denominator could be calculated for each trial).<BR/> <BR/>TREATMENT PREFERENCE</P>
<P>Ten trials reported subject preference for the route of anti-fungal administration (<LINK REF="STD-Adetoro-1990" TYPE="STUDY">Adetoro 1990</LINK>, <LINK REF="STD-Anonymous-1989" TYPE="STUDY">Anonymous 1989</LINK>, <LINK REF="STD-Osser-1991" TYPE="STUDY">Osser 1991</LINK>, <LINK REF="STD-Slavin-1992" TYPE="STUDY">Slavin 1992</LINK>, <LINK REF="STD-Stein-1993" TYPE="STUDY">Stein 1993</LINK>, <LINK REF="STD-Timonen-_x0028_2_x0029_-1992" TYPE="STUDY">Timonen (2) 1992</LINK>, <LINK REF="STD-Timonen-_x0028_1_x0029_-1992" TYPE="STUDY">Timonen (1) 1992</LINK>, <LINK REF="STD-Tobin-1992" TYPE="STUDY">Tobin 1992</LINK>, <LINK REF="STD-Van-Heusden-1990" TYPE="STUDY">Van Heusden 1990</LINK>, <LINK REF="STD-Van-Heusden-1994" TYPE="STUDY">Van Heusden 1994</LINK>). These data were poorly presented. Two trials (<LINK REF="STD-Adetoro-1990" TYPE="STUDY">Adetoro 1990</LINK>, <LINK REF="STD-Stein-1993" TYPE="STUDY">Stein 1993</LINK>) made statements about treatment preference but no quantitative data were presented. The inconsistencies associated with reporting the preferred route of administration limit the use of these data. All studies that reported a preference favoured oral treatment (compared with intra-vaginal or no preference), ranging from 43% of women in the trial by Van Heusden (<LINK REF="STD-Van-Heusden-1990" TYPE="STUDY">Van Heusden 1990</LINK>) to 93% in Timonen's trial (<LINK REF="STD-Timonen-_x0028_1_x0029_-1992" TYPE="STUDY">Timonen (1) 1992</LINK>). The two studies in the update (Mendling 2004, <LINK REF="STD-Seidman-2005" TYPE="STUDY">Seidman 2005</LINK>) did not report patient treatment preference.</P>
<P>COSTS</P>
<P>The trials included in this review did not consider economic issues relating to the use of alternative treatments. No trial evaluated the relative cost-effectiveness of the two modes of treatment (oral and intra-vaginal). The cost of oral and intra-vaginal anti-fungals differ, in general intra-vaginal are cheaper than oral antifungals.<U>
<BR/>
</U>
</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>SCOPE OF THE REVIEW</P>
<P>This review compared the relative effectiveness and safety of oral versus intra-vaginal anti-fungals for the treatment of uncomplicated vulvovaginal candidiasis. A variety of anti-fungals are available worldwide for the treatment of this infection. In some countries, these drugs can be purchased without a prescription enabling customers to self-medicate. The relative effectiveness of oral versus oral preparations, and intra-vaginal versus intra-vaginal treatments was not assessed. The search strategies included all the generic names of identifiable anti-fungals that are available world-wide and which are licensed for the treatment of uncomplicated vulvovaginal candidiasis. The exclusion of ketoconazole from this review was on the basis of its adverse toxicity profile and limited product licence.</P>
<P>LIMITATIONS OF THE REVIEW</P>
<P>Limitations of studies<BR/>Adequate methods of allocation concealment should be used to avoid bias (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>). Allocation concealment was achieved in one trial (<LINK REF="STD-O_x002d_Prasertsawat-1995" TYPE="STUDY">O-Prasertsawat 1995</LINK>). Outcome assessment was not blind in 10 trials (eleven comparisons) (<LINK REF="STD-Adetoro-1990" TYPE="STUDY">Adetoro 1990</LINK>, <LINK REF="STD-Boag-1991" TYPE="STUDY">Boag 1991</LINK>, <LINK REF="STD-Goode-1992" TYPE="STUDY">Goode 1992</LINK>, <LINK REF="STD-Mendling-_x0028_1_x0029_-2004" TYPE="STUDY">Mendling (1) 2004</LINK>, <LINK REF="STD-Mendling-_x0028_2_x0029_-2004" TYPE="STUDY">Mendling (2) 2004</LINK>, <LINK REF="STD-Mikamo-_x0028_1_x0029_-1995" TYPE="STUDY">Mikamo (1) 1995</LINK>, <LINK REF="STD-Mikamo-_x0028_2_x0029_-1995" TYPE="STUDY">Mikamo (2) 1995</LINK>, <LINK REF="STD-Seidman-2005" TYPE="STUDY">Seidman 2005</LINK>, <LINK REF="STD-Stein-1991" TYPE="STUDY">Stein 1991</LINK>, <LINK REF="STD-Stein-1993" TYPE="STUDY">Stein 1993</LINK>, <LINK REF="STD-Timonen-_x0028_1_x0029_-1992" TYPE="STUDY">Timonen (1) 1992</LINK>, <LINK REF="STD-Van-Heusden-1994" TYPE="STUDY">Van Heusden 1994</LINK>) and this may have resulted in performance bias in terms of clinical cure. The denominator could not be calculated for a number of trials because of the poor presentation of data. Seven trials reported pharmaceutical industry support. It is possible that of the 12 remaining trials, some also had pharmaceutical industry involvement that was not reported. Pharmaceutical sponsorship may be associated with publication bias in randomised controlled trials of drug comparisons (<LINK REF="REF-Rochon-1994" TYPE="REFERENCE">Rochon 1994</LINK>). None of the included trials presented economic assessments. </P>
<P>Chronic candidiasis may be more difficult to eradicate than acute episodes of this infection. If so, it is possible that the inclusion of two studies by <LINK REF="STD-Osser-1991" TYPE="STUDY">Osser 1991</LINK> and <LINK REF="STD-Timonen-_x0028_2_x0029_-1992" TYPE="STUDY">Timonen (2) 1992</LINK> may have reduced the findings for overall clinical and mycological cure. </P>
<P>Publication bias<BR/>No unpublished trials were identified for inclusion in this review. This was in spite of contacting the manufacturers of anti-fungal preparations in the UK. The search strategies were not limited to English language publications, therefore the risk of publication bias (<LINK REF="REF-Egger-_x0028_1_x0029_-1997" TYPE="REFERENCE">Egger (1) 1997</LINK>, <LINK REF="REF-Moher-1996" TYPE="REFERENCE">Moher 1996</LINK>) was reduced.</P>
<P>FINDINGS</P>
<P>The results did not show a statistically significant difference between oral and intra-vaginal anti-fungals in terms of short and long term clinical and short term mycological cure. Both routes of administration achieved clinical cure in over 70% of subjects. Similar proportions were observed with short term mycological cure. However, at long term follow-up the proportion of women achieving mycological cure decreased to 72% with oral anti-fungals and 66% for intra-vaginal administration. Six of the 19 studies reported compliance checks. It is possible that non-compliance could have contributed to therapeutic failure (clinical and / or mycological) with some subjects.</P>
<P>One study (<LINK REF="STD-Seidman-2005" TYPE="STUDY">Seidman 2005</LINK>) only reported short term clinical cure as time to first and total relief of symptoms. As the symptoms of vulvovaginal candidiasis are often painful and uncomfortable, these outcomes maybe valuable to the patient (<LINK REF="STD-Seidman-2005" TYPE="STUDY">Seidman 2005</LINK>). Patients kept a diary to record first time to symptom relief and adverse events. The results of total relief of symptoms at 72 hours (3 days) were included in the short term clinical cure analysis. With intra-vaginal treatment (butoconazole) 75% of patients experienced first relief of symptoms at 24.5 hours compared to oral therapy (fluconazole) at 46.3 hours.</P>
<P>It is possible that the proportion of women who did not experience clinical cure following anti-fungal therapy (approximately 20% of subjects participating in the studies included in this review), had vaginitis due to other causes. Most studies excluded subjects with concomitant vaginal infections (e.g. chlamydia, trichomonas). It is possible that some subjects may have had an undiagnosed urogenital infection or condition which, in addition to their fungal infection, contributed to their clinical symptoms. Other factors may have influenced unresponsive women's symptoms, including chemical irritants (e.g. perfumed products, detergents) and physical damage (e.g. due to tampons, sexual intercourse). </P>
<P>In terms of mycological cure, the short-term cure rate of 83% and 80% for oral and intra-vaginal preparations, respectively, requires consideration (i.e. what were the causes of therapeutic failure in approximately 20% of women treated?). Therapeutic failure may have been due to the presence of fungal species outside the spectrum of the anti-fungals used, or, resistance to specific anti-fungals. The prevalence of non-albicans species has increased rapidly in recent years (<LINK REF="REF-Spinillo-1997" TYPE="REFERENCE">Spinillo 1997</LINK>). Non-albicans Candida species are associated with vaginitis but these organisms are more resistant to conventional anti-fungal therapy (<LINK REF="REF-Sobel-1993" TYPE="REFERENCE">Sobel 1993</LINK>). These is evidence that C. glabrata and C. krusei are resistant to fluconazole and itraconazole (<LINK REF="REF-Rex-2000" TYPE="REFERENCE">Rex 2000</LINK>).</P>
<P>The decrease in mycological cure at long-term follow-up may be explained to some extent by the regrowth of normal Candida species as part of the vaginal flora. The higher long-term clinical cure rates support this theory (i.e. the number of women who were mycologically cured decreased between short and long-term follow-up, however, a corresponding reduction in clinical cure for these time points was not shown). Other factors may contribute to the reduction in mycological cure. Women may have been exposed to risk factors associated with vaginal candidiasis following their entry into a study. Fluctuations in hormone balance (e.g. menstruation, contraceptive use), drug use (e.g. antibiotics, corticosteroids), and changes in hygiene, diet or sexual behaviour, may result in Candidal colonisation (<LINK REF="REF-Reed-1992" TYPE="REFERENCE">Reed 1992</LINK>, <LINK REF="REF-Sobel-1993" TYPE="REFERENCE">Sobel 1993</LINK>, <LINK REF="REF-Anonymous-1999" TYPE="REFERENCE">Anonymous 1999</LINK>). Undiagnosed diabetes may also be a contributory factor to recurrent infection (<LINK REF="REF-Anonymous-1999" TYPE="REFERENCE">Anonymous 1999</LINK>). </P>
<P>Single dose anti-fungal treatment was as effective as multiple dose regimens. This contrasts with the results of a review (<LINK REF="REF-Young-2001" TYPE="REFERENCE">Young 2001</LINK>) of the treatment of vaginal candidiasis in pregnancy that showed multiple dose treatment to be more effective than single dose anti-fungal therapy.</P>
<P>No significant changes in the results were shown with the sensitivity analyses based upon the measures of methodological quality. Using the denominator based upon the number of subjects randomised instead of those who were mycologically positive for yeast did not alter the findings of the review. It should be borne in mind that using the former denominator may over-estimate the anti-fungal effect because a proportion of women randomised on the basis of their clinical symptoms will have a negative yeast culture. Using the number of women who had a positive yeast culture as the denominator will under-estimate the number of women experiencing clinical cure if recruitment and randomisation has been performed on the basis of these clinical symptoms. </P>
<P>Side-effect data were poorly reported. Intuitively, the oral administration of any drug, anti-fungal or otherwise, is more likely to be associated with a greater proportion of adverse drug reactions than the intra-vaginal administration of a drug from the same therapeutic category. Furthermore, adverse reactions resulting from anti-fungals given systemically may be more severe or have more serious consequences than those occurring with intra-vaginal administration. </P>
<P>Patient preference for route of anti-fungal administration was assessed as a secondary outcome measure. Percentages of subjects who preferred oral anti-fungals compared with intra-vaginal treatment were presented, but no indication was given of the denominator, nor whether subjects had previous experience of oral and / or intra-vaginal anti-fungal therapy. The oral route was consistently the preferred route of administration for anti-fungals in studies included in this review. It should be borne in mind, however, that oral preparations are usually more expensive than intra-vaginal treatments and, the systemic side-effects associated with oral treatment are likely to be of a more serious nature than intra-vaginal anti-fungals. </P>
<P>The cost-effectiveness of oral and intra-vaginal anti-fungal treatment was also a secondary outcome measure of this trial. Few data were presented in the included trials that could be used in a cost-effectiveness analysis. As mentioned above, oral anti-fungal treatment is generally more expensive than intra-vaginal therapies. Whether it is the woman or her health system who pays for her anti-fungal treatment will have implications in terms of the difference in costs between the two options for route of administration. </P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>No statistically significant differences exist between oral and intra-vaginal anti-fungals in terms of relative effectiveness. </P>
<P>The decision to prescribe or recommend the purchase of an anti-fungal for oral or intra-vaginal administration should take into consideration: cost, treatment preference, and contra-indications. Unless there is a previous history of adverse reaction to one route of administration or contraindications, women who are purchasing their own treatment should be given full information about the characteristics and costs of treatment to make their own decision. If health services are paying the treatment cost, decision-makers should consider whether the higher cost of oral anti-fungal administration is worth the gain in convenience, if this is the patient's preference.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>It is questionable whether further studies need to be conducted comparing oral and intra-vaginal anti-fungals. If further studies are conducted, however, they need to incorporate measures of methodological quality specified in this review, robust methods of assessing and reporting treatment preference, and, full health economic assessments of the treatment options under investigation. Further studies need to address outcomes that are useful to the patients for example time to first relief of symptoms (<LINK REF="STD-Seidman-2005" TYPE="STUDY">Seidman 2005</LINK>), adverse events and patient preferences. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The authors would like to thank Sheila Wallace of the Cochrane Collaboration Incontinence Group for her advice regarding search strategies. We also wish to thank Ms Margaret Ross for performing reference retrieval for the original review. The authors would also like to thank Ahmed Alamry and Alain Mayhew of the Cochrane Effective Practice and Organisation of Care Group for their assistance in the update of this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None<BR/>The views expressed in this review are those of the authors and may not be shared by the funding organisation.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>The original review was conceived by Margaret Watson (MW), Jeremy Grimshaw (JG) and Christine Bond (CB). MW is the guarantor for the original review. She devised and performed the literature searches as well as data collection and abstraction, data entry and preparation of the review for publication. JG performed data abstraction, advised on the method of the review and contributed to the preparation of the review for publication. CB performed data abstraction and contributed to the preparation of the review for publication. Jill Mollison (JM) screened the search results and performed data abstraction. She also advised on the statistical aspects of the review. Anne Ludbrook (AL) prepared the economic sections of the review. For the update JG and Ahmed Alamry (AA) screened the search results. Munira Nurbhai (MN) and JG performed the data abstraction and updated the review for publication. JG is the guarantor for the update of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-10-29 16:57:01 -0400" MODIFIED_BY="Karen Hovhannisyan">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Adetoro-1990" NAME="Adetoro 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adetoro OO</AU>
<TI>Comparative trial of a single dose of fluconazole (150mg) and a single intravaginal tablet of clotrimazole (500mg) in the treatment of vaginal candidiasis</TI>
<SO>Current Therapeutic Research</SO>
<YR>1990</YR>
<VL>48</VL>
<NO>2</NO>
<PG>275-281</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1989" NAME="Anonymous 1989" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>A comparison of single-dose oral fluconazole with 3-day intravaginal clotrimazole in the treatment of vaginal candidiasis</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1989</YR>
<VL>96</VL>
<PG>226-232</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="BOOK">
<AU>Brammer KW, Lees LJ</AU>
<TI>Single dose oral fluconazole in the treatment of vulvovaginal candidiasis: An interim analysis of a comparative study versus three-day intravaginal clotrimazole tablets</TI>
<SO>Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents</SO>
<YR>1987</YR>
<PG>151-156</PG>
<ED>Fromtling RA</ED>
<CY>South Africa</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lassus A</AU>
<TI>A comparative study of fluconazole and clotrimazole</TI>
<SO>Royal Society of Medicine Services International Congress and Symposium Series No. 160</SO>
<YR>1989</YR>
<PG>37-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boag-1991" NAME="Boag 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boag FC, Houang ET, Westrom R, McCormack SM, Lawrence AG</AU>
<TI>Comparison of vaginal flora after treatment with a clotrimazole 500mg vaginal pessary or a fluconazole 150mg capsule for vaginal candidosis</TI>
<SO>Genitourinary Medicine</SO>
<YR>1991</YR>
<VL>67</VL>
<PG>232-234</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goode-1992" NAME="Goode 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Goode MA, Karig AW, Carson DS, Hamadeh G</AU>
<TI>Single dose fluconazole versus clotrimazole in the treatment of vaginal candidiasis</TI>
<SO>International Pharmaceutical Abstracts (ASHP Midyear Clinical Meeting 27:SPG-61 (Dec) 1992)</SO>
<YR>1992</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mendling-_x0028_1_x0029_-2004" NAME="Mendling (1) 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mendling W, Krauss C, Fladung B</AU>
<TI>A clinical multicenter study comparing efficacy and tolerability of topical combination therapy with clotrimazole (Canesten, two formats) with oral single dose fluconazole (Diflucan) in vulvovaginal mycoses</TI>
<SO>Mycoses</SO>
<YR>2004</YR>
<VL>47</VL>
<PG>136-142</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mendling-_x0028_2_x0029_-2004" NAME="Mendling (2) 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mendling W, Krauss C, Fladung B</AU>
<TI>A clinical multicenter study comparing efficacy and tolerability of topical combination therapy with clotrimazole (Canesten, two formats) with oral single dose fluconazole (Diflucan) in vulvovaginal mycoses</TI>
<SO>Mycoses</SO>
<YR>2004</YR>
<VL>47</VL>
<PG>136-142</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mikamo-_x0028_1_x0029_-1995" NAME="Mikamo (1) 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mikamo H, Izumi K, Ito K, Tamaya T</AU>
<TI>Comparative study of the effectiveness of oral fluconazole and intravaginal clotrimazole in the treatment of vaginal candidiasis</TI>
<SO>Infectious Diseases in Obstetrics and Gynaecology</SO>
<YR>1995</YR>
<VL>3</VL>
<PG>7-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mikamo-_x0028_2_x0029_-1995" NAME="Mikamo (2) 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mikamo H, Izumi K, Ito K, Tamaya T</AU>
<TI>Comparative study of the effectiveness of oral fluconazole and intravaginal clotrimazole in the treatment of vaginal candidiasis</TI>
<SO>Infectious Diseases in Obstetrics and Gynaecology</SO>
<YR>1995</YR>
<VL>3</VL>
<PG>7-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x002d_Prasertsawat-1995" NAME="O-Prasertsawat 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O-Prasertsawat P, Bourlert A</AU>
<TI>Comparative study of fluconazole and clotrimazole for the treatment of vulvovaginal candidiasis</TI>
<SO>Sexually Transmitted Diseases</SO>
<YR>1995</YR>
<VL>22</VL>
<NO>4</NO>
<PG>228-230</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Osser-1991" NAME="Osser 1991" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Osser S, Haglund A, Westrom L</AU>
<TI>Treatment of candidal vaginitis. A prospective randomized investigator-blind multicenter study comparing topically applied econazole with oral fluconazole</TI>
<SO>Acta Obstetricia Gynaecologie Scandinavia</SO>
<YR>1991</YR>
<VL>70</VL>
<PG>73-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Westrom L, Haglund A, Svensson L</AU>
<TI>Fluconazole versus econazole in treating vaginal candidiasis</TI>
<SO>International Journal of Gynaecology and Obstetrics</SO>
<YR>1992</YR>
<VL>37</VL>
<NO>Supplement</NO>
<PG>29-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seidman-2005" NAME="Seidman 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Seidman LS, Skokos CK</AU>
<TI>An evaluation of butoconazole nitrate 2% Site Release vaginal cream (Gynazole-1) compared to fluconazole 150 mg tablets (Diflucan) in the time to relief of symptoms in patients with vulvovaginal candidiasis</TI>
<SO>Infectious Diseases in Obstetrics and Gynecology</SO>
<YR>2005</YR>
<VL>13</VL>
<NO>4</NO>
<PG>197-206</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Slavin-1992" NAME="Slavin 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Slavin MB, Benrubi GI, Parker R, Griffin CR, Magee MJ</AU>
<TI>Single dose oral fluconazole vs intravaginal terconazole in treatment of candida vaginitis</TI>
<SO>Journal of Florida Medical Association</SO>
<YR>1992</YR>
<VL>79</VL>
<NO>10</NO>
<PG>693-696</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sobel-1995" NAME="Sobel 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sobel JD, Brooker D, Stein GE, Thomason JL, Wermeling DP, Bradley B, Weinstein L, the Fluconazole Vaginitis Study Group</AU>
<TI>Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis</TI>
<SO>American Journal of Obstetrics and Gynaecology</SO>
<YR>1995</YR>
<VL>172</VL>
<PG>1263-1268</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stein-1991" NAME="Stein 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stein GE, Christensen S, Mummaw N</AU>
<TI>Comparative study of fluconazole and clotrimazole in the treatment of vulvovaginal candidiasis</TI>
<SO>DICP, The Annals of Pharmacotherapy</SO>
<YR>1991</YR>
<VL>25</VL>
<PG>582-585</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stein-1993" NAME="Stein 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stein GE, Mummaw N</AU>
<TI>Placebo-controlled trial of itraconazole for treatment of acute vaginal candidiasis</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1993</YR>
<VL>37</VL>
<NO>1</NO>
<PG>89-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Timonen-_x0028_1_x0029_-1992" NAME="Timonen (1) 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Timonen H, Hartikainen-Vahtera P, Kivijarvi A, Kohtamaki K, Kosunen M, Lehtonen L, Piepponen T</AU>
<TI>A double-blind comparison of the effectiveness of itraconazole oral capsules with econazole vaginal capsules in the treatment of vaginal candidosis</TI>
<SO>Drug Investigation</SO>
<YR>1992</YR>
<VL>4</VL>
<NO>6</NO>
<PG>515-520</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Timonen-_x0028_2_x0029_-1992" NAME="Timonen (2) 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Timonen H, Fluconazole Study Group</AU>
<TI>Shorter treatment for vaginal candidosis: comparison between single-dose oral fluconazole and three-day treatment with local miconazole</TI>
<SO>Mycoses</SO>
<YR>1992</YR>
<VL>35</VL>
<PG>317-320</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tobin-1992" NAME="Tobin 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tobin JM, Loo P, Granger SE</AU>
<TI>Treatment of vaginal candidosis: A comparative study of the efficacy and acceptability of itraconazole and clotrimazole</TI>
<SO>Genitourinary Medicine</SO>
<YR>1992</YR>
<VL>68</VL>
<PG>36-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Heusden-1990" NAME="Van Heusden 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Van Heusden AM, Merkus HMWM, Corbeij RSACM, Oosterbaan HP, Stoot JEGM, Ubachs HMH, Verhoeff A</AU>
<TI>Single-dose oral fluconazole versus single-dose topical miconazole for the treatment of acute vulvovaginal candidosis</TI>
<SO>Acta Obstetricia Gynaecologie Scandinavia</SO>
<YR>1990</YR>
<VL>69</VL>
<PG>417-422</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Heusden-1994" NAME="Van Heusden 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Heusden AM, Merkus HMWM, Euser R, Verhoeff A</AU>
<TI>A randomized, comparative study of a single oral dose of fluconazole versus a single topical dose of clotrimazole in the treatment of vaginal candidosis among general practitioners and gynaecologists</TI>
<SO>European Journal of Obstetrics and Gynaecology and Reproductive Biology</SO>
<YR>1994</YR>
<VL>55</VL>
<PG>123-127</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Woolley-_x0028_1_x0029_-1995" NAME="Woolley (1) 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Woolley PD</AU>
<TI>Comparison of clotrimazole, fluconazole and itraconazole in vaginal candidiasis</TI>
<SO>British Journal of Clinical Practice</SO>
<YR>1995</YR>
<VL>49</VL>
<NO>2</NO>
<PG>65-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Woolley-_x0028_2_x0029_-1995" NAME="Woolley (2) 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Woolley PD</AU>
<TI>Comparison of clotrimazole, fluconazole and itraconazole in vaginal candidiasis</TI>
<SO>British Journal of Clinical Practice</SO>
<YR>1995</YR>
<VL>49</VL>
<NO>2</NO>
<PG>65-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Fong" NAME="Fong" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fong IW</AU>
<TI>The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vagianl candidiasis</TI>
<SO>Genitourinary Medicine</SO>
<YR>1992</YR>
<VL>68</VL>
<PG>374-377</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herzog" NAME="Herzog" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herzog RE, Ansmann EB</AU>
<TI>Treatment of vaginal candidosis with fluconazole</TI>
<SO>Mycoses</SO>
<YR>1989</YR>
<VL>32</VL>
<NO>4</NO>
<PG>204-208</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lopez-Olmos-J-1994" NAME="Lopez Olmos J 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lopez Olmos J, Parra, I</AU>
<TI>Vaginal candidiasis treatment: Prospective comparative study of three commercial products with a single dose</TI>
<SO>Clinica e Investigacion en Ginecologia y Obstetricia</SO>
<YR>1994</YR>
<VL>21</VL>
<NO>7</NO>
<PG>300-306</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="AN 94291310"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mikamo-1998" NAME="Mikamo 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mikamo H, Kawazoe K, Sato Y, Hayasaki Y, Tamaya T</AU>
<TI>Comparative study on the effectiveness of antifungal agents in different regimens against vaginal candidiasis</TI>
<SO>Chemotherapy</SO>
<YR>1998</YR>
<VL>34</VL>
<PG>364-368</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wermeling" NAME="Wermeling" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wermeling DP, McCraney SA</AU>
<TI>Single dose oral fluconazole versus miconazole vaginal cream in the treatment of vaginal candidiasis</TI>
<SO>International Pharmaceutical Abstracts (ASHP Midyear Clinical Meeting 27:SPG-61 (Dec) 1992)</SO>
<PG>196</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-10-29 16:57:01 -0400" MODIFIED_BY="Karen Hovhannisyan">
<ADDITIONAL_REFERENCES MODIFIED="2008-10-29 16:57:01 -0400" MODIFIED_BY="Karen Hovhannisyan">
<REFERENCE ID="REF-Anonymous-1999" MODIFIED="2008-10-29 16:57:01 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Anonymous 1999" TYPE="JOURNAL_ARTICLE">
<AU>Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases)</AU>
<TI>National guideline for the management of vulvovaginal candidiasis</TI>
<SO>Sexually Transmitted Infections</SO>
<YR>1999</YR>
<VL>75</VL>
<NO>Supplement 1</NO>
<PG>S19-S20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-_x0028_1_x0029_-1997" MODIFIED="2008-10-29 16:57:01 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Egger (1) 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Zellweger-Zahner T, Schneider M, Junker C, Lengeler C, Antes G</AU>
<TI>Language bias in randomised controlled trials published in English and German</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>350</VL>
<PG>326-329</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-_x0028_2_x0029_-1997" NAME="Egger (2) 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>British Medical Journal</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-634</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fong-1996" NAME="Fong 1996" TYPE="JOURNAL_ARTICLE">
<AU>Fong IW</AU>
<TI>Clinical and cost considerations in the pharmacotherapy of vulvovaginal candidiasis</TI>
<SO>Pharmacoeconomics</SO>
<YR>1996</YR>
<VL>9</VL>
<NO>6</NO>
<PG>497-505</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Martindale-1999" MODIFIED="2008-10-29 16:57:01 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Martindale 1999" TYPE="BOOK">
<AU>Royal Pharmaceutical Society of Great Britain</AU>
<YR>1999</YR>
<EN>32nd</EN>
<PB>Pharmaceutical Press</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1996" MODIFIED="2008-10-29 16:57:01 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Moher 1996" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Fortin P, Jada AR, Juni P, Klassen T, Le Lorier J, Liberati A, Linde K, Penna A</AU>
<TI>Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>347</VL>
<PG>363-366</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reed-1992" MODIFIED="2008-10-29 16:57:01 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Reed 1992" TYPE="JOURNAL_ARTICLE">
<AU>Reed RD</AU>
<TI>Risk factors for Candida Vulvovaginitis</TI>
<SO>Obstetrical and Gynecological Survey</SO>
<YR>1992</YR>
<VL>47</VL>
<NO>8</NO>
<PG>551-560</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rex-2000" MODIFIED="2008-10-29 16:57:01 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Rex 2000" TYPE="JOURNAL_ARTICLE">
<AU>Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, Edwards JE</AU>
<TI>Practice guidelines for the treatment of candidiasis</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2000</YR>
<VL>30</VL>
<PG>662-678</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rochon-1994" MODIFIED="2008-10-29 16:57:01 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Rochon 1994" TYPE="JOURNAL_ARTICLE">
<AU>Rochon PA, Gurwitz JH, Simms RW</AU>
<TI>A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis</TI>
<SO>Archives Of Internal Medicine</SO>
<YR>1994</YR>
<VL>154</VL>
<PG>157-163</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2008-10-29 16:57:01 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF</AU>
<TI>Subverting randomization in controlled trials</TI>
<SO>Journal of American Medical Association</SO>
<YR>1995</YR>
<VL>274</VL>
<PG>1456-1458</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sobel-1993" MODIFIED="2008-10-29 16:57:01 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Sobel 1993" TYPE="JOURNAL_ARTICLE">
<AU>Sobel JD</AU>
<TI>Candidal vulvovaginitis</TI>
<SO>Clinical Obstetrics and Gynaecology</SO>
<YR>1993</YR>
<VL>36</VL>
<NO>1</NO>
<PG>153-165</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spinillo-1997" MODIFIED="2008-10-29 16:57:01 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Spinillo 1997" TYPE="JOURNAL_ARTICLE">
<AU>Spinillo A, Capuzzo E, Gulminetti R, Marone P, Colonna L, Piazzi G</AU>
<TI>Prevalence and risk factors for fungal vaginitis caused by non-albicans species</TI>
<SO>American Journal of Obstetrics and Gynaecology</SO>
<YR>1997</YR>
<VL>176</VL>
<NO>1</NO>
<PG>138-141</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Young-2001" MODIFIED="2008-10-29 16:57:01 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Young 2001" TYPE="COCHRANE_REVIEW">
<AU>Young GL, Jewell D</AU>
<TI>Topical treatment for vaginal candidiasis in pregnancy (Cochrane Review)</TI>
<SO>The Cochrane Library</SO>
<YR>2001</YR>
<NO>2</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Adetoro-1990">
<CHAR_METHODS>
<P>Random allocation: Done<BR/>Randomisation method: Predetermined code<BR/>Unit of randomisation: Participant<BR/>Level of blinding: Open<BR/>Follow-up: 100%<BR/>Compliance checks: Not specified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Age: &gt;15 (17-30) years<BR/>Country: Nigeria<BR/>Setting: Gynaecological &amp; "special treatment" clinics<BR/>Diagnosis: Mycological culture, positive microscopic smear &amp; clinical symptoms.<BR/>Characteristics: non-lactating</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Fluconazole (oral) 150mg single dose <BR/>Group 2: Clotrimazole 500mg vaginal tablet single dose<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Assessed at 8 &amp; 32 days.<BR/>EFFICACY: <BR/>Mycological cure - negative culture and negative microscopy<BR/>Clinical Improvement: Cure or, persistence of C. albicans and absence of symptoms.<BR/>SAFETY:<BR/>Number of side-effects reported.<BR/>Patient preference: Reported<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance check: Not reported<BR/>Pharmaceutical Industry support: Not specified<BR/>The results do not distinguish between clinical and mycological cure</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Anonymous-1989">
<CHAR_METHODS>
<P>Random allocation: Done<BR/>Randomisation method: Computer-generated randomisation list code, using blocks of four<BR/>Level of blinding: Single blind (investigator)<BR/>Follow-up: 82.7%<BR/>Compliance check: Not specified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Age: &gt; 18<BR/>Country: European<BR/>Setting: Not specified<BR/>Diagnosis: Mycological culture &amp; microscopy<BR/>Characteristics: non-lactating</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Fluconazole (oral) 150mg single dose <BR/>Group 2: Clotrimazole 200mg vaginal tablets for 3 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Assessed at 5-16 days &amp; 27-62 days. <BR/>EFFICACY:<BR/>Clinical improvement: response / relief from symptoms &amp; elimination of signs of vaginal infection. "Favourable" clinical response if cured or improved.<BR/>Mycological cure: Eradication of Candida (negative culture and microscopy)<BR/>Safety: Participant reported side-effects.<BR/>Participant preference: Reported for one study centre.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance check: Not reported<BR/>Pharmaceutical Industry Support: Yes</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Boag-1991">
<CHAR_METHODS>
<P>Random allocation: Done<BR/>Randomisation method: Predetermined code<BR/>Unit of randomisation: Participant<BR/>Level of blinding: Not specified<BR/>Follow-up: 90.9%<BR/>Compliance check: Yes - administered under nurse supervision</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Age: Not specified<BR/>Country: UK<BR/>Setting: Genito-urinary medicine clinic<BR/>Diagnosis: Mycological culture &amp; clinical symptoms<BR/>Characteristics: Non-lactating</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Fluconazole (oral) 150mg single dose <BR/>Group 2: Clotrimazole 500mg pessary (single dose) <BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Assessed at 2, 4, 6 &amp; 10 days after treatment.<BR/>EFFICACY: <BR/>Mycological cure: No yeasts isolated <BR/>SAFETY:<BR/>Not assessed<BR/>Patient preference: Not assessed</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance check: DONE (nurse-administered)<BR/>Pharmaceutical Industry Support: Not specified</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Goode-1992">
<CHAR_METHODS>
<P>Random allocation: Done<BR/>Randomisation method: Not specified<BR/>Unit of randomisation: Participant<BR/>Level of blinding: Not specified<BR/>Follow-up: 42.9%<BR/>Compliance checks: Not specified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Age: Not specified<BR/>Country: USA<BR/>Setting: Not specified<BR/>Diagnosis: Mycological culture<BR/>Characteristics: Not specified</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Fluconazole (oral) 150mg single dose<BR/>Group 2: Clotrimazole vaginal tablets 100mg for 7 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Assessed at 2 &amp; 4 weeks.<BR/>EFFICACY: <BR/>Clinical cure - complete relief of symptoms<BR/>SAFETY: <BR/>Not reported<BR/>Patient preference: Not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance check: Not reported<BR/>Pharmaceutical Industry Support: Not specified</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Mendling-_x0028_1_x0029_-2004">
<CHAR_METHODS>
<P>Random allocation: Done<BR/>Randomisation method: Not specified<BR/>Unit of randomisation: Participant<BR/>Level of blinding: Single blind<BR/>Follow-up:<BR/>Compliance checks: Not specified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Age: Not specified<BR/>Country: Germany<BR/>Setting: Not specified<BR/>Diagnosis: Visual examination, KOH, Mycological culture<BR/>Characteristics: Not specified</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Clotrimazol 500mg vaginal tablet single dose<BR/>Group 2: Fluconazole (oral) 150mg single dose</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Assessed at 2, 4 and 8 weeks<BR/>EFFICACY:<BR/>Mycological cure: Mycological culture results<BR/>Clinical cure: Overall response - resolution of signs &amp; symptoms and culture results<BR/>Safety: Adverse events reported<BR/>Participant preference: Not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance check: Not reported<BR/>Pharmaceutical Industry support: Not specified</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Mendling-_x0028_2_x0029_-2004">
<CHAR_METHODS>
<P>Random allocation: Done<BR/>Randomisation method: Not specified<BR/>Unit of randomisation: Participant<BR/>Level of blinding: Single blind<BR/>Follow-up:<BR/>Compliance checks: Not specified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Age: Not specified<BR/>Country: Germany<BR/>Setting: Not specified<BR/>Diagnosis: Visual examination, KOH, Mycological culture<BR/>Characteristics: Not specified</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Clotrimazol 10% vaginal cream single dose<BR/>Group 2: Fluconazole (oral) 150mg single dose</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Assessed at 2, 4 and 8 weeks<BR/>EFFICACY:<BR/>Mycological cure: Mycological culture results<BR/>Clinical cure: Overall response - resolution of signs &amp; symptoms and culture results<BR/>Safety: Adverse events reported<BR/>Participant preference: Not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance check: Not reported<BR/>Pharmaceutical Industry support: Not specified</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Mikamo-_x0028_1_x0029_-1995">
<CHAR_METHODS>
<P>Random allocation: Done<BR/>Randomisation method: Not specified<BR/>Unit of randomisation: Participant<BR/>Level of blinding: Open<BR/>Follow-up: 100%<BR/>Compliance checks: Not specified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Age: 18-54<BR/>Country: Japan<BR/>Setting: O&amp;G OPD<BR/>Diagnosis: Mycological culture<BR/>Characteristics: Non-pregnant &amp; non-lactating</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Fluconazole (oral) 150mg single dose<BR/>Group 2: Clotrimazole vaginal 100mg for 6 days.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Assessed at 5-15 days &amp; 30-60 days.<BR/>EFFICACY: <BR/>Clinical cure - complete disappearance of presenting signs &amp; symptoms<BR/>Mycological cure: negative culture &amp; microscopy for Candida species<BR/>SAFETY: <BR/>No withdrawals due to adverse drug reaction.<BR/>Patient preference: Not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance check: Not reported<BR/>Pharmaceutical Industry Support: Not specified</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Mikamo-_x0028_2_x0029_-1995">
<CHAR_METHODS>
<P>Random allocation: Done<BR/>Randomisation method: Not specified<BR/>Unit of randomisation: Participant<BR/>Level of blinding: Open<BR/>Follow-up: 100%<BR/>Compliance checks: Not specified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Age: 18-54<BR/>Country: Japan<BR/>Setting: O&amp;G OPD<BR/>Diagnosis: Mycological culture<BR/>Characteristics: Non-pregnant &amp; non-lactating</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Fluconazole (oral) 50mg for 6 days<BR/>Group 2: Clotrimazole vaginal 100mg for 6 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Assessed at 5-15 days &amp; 30-60 days.<BR/>EFFICACY: <BR/>Clinical cure - complete disappearance of presenting signs &amp; symptoms<BR/>Mycological cure: negative culture &amp; microscopy for Candida species<BR/>SAFETY: <BR/>No withdrawals due to adverse drug reaction.<BR/>Patient preference: Not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance check: Not reported<BR/>Pharmaceutical Industry Support: Not specified</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-O_x002d_Prasertsawat-1995">
<CHAR_METHODS>
<P>Random allocation: Done<BR/>Randomisation method: Patients selected a box containing one of the two anti-fungal drugs.<BR/>Unit of randomisation: Participant<BR/>Level of blinding: Single Blind<BR/>(Investigator)<BR/>Follow-up: 95.1%<BR/>Compliance checks: Yes - participant questioned regarding use of anti-fungal drugs</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Age: 25-43 years<BR/>Country: Thailand<BR/>Setting: Obstetrics and gynaecology out-patient department<BR/>Diagnosis: Visual examination, mycological culture &amp; clinical symptoms <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Fluconazole (oral)150mg single dose <BR/>Group 2: Clotrimazole vaginal tablets 200mg for 3 days.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Assessed at 1 and 4 weeks.<BR/>EFFICACY: <BR/>Mycological cure - failure to grow Candida species.<BR/>SAFETY: Reported side-effects<BR/>Participant preference: Not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance Check: DONE (subjects questioned regarding the use of their anti-fungals)<BR/>Pharmaceutical Industry Support: Not specified</P>
<P>The denominator for each outcome was based upon the number randomised as the authors did not indicate at what stage the patient withdrawals from the study occurred.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Osser-1991">
<CHAR_METHODS>
<P>Random allocation: Done<BR/>Randomisation method: Not specified<BR/>Unit of randomisation: Participant<BR/>Level of blinding: Single (investigator)<BR/>Follow-up: 75.3%<BR/>Compliance check: Yes - questioning at 7-10 day follow-up.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Age: 15-60 years<BR/>Country: Sweden<BR/>Setting: O&amp;G OPD<BR/>Diagnosis: Visual examination, KOH, mycological culture, clinical symptoms.<BR/>Characteristics: Non-pregnant<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Econazole 150mg vaginal depot tablet, single dose.<BR/>Group 2: Fluconazole (oral) 150mg single dose.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Measured at 7-10 days, 28-35 days &amp; 80-100 days.<BR/>EFFICACY: Mycological &amp; clinical cure.<BR/>SAFETY: Participant reported side effects.<BR/>Participant preference: Reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance check: DONE (subjects questioned regarding their anti-fungal use at follow-up visit)<BR/>Pharmaceutical Industry Support: YES</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Seidman-2005">
<CHAR_METHODS>
<P>Random allocation: Done<BR/>Randomisation method: Not specified<BR/>Unit of randomisation: Participant<BR/>Level of blinding: Open<BR/>Follow-up: 100%<BR/>Compliance checks: Yes - administered in investigators office</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Age: 18 years and over<BR/>Country: USA<BR/>Setting: Not specified - Research facilities<BR/>Diagnosis: Visual examination, KOH, patient report of signs &amp; symptoms, Severity score<BR/>Characteristics: Non-pregnant</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Butoconazole 5g vaginal cream (2% site release) single dose<BR/>Group 2: Fluconazole (oral) 150mg single dose</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Assessed hourly by patient report<BR/>EFFICACY:<BR/>Clinical cure: time to total relief of symptoms<BR/>Clinical Improvement - time to first relief of symptoms<BR/>Safety: Participant reported adverse events<BR/>Participant preference: Reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance check: DONE<BR/>Pharmaceutical Industry support: Not specified</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Slavin-1992">
<CHAR_METHODS>
<P>Random allocation: Done<BR/>Randomisation method: Random numbers<BR/>Unit of randomisation: Participant<BR/>Level of blinding: Double<BR/>Follow-up: 95.4%<BR/>Compliance check: Yes - participant questioned at 7-14 day follow-up visit</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Age: 18-60 years<BR/>Country: USA<BR/>Setting: Obstetrics and gynaecology out-patient department<BR/>Diagnsosis: Microscopic evidence of hyphae from wet mount with gram stain<BR/>Characteristics: Non-lactating.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Fluconazole (oral) 200mg single dose<BR/>Group 2: Terconazole 80mg intravaginal suppository daily for 3 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Assessed at 7-14 days &amp; 28-34 days.<BR/>EFFICACY:<BR/>Mycological cure - negative gram stain &amp; wet mount.<BR/>Clinical Improvement - favourable clinical response (mycologic cure or improved symptoms.<BR/>Safety: Adverse drug effects reports.<BR/>Participant preference: Reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance check: DONE (subjects questioned regarding their anti-fungal use at yearly follow-up)<BR/>Pharmaceutical Industry Support: Not specified</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sobel-1995">
<CHAR_METHODS>
<P>Random allocation: Done<BR/>Randomisation method: Not specified (stratified)<BR/>Unit of randomisation: Participant<BR/>Level of blinding: Single (investigator)<BR/>Follow-up: 93.8%<BR/>Compliance check: Yes - participant history &amp; pill count</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Age: 17-64 years<BR/>Country: USA<BR/>Setting: Not specified<BR/>Diagnosis: KOH, mycological culture &amp; clinical symptoms.<BR/>Characteristics: Non-lactating</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Fluconazole (oral) 150mg single dose<BR/>Group 2: Clotrimazole vaginal tablets (one tablet, strength not stated) for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Assessed at 14 &amp; 35 days.<BR/>EFFICACY: Mycological - no mycological colonisation<BR/>Clinical cure - absence of signs &amp; symptoms of vaginitis.<BR/>SAFETY: Participant reported side effects<BR/>Participant preference - Not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance check: DONE (subject reported anti-fungal use and pill count)<BR/>Pharmaceutical Industry Support: YES<BR/>Participants had acute or recurrent vaginal candidiasis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Stein-1991">
<CHAR_METHODS>
<P>Random allocation: Done<BR/>Randomisation method: Predetermined randomisation code<BR/>Unit of randomisation: Participant<BR/>Level of blinding: Not specified<BR/>Follow-up: 93.0%<BR/>Compliance check: Not specified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Age: 18-65 years<BR/>Country: USA<BR/>Setting: Primary Care Clinics<BR/>Diagnosis: Visual <BR/>examination, KOH and mycological culture<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Fluconazole (oral) 50mg for 3 days<BR/>Group 2: Clotrimazole intravaginal tablets 200mg for 3 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Assessed at 7-10 days &amp; 30-35 days.<BR/>EFFICACY: Mycological cure - absence of candida species<BR/>Clinical cure - complete resolution of signs &amp; symptoms<BR/>SAFETY:<BR/>Participant reported side effects<BR/>Patient preference: Reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance check: Not reported<BR/>Pharmaceutical Industry Support: YES</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Stein-1993">
<CHAR_METHODS>
<P>Random allocation: Done<BR/>Randomisation method: Predetermined randomisation code<BR/>Unit of randomisation: Participant<BR/>Level of blinding: Not specified<BR/>Follow-up: 77.9%<BR/>Compliance check: Not specified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Age: 18 years and over<BR/>Country: USA<BR/>Setting: Not specified<BR/>Diagnosis: KOH &amp; clinical symptoms &amp; mycological culture.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Itraconazole (oral) 200mg for 3 days<BR/>Group 2: Clotrimazole vaginal tablets 200mg for 3 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Assessed at 1 &amp; 4 weeks.<BR/>EFFICACY: <BR/>Mycological cure - absence of Candida species<BR/>Clinical cure - complete resolution of signs &amp; symptoms SAFETY: Reported side-effects<BR/>Participant preference: Not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance Check: Not reported<BR/>Pharmaceutical Industry Support: YES</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Timonen-_x0028_1_x0029_-1992">
<CHAR_METHODS>
<P>Random allocation: Done<BR/>Randomisation method: Not specified<BR/>Unit of randomisation: Participant<BR/>Level of blinding: Open<BR/>Follow-up: not calculable<BR/>Compliance check: Not specified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Age: 18 years and over<BR/>Country: Finland<BR/>Setting: Not specified<BR/>Diagnosis: Mycological culture &amp; clinical symptoms<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Fluconazole (oral) 150mg single dose<BR/>Group 2: Miconazole 400mg pessary for 3 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Assessed at 1 week &amp; 1 month<BR/>EFFICACY:<BR/>Mycological - negative yeast culture<BR/>Clinical cure - asymptomatic<BR/>SAFETY: Reported side-effects<BR/>Participant preference: Reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance check: Not reported<BR/>Pharmaceutical Industry Support: Not Specified</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Timonen-_x0028_2_x0029_-1992">
<CHAR_METHODS>
<P>Random allocation: Done<BR/>Randomisation method: Not specified<BR/>Unit of randomisation: Participant<BR/>Level of blinding: Double<BR/>Follow-up: Not calculable<BR/>Compliance check: Not specified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Age: 20-51 years<BR/>Country: Finland<BR/>Setting: Out-patients (department not defined)<BR/>Diagnosis: Mycological culture<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Itraconazole 200mg for 3 days.<BR/>Group 2: Econazole 150mg for 3 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Assessed at 1 and 2 weeks<BR/>EFFICACY:<BR/>Mycological cure - negative gram stain &amp; wet mount.<BR/>Clinical Improvement - favourable clinical response (mycologic cure or improved symptoms.<BR/>Safety: Adverse drug effects reports.<BR/>Participant preference: Reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance check: Not reported<BR/>Pharmaceutical Industry Support: YES</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tobin-1992">
<CHAR_METHODS>
<P>Random allocation: Done<BR/>Randomisation method: Not specified<BR/>Unit of randomisation: Participant<BR/>Level of Blinding: Single blind (investigator)<BR/>Follow-up: 68.7%<BR/>Compliance check: Not specified<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Age: 18 years and over<BR/>Country: UK<BR/>Setting: Genito-urinary medicine clinics<BR/>Diagnosis: Visual examination, mycological culture &amp; clinical symptoms (vulvitis, vaginitis).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Itraconazole 200mg BD for one day<BR/>Group 2: Clotrimazole 500mg - Single dose</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Assessed at 5-10 days and 30-40 days:<BR/>Mycological cure: negative culture for Candida species.<BR/>Safety: Not assessed<BR/>Participant preference: Reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance Check: Not reported<BR/>Pharmaceutical Industry Support: YES</P>
<P>Participants permitted to use "bland soothing agent" and to record use in diary.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Van-Heusden-1990">
<CHAR_METHODS>
<P>Random allocation: Done<BR/>Randomisation method: Not specified<BR/>Unit of randomisation: Participant<BR/>Level of blinding: Double<BR/>Follow-up: 93.9%<BR/>Compliance check: Not specified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Age: 18-60 years<BR/>Country: Netherlands<BR/>Setting: Out-patients - department not specified<BR/>Diagnosis: Mycological culture &amp; clinical symptoms<BR/>Characteristics: Non-lactating</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Fluconazole (oral) 150mg single dose<BR/>Group 2: Miconazole 1200mg intravaginal single dose</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Assessed at 6-10 days (short-term) and 22-60 days (long-term) follow-up.<BR/>EFFICACY:<BR/>Mycological cure - complete absence of Candida species at follow-up.<BR/>Clinical cure - physician subjective global assessment.<BR/>SAFETY: Participant reported side effects.<BR/>Participant preference: Reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance check: Not reported<BR/>Pharmaceutical Industry Support: Not specified</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Van-Heusden-1994">
<CHAR_METHODS>
<P>Random allocation: Done<BR/>Randomisation method: Predetermined computer-generated code<BR/>Unit of randomisation: Participant<BR/>Level of blinding: Not specified<BR/>Follow-up: not-calculable<BR/>Compliance check: Not specified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Age: 18-65 years<BR/>Country: Netherlands<BR/>Setting: Obstetrics and Gynaecology Out-Patient Department and General Practices<BR/>Diagnosis: Mycological culture &amp; clinical symptoms<BR/>Characteristics: Non-lactating</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Fluconazole (oral) 150mg single dose<BR/>Group 2: Clotrimazole intra-vaginal tablets 500mg single dose</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Assessed at 7 &amp; 28 days<BR/>EFFICACY:<BR/>Mycological cure- complete absense of Candida species<BR/>Safety: Adverse drug effects reports.<BR/>Participant preference: Reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance check: Not reported<BR/>Pharmaceutical Industry Support: Not specified</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Woolley-_x0028_1_x0029_-1995">
<CHAR_METHODS>
<P>Random allocation: Done<BR/>Randomisation method: Not specified<BR/>Unit of randomisation: Participant<BR/>Level of blinding: Single (investigator)<BR/>Follow-up: 100%<BR/>Compliance check: Not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Age: 16-53 years<BR/>Country: UK<BR/>Setting: Genito-urinary Medicine Clinic<BR/>Diagnosis: Mycological &amp;/or microscopic.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Clotrimazole pessary 500mg (single dose) &amp; 1% cream.<BR/>Group 2: Fluconazole (oral) 150mg single dose</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Assessed at 7-10 days.<BR/>EFFICACY:<BR/>Mycological cure - negative culture &amp; tests for Candida<BR/>Clinical cure - assessed by physician<BR/>SAFETY:<BR/>Not reported<BR/>Patient preference: <BR/>Not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance check: Not reported<BR/>Pharmaceutical Industry Support: Not specified</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Woolley-_x0028_2_x0029_-1995">
<CHAR_METHODS>
<P>Random allocation: Done<BR/>Randomisation method: Not specified<BR/>Unit of randomisation: Participant<BR/>Level of blinding: Single (investigator)<BR/>Follow-up: 100%<BR/>Compliance check: Not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Age: 16-53 years<BR/>Country: UK<BR/>Setting: Genito-urinary Medicine Clinic<BR/>Diagnosis: Mycological &amp;/or microscopic.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Clotrimazole pessary 500mg (single dose) &amp; 1% cream.<BR/>Group 2: Itraconazole (oral) 200mg twice daily for one day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Assessed at 7-10 days.<BR/>EFFICACY:<BR/>Mycological cure - negative culture &amp; tests for Candida<BR/>Clinical cure - assessed by physician<BR/>SAFETY:<BR/>Not reported<BR/>Patient preference: Not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance check: Not reported<BR/>Pharmaceutical Industry Support: Not specified</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>O&amp;G OPD = Obstetrics and Gynaecology Out-Patient Department<BR/>KOH = Potassium Hydroxide</P>
<P>Adetoro - actual subject numbers not presented for mycological outcome - only percentage values given<BR/>Anonymous - % follow-up calculated based on number randomised<BR/>Osser - 19 fluconazole and 14 econazole subjects had experienced at least 3 episodes of VVC in the previous 12 months<BR/>Sobel included acute and chronic cases of vaginal candidiasis. Only the results for acute cases are presented.<BR/>Timonen (1) Results calculated from percentages quoted by authors. Five itraconazole and eight econazole subjects had chronic vaginal candidiasis (i.e. 3 or more episodes in previous 12 months) - results not reported seperately<BR/>Van Heusden (2) Results calculated from percentages quoted by authors<BR/>Seidman Patients were provided with a diary and requested to record the date and time they first started to feel relief of symptoms and the date and time they had complete relief of symtoms. Outcomes were calulated using the dosing time and the time reported for each by the patient.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Fong">
<CHAR_REASON_FOR_EXCLUSION>
<P>All participants had recurrent candidiasis as opposed to acute, uncomplicated vaginal candidiasis which is covered by this review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Herzog">
<CHAR_REASON_FOR_EXCLUSION>
<P>Random allocation not specified.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lopez-Olmos-J-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Random allocation not specified.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mikamo-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>The reviewers believe that the some of the subjects reported in this trial were reported in a previous trial (Mikamo 1995). This trial has been excluded to avoid duplicate use of data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wermeling">
<CHAR_REASON_FOR_EXCLUSION>
<P>No results presented.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Adetoro-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Anonymous-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Boag-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Goode-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Mendling-_x0028_1_x0029_-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Mendling-_x0028_2_x0029_-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Mikamo-_x0028_1_x0029_-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Mikamo-_x0028_2_x0029_-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-O_x002d_Prasertsawat-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Osser-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Seidman-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Slavin-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sobel-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Stein-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Stein-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Timonen-_x0028_1_x0029_-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Timonen-_x0028_2_x0029_-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tobin-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Van-Heusden-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Van-Heusden-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Woolley-_x0028_1_x0029_-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Woolley-_x0028_2_x0029_-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-10-29 16:57:01 -0400" MODIFIED_BY="Karen Hovhannisyan">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-10-29 16:57:01 -0400" MODIFIED_BY="Karen Hovhannisyan" NO="1">
<TITLE>Duration of follow-up (for primary and/or secondary outcome measures)</TITLE>
<TABLE COLS="5" ROWS="20">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>T1</P>
</TH>
<TH>
<P>T2</P>
</TH>
<TH>
<P>T3</P>
</TH>
<TH>
<P>T4</P>
</TH>
</TR>
<TR>
<TD>
<P>Adetoro</P>
</TD>
<TD>
<P>8 days</P>
</TD>
<TD>
<P>32 days</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Anonymous</P>
</TD>
<TD>
<P>5-16 days</P>
</TD>
<TD>
<P>27-62 days</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Boag</P>
</TD>
<TD>
<P>1-3 days</P>
</TD>
<TD>
<P>4-5 days</P>
</TD>
<TD>
<P>6-8 days</P>
</TD>
<TD>
<P>9-12 days</P>
</TD>
</TR>
<TR>
<TD>
<P>Goode</P>
</TD>
<TD>
<P>2 weeks</P>
</TD>
<TD>
<P>4 weeks</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Mendling</P>
</TD>
<TD>
<P>2 weeks</P>
</TD>
<TD>
<P>4 weeks</P>
</TD>
<TD>
<P>8 weeks</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Mikamo</P>
</TD>
<TD>
<P>5 - 15 days</P>
</TD>
<TD>
<P>30-60 days</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>O-Prasertsawat</P>
</TD>
<TD>
<P>1 week</P>
</TD>
<TD>
<P>4 weeks</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Osser</P>
</TD>
<TD>
<P>7 - 10 days</P>
</TD>
<TD>
<P>28-35 days</P>
</TD>
<TD>
<P>80-100 days</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Seidman</P>
</TD>
<TD>
<P>hourly</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Slavin</P>
</TD>
<TD>
<P>7-14 days</P>
</TD>
<TD>
<P>28-34 days</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Sobel</P>
</TD>
<TD>
<P>14 days</P>
</TD>
<TD>
<P>35 days</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Stein (1)</P>
</TD>
<TD>
<P>1 week</P>
</TD>
<TD>
<P>4 weeks</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Stein (2)</P>
</TD>
<TD>
<P>7-10 days</P>
</TD>
<TD>
<P>30-35 days</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Timonen (1)</P>
</TD>
<TD>
<P>1 week</P>
</TD>
<TD>
<P>2 weeks</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Timonen (2)</P>
</TD>
<TD>
<P>1 week</P>
</TD>
<TD>
<P>1 month</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tobin</P>
</TD>
<TD>
<P>5-10 days</P>
</TD>
<TD>
<P>30-40 days</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Van Heusden (1)</P>
</TD>
<TD>
<P>6 - 10 days</P>
</TD>
<TD>
<P>22-60 days</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Van Heusden (2)</P>
</TD>
<TD>
<P>7 days</P>
</TD>
<TD>
<P>28 days</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Woolley</P>
</TD>
<TD>
<P>7-10 days</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" NO="2">
<TITLE>Quality measures</TITLE>
<TABLE COLS="5" ROWS="20">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Random Allocation</P>
</TH>
<TH>
<P>Allocation Concealed</P>
</TH>
<TH>
<P>% Follow-up</P>
</TH>
<TH>
<P>Blinded Outcome</P>
</TH>
</TR>
<TR>
<TD>
<P>Adetoro</P>
</TD>
<TD>
<P>DONE</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Anonymous</P>
</TD>
<TD>
<P>DONE</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>89.4</P>
</TD>
<TD>
<P>DONE</P>
</TD>
</TR>
<TR>
<TD>
<P>Boag</P>
</TD>
<TD>
<P>DONE</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>90.9</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Goode</P>
</TD>
<TD>
<P>DONE</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>83.3</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Mendling</P>
</TD>
<TD>
<P>DONE</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>69.5</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Mikamo</P>
</TD>
<TD>
<P>DONE</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>O-Prasertsawat</P>
</TD>
<TD>
<P>DONE</P>
</TD>
<TD>
<P>DONE</P>
</TD>
<TD>
<P>95.1</P>
</TD>
<TD>
<P>DONE</P>
</TD>
</TR>
<TR>
<TD>
<P>Osser</P>
</TD>
<TD>
<P>DONE</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>75.3</P>
</TD>
<TD>
<P>DONE</P>
</TD>
</TR>
<TR>
<TD>
<P>Seidman</P>
</TD>
<TD>
<P>DONE</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>75.1</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Slavin</P>
</TD>
<TD>
<P>DONE</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>91.3</P>
</TD>
<TD>
<P>DONE</P>
</TD>
</TR>
<TR>
<TD>
<P>Sobel</P>
</TD>
<TD>
<P>DONE</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>90.1</P>
</TD>
<TD>
<P>DONE</P>
</TD>
</TR>
<TR>
<TD>
<P>Stein 1991</P>
</TD>
<TD>
<P>DONE</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>88.6</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Stein 1993</P>
</TD>
<TD>
<P>DONE</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>77.9</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Timonen 1</P>
</TD>
<TD>
<P>DONE</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>DONE</P>
</TD>
</TR>
<TR>
<TD>
<P>Timonen 2</P>
</TD>
<TD>
<P>DONE</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tobin</P>
</TD>
<TD>
<P>DONE</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>68.7</P>
</TD>
<TD>
<P>DONE</P>
</TD>
</TR>
<TR>
<TD>
<P>Van Heusden 1990</P>
</TD>
<TD>
<P>DONE</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>93.9</P>
</TD>
<TD>
<P>DONE</P>
</TD>
</TR>
<TR>
<TD>
<P>Van Heusden 1994</P>
</TD>
<TD>
<P>DONE</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Woolley</P>
</TD>
<TD>
<P>DONE</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>DONE</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2008-10-29 16:57:01 -0400" MODIFIED_BY="Karen Hovhannisyan" NO="3">
<TITLE>Summary of outcomes and sensitivity analyses (Odds ratio and 95% CI)</TITLE>
<TABLE COLS="6" ROWS="5">
<TR>
<TH>
<P>Outcome Measure</P>
</TH>
<TH>
<P>All trials</P>
</TH>
<TH>
<P>No. randomised</P>
</TH>
<TH>
<P>Assessor Blind</P>
</TH>
<TH>
<P>80% follow-up</P>
</TH>
<TH>
<P>Assessor Blind &amp; 80%</P>
</TH>
</TR>
<TR>
<TD>
<P>Clinical cure (short)</P>
</TD>
<TD>
<P>0.94 (0.75 to 1.17)</P>
</TD>
<TD>
<P>0.91 (0.74 to 1.11)</P>
</TD>
<TD>
<P>1.03 (0.71 to 1.47)</P>
</TD>
<TD>
<P>1.02 (0.73 to 1.40)</P>
</TD>
<TD>
<P>0.98 (0.67 to 1.44)</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical cure (long)</P>
</TD>
<TD>
<P>1.07 (0.82 to 1.41)</P>
</TD>
<TD>
<P>1.08 (0.86 to 1.34)</P>
</TD>
<TD>
<P>1.04 (0.65 to 1.67)</P>
</TD>
<TD>
<P>0.95 (0.63 to 1.44)</P>
</TD>
<TD>
<P>1.04 (0.60 to 1.79)</P>
</TD>
</TR>
<TR>
<TD>
<P>Mycological cure (short)</P>
</TD>
<TD>
<P>1.15 (0.94 to 1.42)</P>
</TD>
<TD>
<P>1.10 (0.79 to 1.53)</P>
</TD>
<TD>
<P>1.17 (0.90 to 1.54)</P>
</TD>
<TD>
<P>1.23 (0.94 to 1.61)</P>
</TD>
<TD>
<P>1.12 (0.79 to 1.58)</P>
</TD>
</TR>
<TR>
<TD>
<P>Mycological cure (long)</P>
</TD>
<TD>
<P>1.29 (1.05 to 1.60)</P>
</TD>
<TD>
<P>1.37 (0.98 to 1.91)</P>
</TD>
<TD>
<P>1.22 (0.95 to 1.56)</P>
</TD>
<TD>
<P>1.25 (0.99 to 1.60)</P>
</TD>
<TD>
<P>1.19 (0.88 to 1.62)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Oral vs Intra-vaginal</NAME>
<DICH_OUTCOME CHI2="10.410885865234087" CI_END="1.1733816749816612" CI_START="0.7474686400206854" CI_STUDY="95" CI_TOTAL="95" DF="11.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.936518021622508" ESTIMABLE="YES" EVENTS_1="627" EVENTS_2="673" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.06943930143912516" LOG_CI_START="-0.12640702340710022" LOG_EFFECT_SIZE="-0.028483860983987495" METHOD="MH" NO="1" P_CHI2="0.4938498224203649" P_Q="0.0" P_Z="0.568600550267591" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="849" TOTAL_2="924" WEIGHT="100.0" Z="0.5701137533532543">
<NAME>Clinical cure (short term)</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intra-vaginal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intravaginal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.2389470181009585" CI_END="1.1582457075122676" CI_START="0.6615878264706634" DF="5.0" EFFECT_SIZE="0.8753749254759453" ESTIMABLE="YES" EVENTS_1="323" EVENTS_2="421" I2="19.858271187532466" ID="CMP-001.01.01" LOG_CI_END="0.06380069937189889" LOG_CI_START="-0.1794124946061394" LOG_EFFECT_SIZE="-0.05780589761712026" NO="1" P_CHI2="0.2836578984866678" P_Z="0.35150600410573873" STUDIES="6" TAU2="0.0" TOTAL_1="458" TOTAL_2="597" WEIGHT="66.9767961637231" Z="0.9316721315192795">
<NAME>Fluconazole vs Clotrimazole</NAME>
<DICH_DATA CI_END="95.81881685682004" CI_START="0.1482704656325003" EFFECT_SIZE="3.769230769230769" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="1.9814508040119336" LOG_CI_START="-0.82894534856858" LOG_EFFECT_SIZE="0.5762527277216769" ORDER="365" O_E="0.0" SE="1.6508406117111138" STUDY_ID="STD-Goode-1992" TOTAL_1="3" TOTAL_2="9" VAR="2.725274725274725" WEIGHT="0.29736414538851513"/>
<DICH_DATA CI_END="1.347795770942692" CI_START="0.43982694795804905" EFFECT_SIZE="0.7699330493000609" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="106" LOG_CI_END="0.12962408932672523" LOG_CI_START="-0.3567181651731752" LOG_EFFECT_SIZE="-0.11354703792322499" ORDER="366" O_E="0.0" SE="0.2856798477262279" STUDY_ID="STD-Mendling-_x0028_1_x0029_-2004" TOTAL_1="77" TOTAL_2="161" VAR="0.08161297539688075" WEIGHT="17.685766185459922"/>
<DICH_DATA CI_END="1.598374914089661" CI_START="0.5269659868683796" EFFECT_SIZE="0.9177631578947368" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="95" LOG_CI_END="0.20367865484216283" LOG_CI_START="-0.2782174155124752" LOG_EFFECT_SIZE="-0.037269380335156185" ORDER="367" O_E="0.0" SE="0.28306813715033424" STUDY_ID="STD-Mendling-_x0028_2_x0029_-2004" TOTAL_1="77" TOTAL_2="157" VAR="0.08012757026976043" WEIGHT="16.641443823451944"/>
<DICH_DATA CI_END="2.3041832040732846" CI_START="0.7664204712435674" EFFECT_SIZE="1.328899235118058" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="97" LOG_CI_END="0.3625170065892582" LOG_CI_START="-0.1155329036824037" LOG_EFFECT_SIZE="0.1234920514534272" ORDER="368" O_E="0.0" SE="0.2808088836787946" STUDY_ID="STD-Sobel-1995" TOTAL_1="139" TOTAL_2="134" VAR="0.07885362915293079" WEIGHT="14.109254204075187"/>
<DICH_DATA CI_END="1.6606650587733562" CI_START="0.30430974730554333" EFFECT_SIZE="0.7108843537414966" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="84" LOG_CI_END="0.22028204798733053" LOG_CI_START="-0.516684136589537" LOG_EFFECT_SIZE="-0.14820104430110329" ORDER="369" O_E="0.0" SE="0.4328975848619005" STUDY_ID="STD-Stein-1991" TOTAL_1="90" TOTAL_2="95" VAR="0.18740031897926634" WEIGHT="8.14270817409815"/>
<DICH_DATA CI_END="1.0016332840973405" CI_START="0.1629824514510324" EFFECT_SIZE="0.40404040404040403" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="33" LOG_CI_END="7.087476351616267E-4" LOG_CI_START="-0.7878591541743367" LOG_EFFECT_SIZE="-0.3935752032695875" ORDER="370" O_E="0.0" SE="0.4632086889969677" STUDY_ID="STD-Woolley-_x0028_1_x0029_-1995" TOTAL_1="72" TOTAL_2="41" VAR="0.21456228956228957" WEIGHT="10.100259631249386"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2868213264156916" CI_END="2.3665044712881333" CI_START="0.5553141180770165" DF="1.0" EFFECT_SIZE="1.1463652748573143" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="46" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.37410732936345875" LOG_CI_START="-0.2554612850633572" LOG_EFFECT_SIZE="0.059323022150050767" NO="2" P_CHI2="0.5922648075048538" P_Z="0.7118540702218652" STUDIES="2" TAU2="0.0" TOTAL_1="123" TOTAL_2="61" WEIGHT="8.649682234343665" Z="0.3693671641304072">
<NAME>Itraconazole vs Clotrimazole</NAME>
<DICH_DATA CI_END="4.433472042367958" CI_START="0.4740397772405399" EFFECT_SIZE="1.4497041420118344" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="13" LOG_CI_END="0.6467439741329762" LOG_CI_START="-0.3241852146312585" LOG_EFFECT_SIZE="0.16127937975085893" ORDER="371" O_E="0.0" SE="0.5703286116571089" STUDY_ID="STD-Stein-1993" TOTAL_1="48" TOTAL_2="20" VAR="0.3252747252747253" WEIGHT="3.1835455565123385"/>
<DICH_DATA CI_END="2.52610603410954" CI_START="0.3722378238849141" EFFECT_SIZE="0.9696969696969697" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="33" LOG_CI_END="0.40245157625184197" LOG_CI_START="-0.429179499367805" LOG_EFFECT_SIZE="-0.01336396155798149" ORDER="372" O_E="0.0" SE="0.48850421045919723" STUDY_ID="STD-Woolley-_x0028_2_x0029_-1995" TOTAL_1="75" TOTAL_2="41" VAR="0.23863636363636365" WEIGHT="5.466136677831326"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3974533905840224E-31" CI_END="3.4174563347034663" CI_START="0.4455631819325953" DF="0.0" EFFECT_SIZE="1.2339743589743593" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="39" I2="99.99999999999999" ID="CMP-001.01.03" LOG_CI_END="0.5337029742366455" LOG_CI_START="-0.3510907032565296" LOG_EFFECT_SIZE="0.09130613549005799" NO="3" P_CHI2="0.0" P_Z="0.6858330870806608" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="50" WEIGHT="4.29739152045338" Z="0.40451631081965655">
<NAME>Fluconazole vs Miconazole</NAME>
<DICH_DATA CI_END="3.4174563347034654" CI_START="0.4455631819325952" EFFECT_SIZE="1.233974358974359" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="39" LOG_CI_END="0.5337029742366455" LOG_CI_START="-0.3510907032565297" LOG_EFFECT_SIZE="0.09130613549005791" ORDER="373" O_E="0.0" SE="0.5197321859588312" STUDY_ID="STD-Van-Heusden-1990" TOTAL_1="43" TOTAL_2="50" VAR="0.2701215451215451" WEIGHT="4.29739152045338"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.8933942205235725" CI_START="0.4638997681657373" DF="0.0" EFFECT_SIZE="1.5066666666666666" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="105" I2="0.0" ID="CMP-001.01.04" LOG_CI_END="0.6896102047036238" LOG_CI_START="-0.3335758445201845" LOG_EFFECT_SIZE="0.17801718009171966" NO="4" P_CHI2="1.0" P_Z="0.4952379433817329" STUDIES="1" TAU2="0.0" TOTAL_1="118" TOTAL_2="112" WEIGHT="2.923915008168008" Z="0.6820016005375235">
<NAME>Fluconazole vs Econazole</NAME>
<DICH_DATA CI_END="4.8933942205235725" CI_START="0.4638997681657373" EFFECT_SIZE="1.5066666666666666" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="105" LOG_CI_END="0.6896102047036238" LOG_CI_START="-0.3335758445201845" LOG_EFFECT_SIZE="0.17801718009171966" ORDER="374" O_E="0.0" SE="0.6010245501666935" STUDY_ID="STD-Osser-1991" TOTAL_1="118" TOTAL_2="112" VAR="0.36123050990307626" WEIGHT="2.923915008168008"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.546606528907487" CI_START="0.6388944136288244" DF="0.0" EFFECT_SIZE="1.7043478260869565" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="23" I2="0.0" ID="CMP-001.01.05" LOG_CI_END="0.6576873712452935" LOG_CI_START="-0.19457090923956488" LOG_EFFECT_SIZE="0.23155823100286432" NO="5" P_CHI2="1.0" P_Z="0.28685655618710026" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="37" WEIGHT="3.9282566077990513" Z="1.0650428478822707">
<NAME>Itraconazole vs Econazole</NAME>
<DICH_DATA CI_END="4.546606528907489" CI_START="0.6388944136288243" EFFECT_SIZE="1.7043478260869565" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="23" LOG_CI_END="0.6576873712452936" LOG_CI_START="-0.19457090923956497" LOG_EFFECT_SIZE="0.23155823100286432" ORDER="375" O_E="0.0" SE="0.5006207327033334" STUDY_ID="STD-Timonen-_x0028_2_x0029_-1992" TOTAL_1="38" TOTAL_2="37" VAR="0.2506211180124224" WEIGHT="3.9282566077990513"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2956154731911895" CI_START="0.3342978633442281" DF="0.0" EFFECT_SIZE="0.6581196581196581" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="39" I2="0.0" ID="CMP-001.01.06" LOG_CI_END="0.11247612603266213" LOG_CI_START="-0.4758663991800216" LOG_EFFECT_SIZE="-0.18169513657367978" NO="6" P_CHI2="1.0" P_Z="0.2260589424693451" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="67" WEIGHT="13.22395846551279" Z="1.2105734621911415">
<NAME>Fluconazole vs Butoconazole</NAME>
<DICH_DATA CI_END="1.2956154731911895" CI_START="0.3342978633442281" EFFECT_SIZE="0.6581196581196581" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="39" LOG_CI_END="0.11247612603266213" LOG_CI_START="-0.4758663991800216" LOG_EFFECT_SIZE="-0.18169513657367978" ORDER="376" O_E="0.0" SE="0.34559531165239993" STUDY_ID="STD-Seidman-2005" TOTAL_1="69" TOTAL_2="67" VAR="0.11943611943611944" WEIGHT="13.22395846551279"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.448184396501637" CI_END="1.412453120193658" CI_START="0.8164076540790839" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0738424178407122" ESTIMABLE="YES" EVENTS_1="467" EVENTS_2="553" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.14997404234699824" LOG_CI_START="-0.08809293228922557" LOG_EFFECT_SIZE="0.03094055502888635" METHOD="MH" NO="2" P_CHI2="0.8145945408911904" P_Q="0.0" P_Z="0.6104323445122769" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="585" TOTAL_2="723" WEIGHT="100.0" Z="0.5094564133556193">
<NAME>Clinical cure (long term)</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intra-vaginal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intravaginal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.2508662383476796" CI_END="1.4095350024187079" CI_START="0.7498472540464667" DF="4.0" EFFECT_SIZE="1.0280739034943198" ESTIMABLE="YES" EVENTS_1="287" EVENTS_2="397" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.14907586500262074" LOG_CI_START="-0.12502719458267425" LOG_EFFECT_SIZE="0.012024335209973262" NO="1" P_CHI2="0.6897283399734275" P_Z="0.8634696477452933" STUDIES="5" TAU2="0.0" TOTAL_1="374" TOTAL_2="536" WEIGHT="77.03643510685227" Z="0.17195914547791347">
<NAME>Fluconazole vs Clotrimzole</NAME>
<DICH_DATA CI_END="144.10212194156446" CI_START="0.20570117156680215" EFFECT_SIZE="5.444444444444445" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="2.158670375961299" LOG_CI_START="-0.6867632347829211" LOG_EFFECT_SIZE="0.7359535705891889" ORDER="377" O_E="0.0" SE="1.6714217880746898" STUDY_ID="STD-Goode-1992" TOTAL_1="3" TOTAL_2="7" VAR="2.7936507936507935" WEIGHT="0.37928777978058426"/>
<DICH_DATA CI_END="1.7714644781700652" CI_START="0.530953659279415" EFFECT_SIZE="0.9698275862068966" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="116" LOG_CI_END="0.24833244817955502" LOG_CI_START="-0.2749433817386294" LOG_EFFECT_SIZE="-0.013305466779537178" ORDER="378" O_E="0.0" SE="0.30737481275107476" STUDY_ID="STD-Mendling-_x0028_1_x0029_-2004" TOTAL_1="77" TOTAL_2="161" VAR="0.09447927551375827" WEIGHT="21.690586308124388"/>
<DICH_DATA CI_END="2.3740361103134537" CI_START="0.723612011179328" EFFECT_SIZE="1.3106796116504855" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="103" LOG_CI_END="0.37548732051183387" LOG_CI_START="-0.140494232932166" LOG_EFFECT_SIZE="0.11749654378983393" ORDER="379" O_E="0.0" SE="0.3030901186428878" STUDY_ID="STD-Mendling-_x0028_2_x0029_-2004" TOTAL_1="77" TOTAL_2="157" VAR="0.09186362001895981" WEIGHT="19.58897114490721"/>
<DICH_DATA CI_END="1.7070358340487832" CI_START="0.4804630429527597" EFFECT_SIZE="0.9056310679611651" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="103" LOG_CI_END="0.23224263790811708" LOG_CI_START="-0.3183400124885836" LOG_EFFECT_SIZE="-0.04304868729023331" ORDER="380" O_E="0.0" SE="0.3234149742710966" STUDY_ID="STD-Sobel-1995" TOTAL_1="131" TOTAL_2="125" VAR="0.10459724558277407" WEIGHT="20.34720901947926"/>
<DICH_DATA CI_END="1.7094214204110778" CI_START="0.37264001971396044" EFFECT_SIZE="0.7981220657276995" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="71" LOG_CI_END="0.23284914171276916" LOG_CI_START="-0.42871050583369674" LOG_EFFECT_SIZE="-0.0979306820604638" ORDER="381" O_E="0.0" SE="0.3886034117418643" STUDY_ID="STD-Stein-1991" TOTAL_1="86" TOTAL_2="86" VAR="0.15101261161741691" WEIGHT="15.030380854560827"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.37046161706882" CI_START="0.6258403716985884" DF="0.0" EFFECT_SIZE="2.147727272727273" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="11" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.8674946888722916" LOG_CI_START="-0.20353642482614062" LOG_EFFECT_SIZE="0.33197913202307555" NO="2" P_CHI2="1.0" P_Z="0.22435490332047592" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="18" WEIGHT="3.3587244901324693" Z="1.2150293937535463">
<NAME>Itraconazole vs Clotrimazole</NAME>
<DICH_DATA CI_END="7.370461617068818" CI_START="0.6258403716985885" EFFECT_SIZE="2.147727272727273" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="11" LOG_CI_END="0.8674946888722916" LOG_CI_START="-0.20353642482614054" LOG_EFFECT_SIZE="0.33197913202307555" ORDER="382" O_E="0.0" SE="0.6291289778759763" STUDY_ID="STD-Stein-1993" TOTAL_1="35" TOTAL_2="18" VAR="0.39580327080327077" WEIGHT="3.3587244901324693"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.661427859815934" CI_START="0.5098729793932629" DF="0.0" EFFECT_SIZE="1.5416666666666667" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="40" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="0.668518967474315" LOG_CI_START="-0.2925380027635371" LOG_EFFECT_SIZE="0.18799048235538898" NO="3" P_CHI2="1.0" P_Z="0.44321859394441243" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="50" WEIGHT="5.220304926012342" Z="0.7667694762396574">
<NAME>Fluconazole vs Miconazole</NAME>
<DICH_DATA CI_END="4.661427859815934" CI_START="0.5098729793932629" EFFECT_SIZE="1.5416666666666667" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="40" LOG_CI_END="0.668518967474315" LOG_CI_START="-0.2925380027635371" LOG_EFFECT_SIZE="0.18799048235538898" ORDER="383" O_E="0.0" SE="0.5645296216264419" STUDY_ID="STD-Van-Heusden-1990" TOTAL_1="43" TOTAL_2="50" VAR="0.3186936936936937" WEIGHT="5.220304926012342"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.718653172644254" CI_START="0.40394602913590294" DF="0.0" EFFECT_SIZE="1.047945205479452" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="73" I2="0.0" ID="CMP-001.02.04" LOG_CI_END="0.4343538067731431" LOG_CI_START="-0.3936766567068197" LOG_EFFECT_SIZE="0.020338575033161693" NO="4" P_CHI2="1.0" P_Z="0.9232953404914563" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="82" WEIGHT="8.34290257596464" Z="0.09628359419128323">
<NAME>Fluconazole vs Econazole</NAME>
<DICH_DATA CI_END="2.718653172644254" CI_START="0.40394602913590294" EFFECT_SIZE="1.047945205479452" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="73" LOG_CI_END="0.4343538067731431" LOG_CI_START="-0.3936766567068197" LOG_EFFECT_SIZE="0.020338575033161693" ORDER="384" O_E="0.0" SE="0.4863891930650293" STUDY_ID="STD-Osser-1991" TOTAL_1="95" TOTAL_2="82" VAR="0.23657444713045034" WEIGHT="8.34290257596464"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4137776545770064" CI_START="0.19836730686281448" DF="0.0" EFFECT_SIZE="0.6919642857142857" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="32" I2="0.0" ID="CMP-001.02.05" LOG_CI_END="0.38269726251459457" LOG_CI_START="-0.7025299028423373" LOG_EFFECT_SIZE="-0.15991632016387133" NO="5" P_CHI2="1.0" P_Z="0.5635135225550659" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="37" WEIGHT="6.041632901038284" Z="0.577630634519321">
<NAME>Itraconazole vs Econazole</NAME>
<DICH_DATA CI_END="2.4137776545770064" CI_START="0.19836730686281448" EFFECT_SIZE="0.6919642857142857" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="32" LOG_CI_END="0.38269726251459457" LOG_CI_START="-0.7025299028423373" LOG_EFFECT_SIZE="-0.15991632016387133" ORDER="385" O_E="0.0" SE="0.6374678088917681" STUDY_ID="STD-Timonen-_x0028_2_x0029_-1992" TOTAL_1="38" TOTAL_2="37" VAR="0.40636520737327186" WEIGHT="6.041632901038284"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="23.721110600436596" CI_END="1.4170070847156255" CI_START="0.9396614079345195" CI_STUDY="95" CI_TOTAL="95" DF="18.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1539093865105152" ESTIMABLE="YES" EVENTS_1="1068" EVENTS_2="1032" I2="24.118224044414244" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.15137202162728414" LOG_CI_START="-0.027028609332001904" LOG_EFFECT_SIZE="0.062171706147641115" METHOD="MH" NO="3" P_CHI2="0.16437873908884815" P_Q="0.0" P_Z="0.17191548069888707" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="19" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1289" TOTAL_2="1290" WEIGHT="100.00000000000001" Z="1.3660748199325956">
<NAME>Mycological cure (short term)</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intra-vaginal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intravaginal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="11.573302066819304" CI_END="1.4034385648941252" CI_START="0.8506580394334095" DF="11.0" EFFECT_SIZE="1.0926327370521507" ESTIMABLE="YES" EVENTS_1="669" EVENTS_2="710" I2="4.953660273526972" ID="CMP-001.03.01" LOG_CI_END="0.14719340627473804" LOG_CI_START="-0.07024498919106728" LOG_EFFECT_SIZE="0.03847420854183537" NO="1" P_CHI2="0.39655547823051085" P_Z="0.48793063175831886" STUDIES="12" TAU2="0.0" TOTAL_1="814" TOTAL_2="887" WEIGHT="69.2194637864403" Z="0.6936039324070474">
<NAME>Fluconazole vs Clotrimazole</NAME>
<DICH_DATA CI_END="10.790662515787629" CI_START="0.45764304070423595" EFFECT_SIZE="2.2222222222222223" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="15" LOG_CI_END="1.0330481099394218" LOG_CI_START="-0.3394731374901092" LOG_EFFECT_SIZE="0.3467874862246563" ORDER="386" O_E="0.0" SE="0.8062257748298549" STUDY_ID="STD-Adetoro-1990" TOTAL_1="23" TOTAL_2="20" VAR="0.6499999999999999" WEIGHT="1.2337603099409078"/>
<DICH_DATA CI_END="2.2410155109922187" CI_START="0.7079138915028291" EFFECT_SIZE="1.2595419847328244" ESTIMABLE="YES" EVENTS_1="143" EVENTS_2="131" LOG_CI_END="0.3504448624766127" LOG_CI_START="-0.15001956536032862" LOG_EFFECT_SIZE="0.10021264855814202" ORDER="387" O_E="0.0" SE="0.2939752822502911" STUDY_ID="STD-Anonymous-1989" TOTAL_1="169" TOTAL_2="161" VAR="0.08642146657413832" WEIGHT="12.167950671604407"/>
<DICH_DATA CI_END="59.657390681735166" CI_START="0.4190595618466103" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="1.775664254099694" LOG_CI_START="-0.3777242454276566" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="388" O_E="0.0" SE="1.2649110640673518" STUDY_ID="STD-Boag-1991" TOTAL_1="11" TOTAL_2="9" VAR="1.6" WEIGHT="0.3536779555163935"/>
<DICH_DATA CI_END="5.984724040261197" CI_START="0.01044325512413639" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.7770441295870611" LOG_CI_START="-1.9811641122429862" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="389" O_E="0.0" SE="1.620185174601965" STUDY_ID="STD-Goode-1992" TOTAL_1="3" TOTAL_2="9" VAR="2.625" WEIGHT="0.7859510122586523"/>
<DICH_DATA CI_END="1.5645094604074177" CI_START="0.42257262133705176" EFFECT_SIZE="0.8130921619293713" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="129" LOG_CI_END="0.19437819361855976" LOG_CI_START="-0.3740986444995695" LOG_EFFECT_SIZE="-0.08986022544050483" ORDER="390" O_E="0.0" SE="0.3339261087163215" STUDY_ID="STD-Mendling-_x0028_1_x0029_-2004" TOTAL_1="77" TOTAL_2="161" VAR="0.11150664608242455" WEIGHT="11.501963763432295"/>
<DICH_DATA CI_END="2.023147621169975" CI_START="0.5754040939185181" EFFECT_SIZE="1.0789473684210527" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="116" LOG_CI_END="0.3060275726969088" LOG_CI_START="-0.2400270524910581" LOG_EFFECT_SIZE="0.033000260102925345" ORDER="391" O_E="0.0" SE="0.3207551898494001" STUDY_ID="STD-Mendling-_x0028_2_x0029_-2004" TOTAL_1="77" TOTAL_2="157" VAR="0.1028838918153247" WEIGHT="11.104077121910704"/>
<DICH_DATA CI_END="3.654878779648415" CI_START="0.4149376027671457" EFFECT_SIZE="1.2314814814814814" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="18" LOG_CI_END="0.5628729774080202" LOG_CI_START="-0.38201720644774817" LOG_EFFECT_SIZE="0.09042788548013607" ORDER="392" O_E="0.0" SE="0.5550331712787226" STUDY_ID="STD-Mikamo-_x0028_1_x0029_-1995" TOTAL_1="50" TOTAL_2="25" VAR="0.3080618212197159" WEIGHT="3.395308372957378"/>
<DICH_DATA CI_END="9.665075609073707" CI_START="0.8414894320408011" EFFECT_SIZE="2.8518518518518516" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="18" LOG_CI_END="0.9852052558270709" LOG_CI_START="-0.07495133380008195" LOG_EFFECT_SIZE="0.4551269610134945" ORDER="393" O_E="0.0" SE="0.6227412286067446" STUDY_ID="STD-Mikamo-_x0028_2_x0029_-1995" TOTAL_1="50" TOTAL_2="25" VAR="0.3878066378066378" WEIGHT="1.697654186478689"/>
<DICH_DATA CI_END="2.4920340812689235" CI_START="0.3656278345637371" EFFECT_SIZE="0.9545454545454546" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="40" LOG_CI_END="0.3965539774758227" LOG_CI_START="-0.4369607496523966" LOG_EFFECT_SIZE="-0.02020338608828695" ORDER="394" O_E="0.0" SE="0.48961067667955804" STUDY_ID="STD-O_x002d_Prasertsawat-1995" TOTAL_1="53" TOTAL_2="50" VAR="0.23971861471861472" WEIGHT="5.036190952336995"/>
<DICH_DATA CI_END="2.4416602594469405" CI_START="0.7614205073152126" EFFECT_SIZE="1.363499245852187" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="102" LOG_CI_END="0.3876852346653287" LOG_CI_START="-0.11837543052414828" LOG_EFFECT_SIZE="0.1346549020705902" ORDER="395" O_E="0.0" SE="0.2972625397729923" STUDY_ID="STD-Sobel-1995" TOTAL_1="139" TOTAL_2="134" VAR="0.08836501755228982" WEIGHT="11.452429035768933"/>
<DICH_DATA CI_END="1.7510902805652628" CI_START="0.23126087911082874" EFFECT_SIZE="0.6363636363636364" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="88" LOG_CI_END="0.24330853748297288" LOG_CI_START="-0.6358978277709093" LOG_EFFECT_SIZE="-0.19629464514396822" ORDER="396" O_E="0.0" SE="0.5164501710918288" STUDY_ID="STD-Stein-1991" TOTAL_1="90" TOTAL_2="95" VAR="0.2667207792207792" WEIGHT="5.6078666820617356"/>
<DICH_DATA CI_END="1.2084099844096516" CI_START="0.05440721314835266" EFFECT_SIZE="0.2564102564102564" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="39" LOG_CI_END="0.08221430494624701" LOG_CI_START="-1.2643435189992456" LOG_EFFECT_SIZE="-0.5910646070264993" ORDER="397" O_E="0.0" SE="0.7909747313543117" STUDY_ID="STD-Woolley-_x0028_1_x0029_-1995" TOTAL_1="72" TOTAL_2="41" VAR="0.6256410256410256" WEIGHT="4.882633722173221"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.541538999469207" CI_END="1.484837373636359" CI_START="0.49480469683112" DF="2.0" EFFECT_SIZE="0.8571490573439692" ESTIMABLE="YES" EVENTS_1="180" EVENTS_2="127" I2="43.52737608424607" ID="CMP-001.03.02" LOG_CI_END="0.1716788902862678" LOG_CI_START="-0.3055661865729158" LOG_EFFECT_SIZE="-0.06694364814332401" NO="2" P_CHI2="0.17020202064626944" P_Z="0.5824207209275469" STUDIES="3" TAU2="0.0" TOTAL_1="222" TOTAL_2="157" WEIGHT="16.317490853696167" Z="0.5498522487361388">
<NAME>Itraconazole vs Clotrimazole</NAME>
<DICH_DATA CI_END="1.1678912736102955" CI_START="0.017192529125537443" EFFECT_SIZE="0.1417004048582996" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="19" LOG_CI_END="0.06740241343649361" LOG_CI_START="-1.7646602312552737" LOG_EFFECT_SIZE="-0.8486289089093901" ORDER="398" O_E="0.0" SE="1.076162666348296" STUDY_ID="STD-Stein-1993" TOTAL_1="48" TOTAL_2="20" VAR="1.158126084441874" WEIGHT="4.28227720649751"/>
<DICH_DATA CI_END="2.0651849856646223" CI_START="0.5844796733731755" EFFECT_SIZE="1.0986622073578596" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="69" LOG_CI_END="0.31495895897313825" LOG_CI_START="-0.2332305878303983" LOG_EFFECT_SIZE="0.04086418557136995" ORDER="399" O_E="0.0" SE="0.3220092533744181" STUDY_ID="STD-Tobin-1992" TOTAL_1="99" TOTAL_2="96" VAR="0.1036899592587502" WEIGHT="10.846123969169401"/>
<DICH_DATA CI_END="7.681216010342334" CI_START="0.19720743400116586" EFFECT_SIZE="1.2307692307692308" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="39" LOG_CI_END="0.8854299784660475" LOG_CI_START="-0.7050767177678713" LOG_EFFECT_SIZE="0.09017663034908804" ORDER="400" O_E="0.0" SE="0.9342715065029266" STUDY_ID="STD-Woolley-_x0028_2_x0029_-1995" TOTAL_1="75" TOTAL_2="41" VAR="0.8728632478632479" WEIGHT="1.1890896780292541"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.61177103842756" CI_END="2.0598208400121916" CI_START="0.26240231121054036" DF="1.0" EFFECT_SIZE="0.7351882405879706" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="90" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="0.31382944775856975" LOG_CI_START="-0.5810323440617594" LOG_EFFECT_SIZE="-0.13360144815159483" NO="3" P_CHI2="0.4341219469493197" P_Z="0.5583870027660043" STUDIES="2" TAU2="0.0" TOTAL_1="97" TOTAL_2="97" WEIGHT="5.020698242154362" Z="0.5852390370290756">
<NAME>Fluconazole vs Miconazole</NAME>
<DICH_DATA CI_END="1.9203524182699245" CI_START="0.18450175428834964" EFFECT_SIZE="0.5952380952380952" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="42" LOG_CI_END="0.2833809366541281" LOG_CI_START="-0.7339995001058539" LOG_EFFECT_SIZE="-0.22530928172586287" ORDER="401" O_E="0.0" SE="0.5976143046671968" STUDY_ID="STD-Timonen-_x0028_1_x0029_-1992" TOTAL_1="54" TOTAL_2="47" VAR="0.35714285714285715" WEIGHT="4.412220039115405"/>
<DICH_DATA CI_END="19.995970862538606" CI_START="0.1531558542994995" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="48" LOG_CI_END="1.300942495241589" LOG_CI_START="-0.814866397869" LOG_EFFECT_SIZE="0.24303804868629442" ORDER="402" O_E="0.0" SE="1.2428366172360938" STUDY_ID="STD-Van-Heusden-1990" TOTAL_1="43" TOTAL_2="50" VAR="1.544642857142857" WEIGHT="0.6084782030389566"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0070767677616394E-31" CI_END="3.8260085108974082" CI_START="0.970877060550408" DF="0.0" EFFECT_SIZE="1.9273255813953487" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="86" I2="100.0" ID="CMP-001.03.04" LOG_CI_END="0.5827459317737834" LOG_CI_START="-0.012835760107297367" LOG_EFFECT_SIZE="0.28495508583324297" NO="4" P_CHI2="0.0" P_Z="0.06072628930446959" STUDIES="1" TAU2="0.0" TOTAL_1="118" TOTAL_2="112" WEIGHT="7.053056040442862" Z="1.8754831219902295">
<NAME>Fluconazole vs Econazole</NAME>
<DICH_DATA CI_END="3.8260085108974082" CI_START="0.9708770605504082" EFFECT_SIZE="1.927325581395349" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="86" LOG_CI_END="0.5827459317737834" LOG_CI_START="-0.012835760107297266" LOG_EFFECT_SIZE="0.284955085833243" ORDER="403" O_E="0.0" SE="0.34984763398786917" STUDY_ID="STD-Osser-1991" TOTAL_1="118" TOTAL_2="112" VAR="0.12239336700691009" WEIGHT="7.053056040442862"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.772107798665871" CI_START="1.2915525898575506" DF="0.0" EFFECT_SIZE="3.5526315789473686" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="19" I2="0.0" ID="CMP-001.03.05" LOG_CI_END="0.9899882491433477" LOG_CI_START="0.11111209461304425" LOG_EFFECT_SIZE="0.550550171878196" NO="5" P_CHI2="1.0" P_Z="0.014067244404033175" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="37" WEIGHT="2.389291077266303" Z="2.455541666482647">
<NAME>Itraconazole vs Econazole</NAME>
<DICH_DATA CI_END="9.772107798665871" CI_START="1.2915525898575506" EFFECT_SIZE="3.5526315789473686" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="19" LOG_CI_END="0.9899882491433477" LOG_CI_START="0.11111209461304425" LOG_EFFECT_SIZE="0.550550171878196" ORDER="404" O_E="0.0" SE="0.5162562036782292" STUDY_ID="STD-Timonen-_x0028_2_x0029_-1992" TOTAL_1="38" TOTAL_2="37" VAR="0.26652046783625727" WEIGHT="2.389291077266303"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="18.574587796508055" CI_END="1.6009336528651417" CI_START="1.0467633393782334" CI_STUDY="95" CI_TOTAL="95" DF="13.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.2945264217450756" ESTIMABLE="YES" EVENTS_1="634" EVENTS_2="517" I2="30.011905823051723" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.20437333392328416" LOG_CI_START="0.019848504009359155" LOG_EFFECT_SIZE="0.11211091896632167" METHOD="MH" NO="4" P_CHI2="0.1368958256901308" P_Q="0.0" P_Z="0.01723700317725389" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="880" TOTAL_2="781" WEIGHT="99.99999999999997" Z="2.3816129628752685">
<NAME>Mycological cure (long term)</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intra-vaginal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intravaginal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="11.592497615692817" CI_END="1.7125226543534988" CI_START="0.9993322816575618" DF="7.0" EFFECT_SIZE="1.3081969162038818" ESTIMABLE="YES" EVENTS_1="392" EVENTS_2="313" I2="39.61611869970051" ID="CMP-001.04.01" LOG_CI_END="0.23363632532979994" LOG_CI_START="-2.900832493210348E-4" LOG_EFFECT_SIZE="0.11667312104023948" NO="1" P_CHI2="0.11478165118569561" P_Z="0.050570910614380675" STUDIES="8" TAU2="0.0" TOTAL_1="544" TOTAL_2="471" WEIGHT="61.86583067885539" Z="1.9551030308355026">
<NAME>Fluconazole vs Clotrimazole</NAME>
<DICH_DATA CI_END="20.0706120799998" CI_START="0.9841795726517416" EFFECT_SIZE="4.444444444444445" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="12" LOG_CI_END="1.302560617077074" LOG_CI_START="-0.006925653299799112" LOG_EFFECT_SIZE="0.6478174818886375" ORDER="405" O_E="0.0" SE="0.769198717280955" STUDY_ID="STD-Adetoro-1990" TOTAL_1="23" TOTAL_2="20" VAR="0.5916666666666666" WEIGHT="1.1212078231758655"/>
<DICH_DATA CI_END="2.5262271800482416" CI_START="0.9654696138197303" EFFECT_SIZE="1.5617283950617284" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="90" LOG_CI_END="0.40247240346590846" LOG_CI_START="-0.015261390199534475" LOG_EFFECT_SIZE="0.19360550663318699" ORDER="406" O_E="0.0" SE="0.2453788982147091" STUDY_ID="STD-Anonymous-1989" TOTAL_1="160" TOTAL_2="145" VAR="0.06021080368906456" WEIGHT="17.783091293813932"/>
<DICH_DATA CI_END="144.10212194156446" CI_START="0.20570117156680215" EFFECT_SIZE="5.444444444444445" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="2.158670375961299" LOG_CI_START="-0.6867632347829211" LOG_EFFECT_SIZE="0.7359535705891889" ORDER="407" O_E="0.0" SE="1.6714217880746898" STUDY_ID="STD-Goode-1992" TOTAL_1="3" TOTAL_2="7" VAR="2.7936507936507935" WEIGHT="0.2511038353987615"/>
<DICH_DATA CI_END="4.241327456421064" CI_START="0.5705178652868271" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="15" LOG_CI_END="0.6275018039444425" LOG_CI_START="-0.24373075146661616" LOG_EFFECT_SIZE="0.19188552623891314" ORDER="408" O_E="0.0" SE="0.511766315719159" STUDY_ID="STD-Mikamo-_x0028_1_x0029_-1995" TOTAL_1="50" TOTAL_2="25" VAR="0.26190476190476186" WEIGHT="4.017661366380184"/>
<DICH_DATA CI_END="7.685464235589032" CI_START="0.9252676081923238" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="15" LOG_CI_END="0.8856701059106222" LOG_CI_START="-0.03373264136605994" LOG_EFFECT_SIZE="0.4259687322722811" ORDER="409" O_E="0.0" SE="0.5400617248673216" STUDY_ID="STD-Mikamo-_x0028_2_x0029_-1995" TOTAL_1="50" TOTAL_2="25" VAR="0.29166666666666663" WEIGHT="2.678440910920123"/>
<DICH_DATA CI_END="1.7528708389658247" CI_START="0.3515453955833325" EFFECT_SIZE="0.784992784992785" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="33" LOG_CI_END="0.24374991609891708" LOG_CI_START="-0.45401858592617084" LOG_EFFECT_SIZE="-0.10513433491362682" ORDER="410" O_E="0.0" SE="0.4098726720993272" STUDY_ID="STD-O_x002d_Prasertsawat-1995" TOTAL_1="53" TOTAL_2="50" VAR="0.1679956073338426" WEIGHT="9.010483258580802"/>
<DICH_DATA CI_END="2.0756174032336396" CI_START="0.7345393318097904" EFFECT_SIZE="1.2347560975609757" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="80" LOG_CI_END="0.31714730342617103" LOG_CI_START="-0.133984944420192" LOG_EFFECT_SIZE="0.09158117950298951" ORDER="411" O_E="0.0" SE="0.2649973155255962" STUDY_ID="STD-Sobel-1995" TOTAL_1="131" TOTAL_2="125" VAR="0.07022357723577237" WEIGHT="17.158762085582037"/>
<DICH_DATA CI_END="1.2365634247277955" CI_START="0.22196041283071535" EFFECT_SIZE="0.5238970588235294" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="64" LOG_CI_END="0.09221639672067108" LOG_CI_START="-0.6537244761000104" LOG_EFFECT_SIZE="-0.28075403968966967" ORDER="412" O_E="0.0" SE="0.43816936116174016" STUDY_ID="STD-Stein-1991" TOTAL_1="74" TOTAL_2="74" VAR="0.1919923890608875" WEIGHT="9.845080105003696"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.21256730933359236" CI_END="1.9825958646997777" CI_START="0.5954872790554879" DF="1.0" EFFECT_SIZE="1.086559071995965" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="53" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.2972341959914328" LOG_CI_START="-0.22512751158677058" LOG_EFFECT_SIZE="0.03605334220233108" NO="2" P_CHI2="0.6447625861233232" P_Z="0.7867348820513776" STUDIES="2" TAU2="0.0" TOTAL_1="106" TOTAL_2="94" WEIGHT="13.63285513060422" Z="0.2705529567489892">
<NAME>Itraconazole vs Clotrimazole</NAME>
<DICH_DATA CI_END="7.8237494035798365" CI_START="0.30707783136570205" EFFECT_SIZE="1.55" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="15" LOG_CI_END="0.8934149314542115" LOG_CI_START="-0.5127515351136283" LOG_EFFECT_SIZE="0.1903316981702915" ORDER="413" O_E="0.0" SE="0.8259891430982182" STUDY_ID="STD-Stein-1993" TOTAL_1="35" TOTAL_2="18" VAR="0.6822580645161289" WEIGHT="1.5160986288227112"/>
<DICH_DATA CI_END="1.9644235643935033" CI_START="0.5385596074337988" EFFECT_SIZE="1.0285714285714285" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="38" LOG_CI_END="0.2932351351035731" LOG_CI_START="-0.26876622226955" LOG_EFFECT_SIZE="0.012234456417011586" ORDER="414" O_E="0.0" SE="0.3301223792725582" STUDY_ID="STD-Tobin-1992" TOTAL_1="71" TOTAL_2="76" VAR="0.10898078529657476" WEIGHT="12.11675650178151"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.10177370813891942" CI_END="1.404219744218036" CI_START="0.3694930022006886" DF="1.0" EFFECT_SIZE="0.7203119942362511" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="77" I2="0.0" ID="CMP-001.04.03" LOG_CI_END="0.1474350751967751" LOG_CI_START="-0.43239378226077907" LOG_EFFECT_SIZE="-0.142479353532002" NO="3" P_CHI2="0.7497114365962709" P_Z="0.3354319066284177" STUDIES="2" TAU2="0.0" TOTAL_1="97" TOTAL_2="97" WEIGHT="13.654687771730604" Z="0.963230435572849">
<NAME>Fluconazole vs Miconazole</NAME>
<DICH_DATA CI_END="1.9545900213491074" CI_START="0.3229024851324125" EFFECT_SIZE="0.7944444444444444" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="36" LOG_CI_END="0.29105567726243425" LOG_CI_START="-0.4909286125389228" LOG_EFFECT_SIZE="-0.09993646763824428" ORDER="415" O_E="0.0" SE="0.4593414427139805" STUDY_ID="STD-Timonen-_x0028_1_x0029_-1992" TOTAL_1="54" TOTAL_2="47" VAR="0.210994560994561" WEIGHT="7.160188573746864"/>
<DICH_DATA CI_END="1.7269831540604972" CI_START="0.23612598930975515" EFFECT_SIZE="0.6385809312638581" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="41" LOG_CI_END="0.2372881012418936" LOG_CI_START="-0.626856209479353" LOG_EFFECT_SIZE="-0.1947840541187297" ORDER="416" O_E="0.0" SE="0.5076026457009863" STUDY_ID="STD-Van-Heusden-1990" TOTAL_1="43" TOTAL_2="50" VAR="0.25766044592264103" WEIGHT="6.494499197983739"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.422323350103027" CI_START="1.060459358911396" DF="0.0" EFFECT_SIZE="2.1655701754385963" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="57" I2="0.0" ID="CMP-001.04.04" LOG_CI_END="0.6456504940164205" LOG_CI_START="0.025494029251705155" LOG_EFFECT_SIZE="0.33557226163406284" NO="4" P_CHI2="1.0" P_Z="0.03391268023564227" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="82" WEIGHT="6.900390143387435" Z="2.1211084117713668">
<NAME>Fluconazole vs Econazole</NAME>
<DICH_DATA CI_END="4.422323350103027" CI_START="1.060459358911396" EFFECT_SIZE="2.1655701754385963" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="57" LOG_CI_END="0.6456504940164205" LOG_CI_START="0.025494029251705155" LOG_EFFECT_SIZE="0.33557226163406284" ORDER="417" O_E="0.0" SE="0.3642829772268038" STUDY_ID="STD-Osser-1991" TOTAL_1="95" TOTAL_2="82" VAR="0.13270208749722406" WEIGHT="6.900390143387435"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.7412625593775255" CI_START="0.8915548211472322" DF="0.0" EFFECT_SIZE="2.262443438914027" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="17" I2="0.0" ID="CMP-001.04.05" LOG_CI_END="0.7590074084738596" LOG_CI_START="-0.04985194717204332" LOG_EFFECT_SIZE="0.3545777306509081" NO="5" P_CHI2="1.0" P_Z="0.08572925856538376" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="37" WEIGHT="3.9462362754223146" Z="1.7183693974603882">
<NAME>Itraconazole vs Econazole</NAME>
<DICH_DATA CI_END="5.7412625593775255" CI_START="0.8915548211472322" EFFECT_SIZE="2.262443438914027" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="17" LOG_CI_END="0.7590074084738596" LOG_CI_START="-0.04985194717204332" LOG_EFFECT_SIZE="0.3545777306509081" ORDER="418" O_E="0.0" SE="0.4751279894247882" STUDY_ID="STD-Timonen-_x0028_2_x0029_-1992" TOTAL_1="38" TOTAL_2="37" VAR="0.22574660633484162" WEIGHT="3.9462362754223146"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Oral vs Intra-vaginal (no. randomised)</NAME>
<DICH_OUTCOME CHI2="12.913230204160497" CI_END="1.1120484376701951" CI_START="0.739749133715076" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9069933122221633" ESTIMABLE="YES" EVENTS_1="519" EVENTS_2="576" I2="22.560042360445856" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.04612370429166502" LOG_CI_START="-0.13091553474858322" LOG_EFFECT_SIZE="-0.042395915228459084" METHOD="MH" NO="1" P_CHI2="0.22856386143789986" P_Q="0.0" P_Z="0.3478784222675225" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="854" TOTAL_2="1001" WEIGHT="100.0" Z="0.9387124277065186">
<NAME>Clinical cure (short term)</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intra-vaginal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intravaginal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.309863435398685" CI_END="0.9931029802193464" CI_START="0.5854665229882133" DF="4.0" EFFECT_SIZE="0.7625146220225899" ESTIMABLE="YES" EVENTS_1="215" EVENTS_2="324" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="-0.00300571482576296" LOG_CI_START="-0.2324979328668507" LOG_EFFECT_SIZE="-0.11775182384630684" NO="1" P_CHI2="0.5073711956325577" P_Z="0.044293332534514396" STUDIES="5" TAU2="0.0" TOTAL_1="424" TOTAL_2="623" WEIGHT="65.23302769348878" Z="2.011304224802483">
<NAME>Fluconazole vs Clotrimazole</NAME>
<DICH_DATA CI_END="1.9093297707241907" CI_START="0.06925540416652255" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.280880944232929" LOG_CI_START="-1.1595463318934542" LOG_EFFECT_SIZE="-0.43933269383026263" ORDER="419" O_E="0.0" SE="0.8461141122266492" STUDY_ID="STD-Goode-1992" TOTAL_1="14" TOTAL_2="14" VAR="0.7159090909090908" WEIGHT="2.4233935730024507"/>
<DICH_DATA CI_END="1.2086877593609544" CI_START="0.4852152875134882" EFFECT_SIZE="0.7658157602663707" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="106" LOG_CI_END="0.0823141239373521" LOG_CI_START="-0.31406552442096747" LOG_EFFECT_SIZE="-0.11587570024180767" ORDER="420" O_E="0.0" SE="0.23283536755658077" STUDY_ID="STD-Mendling-_x0028_1_x0029_-2004" TOTAL_1="114" TOTAL_2="226" VAR="0.05421230838520806" WEIGHT="21.79585492324628"/>
<DICH_DATA CI_END="1.4455575908922067" CI_START="0.5760592892869019" EFFECT_SIZE="0.9125386996904025" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="95" LOG_CI_END="0.16003539860678767" LOG_CI_START="-0.23953281573473992" LOG_EFFECT_SIZE="-0.03974870856397615" ORDER="421" O_E="0.0" SE="0.2347083469987734" STUDY_ID="STD-Mendling-_x0028_2_x0029_-2004" TOTAL_1="113" TOTAL_2="226" VAR="0.05508800815089662" WEIGHT="19.591643402372544"/>
<DICH_DATA CI_END="1.464241571398222" CI_START="0.4673257886947396" EFFECT_SIZE="0.8272108843537415" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="84" LOG_CI_END="0.1656127327814197" LOG_CI_START="-0.3303802524043397" LOG_EFFECT_SIZE="-0.08238375981145998" ORDER="422" O_E="0.0" SE="0.29134873470298883" STUDY_ID="STD-Stein-1991" TOTAL_1="111" TOTAL_2="116" VAR="0.08488408521303258" WEIGHT="13.315562603761965"/>
<DICH_DATA CI_END="1.0016332840973405" CI_START="0.1629824514510324" EFFECT_SIZE="0.40404040404040403" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="33" LOG_CI_END="7.087476351616267E-4" LOG_CI_START="-0.7878591541743367" LOG_EFFECT_SIZE="-0.3935752032695875" ORDER="423" O_E="0.0" SE="0.4632086889969677" STUDY_ID="STD-Woolley-_x0028_1_x0029_-1995" TOTAL_1="72" TOTAL_2="41" VAR="0.21456228956228957" WEIGHT="8.106573191105543"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7423021355673582" CI_END="2.5729429419043246" CI_START="0.6441443826546371" DF="1.0" EFFECT_SIZE="1.2873797974640457" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="46" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.41043015531611377" LOG_CI_START="-0.1910167761772038" LOG_EFFECT_SIZE="0.10970668956945502" NO="2" P_CHI2="0.3889244489364101" P_Z="0.47460107112661765" STUDIES="2" TAU2="0.0" TOTAL_1="125" TOTAL_2="64" WEIGHT="7.133489541176859" Z="0.7150129102342486">
<NAME>Itraconazole vs Clotrimazole</NAME>
<DICH_DATA CI_END="4.989963285479625" CI_START="0.6456089104705003" EFFECT_SIZE="1.794871794871795" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="13" LOG_CI_END="0.6980973502381669" LOG_CI_START="-0.19003048426265154" LOG_EFFECT_SIZE="0.25403343298775766" ORDER="424" O_E="0.0" SE="0.5216906862894642" STUDY_ID="STD-Stein-1993" TOTAL_1="50" TOTAL_2="23" VAR="0.2721611721611722" WEIGHT="2.7463115210862146"/>
<DICH_DATA CI_END="2.52610603410954" CI_START="0.3722378238849141" EFFECT_SIZE="0.9696969696969697" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="33" LOG_CI_END="0.40245157625184197" LOG_CI_START="-0.429179499367805" LOG_EFFECT_SIZE="-0.01336396155798149" ORDER="425" O_E="0.0" SE="0.48850421045919723" STUDY_ID="STD-Woolley-_x0028_2_x0029_-1995" TOTAL_1="75" TOTAL_2="41" VAR="0.23863636363636365" WEIGHT="4.387178020090644"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.755392595897594" CI_START="0.28324477773764645" DF="0.0" EFFECT_SIZE="0.7051282051282052" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="39" I2="0.0" ID="CMP-002.01.03" LOG_CI_END="0.24437426220582886" LOG_CI_START="-0.547838088598302" LOG_EFFECT_SIZE="-0.15173191319623652" NO="3" P_CHI2="1.0" P_Z="0.45278432799356705" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="50" WEIGHT="5.670162372828508" Z="0.7507812390658092">
<NAME>Fluconazole vs Miconazole</NAME>
<DICH_DATA CI_END="1.755392595897594" CI_START="0.2832447777376464" EFFECT_SIZE="0.7051282051282052" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="39" LOG_CI_END="0.24437426220582886" LOG_CI_START="-0.547838088598302" LOG_EFFECT_SIZE="-0.15173191319623652" ORDER="426" O_E="0.0" SE="0.4653494563767283" STUDY_ID="STD-Van-Heusden-1990" TOTAL_1="49" TOTAL_2="50" VAR="0.21655011655011655" WEIGHT="5.670162372828508"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.586999149210234" CI_START="0.8969010127232577" DF="0.0" EFFECT_SIZE="1.7936507936507937" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="105" I2="0.0" ID="CMP-002.01.04" LOG_CI_END="0.5547312736669494" LOG_CI_START="-0.04725548560727332" LOG_EFFECT_SIZE="0.25373789402983804" NO="4" P_CHI2="1.0" P_Z="0.0984830407697882" STUDIES="1" TAU2="0.0" TOTAL_1="128" TOTAL_2="130" WEIGHT="6.276230712321357" Z="1.6522527319740623">
<NAME>Fluconazole vs Econazole</NAME>
<DICH_DATA CI_END="3.586999149210234" CI_START="0.8969010127232577" EFFECT_SIZE="1.7936507936507937" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="105" LOG_CI_END="0.5547312736669494" LOG_CI_START="-0.04725548560727332" LOG_EFFECT_SIZE="0.25373789402983804" ORDER="427" O_E="0.0" SE="0.3536100022801958" STUDY_ID="STD-Osser-1991" TOTAL_1="128" TOTAL_2="130" VAR="0.12504003371260008" WEIGHT="6.276230712321357"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.2607979661100596E-31" CI_END="4.560638835051637" CI_START="0.7311680870561796" DF="0.0" EFFECT_SIZE="1.8260869565217392" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="23" I2="100.0" ID="CMP-002.01.05" LOG_CI_END="0.6590256810647365" LOG_CI_START="-0.13598277230412115" LOG_EFFECT_SIZE="0.2615214543803076" NO="5" P_CHI2="0.0" P_Z="0.1972322425780931" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="41" WEIGHT="3.5031772413323865" Z="1.2894771863063978">
<NAME>Itraconazole vs Econazole</NAME>
<DICH_DATA CI_END="4.560638835051635" CI_START="0.7311680870561795" EFFECT_SIZE="1.826086956521739" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="23" LOG_CI_END="0.6590256810647362" LOG_CI_START="-0.13598277230412123" LOG_EFFECT_SIZE="0.26152145438030755" ORDER="428" O_E="0.0" SE="0.4669919008641797" STUDY_ID="STD-Timonen-_x0028_2_x0029_-1992" TOTAL_1="40" TOTAL_2="41" VAR="0.2180814354727398" WEIGHT="3.5031772413323865"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5085691606694378" CI_START="0.45750472221414656" DF="0.0" EFFECT_SIZE="0.8307692307692308" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="39" I2="0.0" ID="CMP-002.01.06" LOG_CI_END="0.17856522528898897" LOG_CI_START="-0.33960441892876314" LOG_EFFECT_SIZE="-0.08051959681988703" NO="6" P_CHI2="1.0" P_Z="0.5424403951323613" STUDIES="1" TAU2="0.0" TOTAL_1="88" TOTAL_2="93" WEIGHT="12.183912438852099" Z="0.6091268046197825">
<NAME>Fluconazole vs Butoconazole</NAME>
<DICH_DATA CI_END="1.5085691606694378" CI_START="0.45750472221414656" EFFECT_SIZE="0.8307692307692308" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="39" LOG_CI_END="0.17856522528898897" LOG_CI_START="-0.33960441892876314" LOG_EFFECT_SIZE="-0.08051959681988703" ORDER="429" O_E="0.0" SE="0.304375413994614" STUDY_ID="STD-Seidman-2005" TOTAL_1="88" TOTAL_2="93" VAR="0.09264439264439264" WEIGHT="12.183912438852099"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.7115242414650442" CI_END="1.3410218528052071" CI_START="0.8644857223074817" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0767052730679956" ESTIMABLE="YES" EVENTS_1="361" EVENTS_2="450" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.12743585501445337" LOG_CI_START="-0.06324217506129029" LOG_EFFECT_SIZE="0.03209683997658156" METHOD="MH" NO="2" P_CHI2="0.8123397769597409" P_Q="0.0" P_Z="0.5093554740209789" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="619" TOTAL_2="826" WEIGHT="99.99999999999999" Z="0.6598416225157758">
<NAME>Clinical cure (long term)</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intra-vaginal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intravaginal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7635059648935061" CI_END="1.2988032100701499" CI_START="0.7562537785367459" DF="3.0" EFFECT_SIZE="0.991072568075217" ESTIMABLE="YES" EVENTS_1="181" EVENTS_2="294" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.11354335334018945" LOG_CI_START="-0.12133244243063651" LOG_EFFECT_SIZE="-0.003894544545223552" NO="1" P_CHI2="0.8581745402544441" P_Z="0.9481760092187629" STUDIES="4" TAU2="0.0" TOTAL_1="352" TOTAL_2="582" WEIGHT="68.70621664412062" Z="0.06499747681342997">
<NAME>Fluconazole vs Clotrimzole</NAME>
<DICH_DATA CI_END="3.82516103230919" CI_START="0.12153110133959846" EFFECT_SIZE="0.6818181818181818" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5826497228807976" LOG_CI_START="-0.9153125664138475" LOG_EFFECT_SIZE="-0.16633142176652504" ORDER="430" O_E="0.0" SE="0.8799104637645947" STUDY_ID="STD-Goode-1992" TOTAL_1="14" TOTAL_2="14" VAR="0.7742424242424242" WEIGHT="2.045889630172805"/>
<DICH_DATA CI_END="1.387124454400179" CI_START="0.5633461353705448" EFFECT_SIZE="0.8839859731151374" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="116" LOG_CI_END="0.1421154282214219" LOG_CI_START="-0.24922468065460945" LOG_EFFECT_SIZE="-0.053554626216593765" ORDER="431" O_E="0.0" SE="0.22987511711856196" STUDY_ID="STD-Mendling-_x0028_1_x0029_-2004" TOTAL_1="114" TOTAL_2="226" VAR="0.05284256947027258" WEIGHT="26.207080321475598"/>
<DICH_DATA CI_END="1.7801134633424491" CI_START="0.7203730889626985" EFFECT_SIZE="1.1324070974221627" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="103" LOG_CI_END="0.25044768485555885" LOG_CI_START="-0.14244251952449433" LOG_EFFECT_SIZE="0.054002582665532296" ORDER="432" O_E="0.0" SE="0.23078565089072087" STUDY_ID="STD-Mendling-_x0028_2_x0029_-2004" TOTAL_1="113" TOTAL_2="226" VAR="0.053262016657053685" WEIGHT="22.94315166386869"/>
<DICH_DATA CI_END="1.7098816759569284" CI_START="0.587520718325615" EFFECT_SIZE="1.0022928267278086" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="71" LOG_CI_END="0.23296605819510605" LOG_CI_START="-0.2309768138292697" LOG_EFFECT_SIZE="9.946221829181443E-4" ORDER="433" O_E="0.0" SE="0.27252233958137323" STUDY_ID="STD-Stein-1991" TOTAL_1="111" TOTAL_2="116" VAR="0.0742684255709053" WEIGHT="17.51009502860353"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.443942996915623" CI_START="0.47620398297665384" DF="0.0" EFFECT_SIZE="1.2806324110671936" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="11" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="0.5370559545325251" LOG_CI_START="-0.32220697647093666" LOG_EFFECT_SIZE="0.10742448903079418" NO="2" P_CHI2="1.0" P_Z="0.6240866121385583" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="23" WEIGHT="4.512167540518104" Z="0.49006682811765917">
<NAME>Itraconazole vs Clotrimazole</NAME>
<DICH_DATA CI_END="3.443942996915623" CI_START="0.47620398297665384" EFFECT_SIZE="1.2806324110671936" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="11" LOG_CI_END="0.5370559545325251" LOG_CI_START="-0.32220697647093666" LOG_EFFECT_SIZE="0.10742448903079418" ORDER="434" O_E="0.0" SE="0.5047352990915401" STUDY_ID="STD-Stein-1993" TOTAL_1="50" TOTAL_2="23" VAR="0.2547577221490265" WEIGHT="4.512167540518104"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.994858063174443" CI_START="0.2978577968761573" DF="0.0" EFFECT_SIZE="0.7708333333333334" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="40" I2="0.0" ID="CMP-002.02.03" LOG_CI_END="0.299912000487411" LOG_CI_START="-0.5259910271045954" LOG_EFFECT_SIZE="-0.11303951330859219" NO="3" P_CHI2="1.0" P_Z="0.5916048601906261" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="50" WEIGHT="6.312386737723255" Z="0.5365118361673413">
<NAME>Fluconazole vs Miconazole</NAME>
<DICH_DATA CI_END="1.994858063174443" CI_START="0.2978577968761573" EFFECT_SIZE="0.7708333333333334" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="40" LOG_CI_END="0.299912000487411" LOG_CI_START="-0.5259910271045954" LOG_EFFECT_SIZE="-0.11303951330859219" ORDER="435" O_E="0.0" SE="0.48513952669346616" STUDY_ID="STD-Van-Heusden-1990" TOTAL_1="49" TOTAL_2="50" VAR="0.23536036036036037" WEIGHT="6.312386737723255"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.556320971577371" CI_START="0.9319434245608207" DF="0.0" EFFECT_SIZE="1.5434851863650845" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="73" I2="0.0" ID="CMP-002.02.04" LOG_CI_END="0.40761538291094923" LOG_CI_START="-0.030610451537465787" LOG_EFFECT_SIZE="0.18850246568674173" NO="4" P_CHI2="1.0" P_Z="0.09176620993589389" STUDIES="1" TAU2="0.0" TOTAL_1="128" TOTAL_2="130" WEIGHT="15.840145469974292" Z="1.686153643625505">
<NAME>Fluconazole vs Econazole</NAME>
<DICH_DATA CI_END="2.556320971577371" CI_START="0.9319434245608207" EFFECT_SIZE="1.5434851863650845" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="73" LOG_CI_END="0.40761538291094923" LOG_CI_START="-0.030610451537465787" LOG_EFFECT_SIZE="0.18850246568674173" ORDER="436" O_E="0.0" SE="0.25741602440786476" STUDY_ID="STD-Osser-1991" TOTAL_1="128" TOTAL_2="130" VAR="0.06626300962195042" WEIGHT="15.840145469974292"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.761918244473181" CI_START="0.3397915794133178" DF="0.0" EFFECT_SIZE="0.96875" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="32" I2="0.0" ID="CMP-002.02.05" LOG_CI_END="0.44121081888429836" LOG_CI_START="-0.46878738785556495" LOG_EFFECT_SIZE="-0.013788284485633295" NO="5" P_CHI2="1.0" P_Z="0.9526377243196551" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="41" WEIGHT="4.62908360766372" Z="0.05939471264949211">
<NAME>Itraconazole vs Econazole</NAME>
<DICH_DATA CI_END="2.7619182444731805" CI_START="0.33979157941331783" EFFECT_SIZE="0.96875" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="32" LOG_CI_END="0.4412108188842983" LOG_CI_START="-0.46878738785556484" LOG_EFFECT_SIZE="-0.013788284485633295" ORDER="437" O_E="0.0" SE="0.5345374512027676" STUDY_ID="STD-Timonen-_x0028_2_x0029_-1992" TOTAL_1="40" TOTAL_2="41" VAR="0.2857302867383512" WEIGHT="4.62908360766372"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="32.80546635425282" CI_END="1.525764091934023" CI_START="0.7929873760865793" CI_STUDY="95" CI_TOTAL="95" DF="15.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0999598464443525" ESTIMABLE="YES" EVENTS_1="840" EVENTS_2="821" I2="54.27591292859205" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.18348738978440526" LOG_CI_START="-0.10073372635147251" LOG_EFFECT_SIZE="0.04137683171646644" METHOD="MH" NO="3" P_CHI2="0.004993430327665083" P_Q="0.0" P_Z="0.5682287626914748" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.19374818289760184" TOTALS="YES" TOTAL_1="1151" TOTAL_2="1232" WEIGHT="99.99999999999999" Z="0.5706620328651348">
<NAME>Mycological cure (short term)</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intra-vaginal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intravaginal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="16.855960690620606" CI_END="1.4312420492309188" CI_START="0.6961298071262587" DF="9.0" EFFECT_SIZE="0.9981634393635699" ESTIMABLE="YES" EVENTS_1="514" EVENTS_2="568" I2="46.60642507900488" ID="CMP-002.03.01" LOG_CI_END="0.15571308711821316" LOG_CI_START="-0.15730977007011468" LOG_EFFECT_SIZE="-7.983414759506921E-4" NO="1" P_CHI2="0.05102002543395867" P_Z="0.9920232945582904" STUDIES="10" TAU2="0.12710956390361103" TOTAL_1="746" TOTAL_2="885" WEIGHT="64.7997300008724" Z="0.009997484236664137">
<NAME>Fluconazole vs Clotrimazole</NAME>
<DICH_DATA CI_END="10.790662515787629" CI_START="0.45764304070423595" EFFECT_SIZE="2.2222222222222223" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="15" LOG_CI_END="1.0330481099394218" LOG_CI_START="-0.3394731374901092" LOG_EFFECT_SIZE="0.3467874862246563" ORDER="438" O_E="0.0" SE="0.8062257748298549" STUDY_ID="STD-Adetoro-1990" TOTAL_1="23" TOTAL_2="20" VAR="0.6499999999999999" WEIGHT="3.303505503551167"/>
<DICH_DATA CI_END="1.9354151256279" CI_START="0.7600993023522122" EFFECT_SIZE="1.2128922815945717" ESTIMABLE="YES" EVENTS_1="143" EVENTS_2="131" LOG_CI_END="0.28677413081918307" LOG_CI_START="-0.11912966607923761" LOG_EFFECT_SIZE="0.0838222323699727" ORDER="439" O_E="0.0" SE="0.23842989955433183" STUDY_ID="STD-Anonymous-1989" TOTAL_1="188" TOTAL_2="181" VAR="0.05684881700148876" WEIGHT="11.122745950414066"/>
<DICH_DATA CI_END="89.46950105985752" CI_START="0.7761800794885875" EFFECT_SIZE="8.333333333333334" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="1.9516750154414915" LOG_CI_START="-0.11003750753674088" LOG_EFFECT_SIZE="0.9208187539523752" ORDER="440" O_E="0.0" SE="1.2110601416389968" STUDY_ID="STD-Boag-1991" TOTAL_1="11" TOTAL_2="11" VAR="1.4666666666666668" WEIGHT="1.678692988408881"/>
<DICH_DATA CI_END="0.7818728781680344" CI_START="0.01998406702200763" EFFECT_SIZE="0.125" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.10686385154113255" LOG_CI_START="-1.6993161224427544" LOG_EFFECT_SIZE="-0.9030899869919435" ORDER="441" O_E="0.0" SE="0.9354143466934853" STUDY_ID="STD-Goode-1992" TOTAL_1="14" TOTAL_2="14" VAR="0.875" WEIGHT="2.6080294782410705"/>
<DICH_DATA CI_END="1.2676157616204886" CI_START="0.5132808501946672" EFFECT_SIZE="0.8066243833685695" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="129" LOG_CI_END="0.10298763059892488" LOG_CI_START="-0.2896449383691323" LOG_EFFECT_SIZE="-0.09332865388510374" ORDER="442" O_E="0.0" SE="0.2306343145743986" STUDY_ID="STD-Mendling-_x0028_1_x0029_-2004" TOTAL_1="114" TOTAL_2="226" VAR="0.05319218705920265" WEIGHT="11.287448732263144"/>
<DICH_DATA CI_END="1.5711235911945136" CI_START="0.6364871647301199" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="116" LOG_CI_END="0.19621034981564744" LOG_CI_START="-0.19621034981564747" LOG_EFFECT_SIZE="0.0" ORDER="443" O_E="0.0" SE="0.23050986147721428" STUDY_ID="STD-Mendling-_x0028_2_x0029_-2004" TOTAL_1="113" TOTAL_2="226" VAR="0.05313479623824452" WEIGHT="11.29007263104926"/>
<DICH_DATA CI_END="3.654878779648415" CI_START="0.4149376027671457" EFFECT_SIZE="1.2314814814814814" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="18" LOG_CI_END="0.5628729774080202" LOG_CI_START="-0.38201720644774817" LOG_EFFECT_SIZE="0.09042788548013607" ORDER="444" O_E="0.0" SE="0.5550331712787226" STUDY_ID="STD-Mikamo-_x0028_1_x0029_-1995" TOTAL_1="50" TOTAL_2="25" VAR="0.3080618212197159" WEIGHT="5.55454602926146"/>
<DICH_DATA CI_END="9.665075609073707" CI_START="0.8414894320408011" EFFECT_SIZE="2.8518518518518516" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="18" LOG_CI_END="0.9852052558270709" LOG_CI_START="-0.07495133380008195" LOG_EFFECT_SIZE="0.4551269610134945" ORDER="445" O_E="0.0" SE="0.6227412286067446" STUDY_ID="STD-Mikamo-_x0028_2_x0029_-1995" TOTAL_1="50" TOTAL_2="25" VAR="0.3878066378066378" WEIGHT="4.792887388394757"/>
<DICH_DATA CI_END="1.4871529028066086" CI_START="0.45336885435879637" EFFECT_SIZE="0.8211143695014663" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="88" LOG_CI_END="0.17235562314961203" LOG_CI_START="-0.343548318450169" LOG_EFFECT_SIZE="-0.08559634765027847" ORDER="446" O_E="0.0" SE="0.3030445290614089" STUDY_ID="STD-Stein-1991" TOTAL_1="111" TOTAL_2="116" VAR="0.09183598659405111" WEIGHT="9.760088490811786"/>
<DICH_DATA CI_END="1.2084099844096516" CI_START="0.05440721314835266" EFFECT_SIZE="0.2564102564102564" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="39" LOG_CI_END="0.08221430494624701" LOG_CI_START="-1.2643435189992456" LOG_EFFECT_SIZE="-0.5910646070264993" ORDER="447" O_E="0.0" SE="0.7909747313543117" STUDY_ID="STD-Woolley-_x0028_1_x0029_-1995" TOTAL_1="72" TOTAL_2="41" VAR="0.6256410256410256" WEIGHT="3.401712808476809"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6651005265088402" CI_END="1.8245938915927007" CI_START="0.2350656782421976" DF="1.0" EFFECT_SIZE="0.6549041156106816" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="58" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="0.2611662165915575" LOG_CI_START="-0.6288107772474909" LOG_EFFECT_SIZE="-0.18382228032796666" NO="2" P_CHI2="0.4147653323292657" P_Z="0.4181412246440235" STUDIES="2" TAU2="0.0" TOTAL_1="125" TOTAL_2="64" WEIGHT="7.324617646543556" Z="0.8096502527434943">
<NAME>Itraconazole vs Clotrimazole</NAME>
<DICH_DATA CI_END="1.691199409209138" CI_START="0.14268277035475552" EFFECT_SIZE="0.49122807017543857" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="19" LOG_CI_END="0.22819481825021473" LOG_CI_START="-0.8456284669107591" LOG_EFFECT_SIZE="-0.3087168243302722" ORDER="448" O_E="0.0" SE="0.6307691132145451" STUDY_ID="STD-Stein-1993" TOTAL_1="50" TOTAL_2="23" VAR="0.39786967418546365" WEIGHT="4.711363479723657"/>
<DICH_DATA CI_END="7.681216010342334" CI_START="0.19720743400116586" EFFECT_SIZE="1.2307692307692308" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="39" LOG_CI_END="0.8854299784660475" LOG_CI_START="-0.7050767177678713" LOG_EFFECT_SIZE="0.09017663034908804" ORDER="449" O_E="0.0" SE="0.9342715065029266" STUDY_ID="STD-Woolley-_x0028_2_x0029_-1995" TOTAL_1="75" TOTAL_2="41" VAR="0.8728632478632479" WEIGHT="2.613254166819899"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.924548298951322" CI_END="2.8937064361265357" CI_START="0.1446189475355273" DF="1.0" EFFECT_SIZE="0.646903995403801" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="90" I2="65.80668541673332" ID="CMP-002.03.03" LOG_CI_END="0.46145447023942987" LOG_CI_START="-0.8397748033689793" LOG_EFFECT_SIZE="-0.18916016656477477" NO="3" P_CHI2="0.0872417886864798" P_Z="0.5687853194085399" STUDIES="2" TAU2="0.8074320194707483" TOTAL_1="112" TOTAL_2="112" WEIGHT="11.23428978678788" Z="0.5698413358753388">
<NAME>Fluconazole vs Miconazole</NAME>
<DICH_DATA CI_END="2.5534616750999977" CI_START="0.5550244101608465" EFFECT_SIZE="1.1904761904761905" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="42" LOG_CI_END="0.40712934391566424" LOG_CI_START="-0.2556879160394275" LOG_EFFECT_SIZE="0.07572071393811834" ORDER="450" O_E="0.0" SE="0.3893421394959729" STUDY_ID="STD-Timonen-_x0028_1_x0029_-1992" TOTAL_1="63" TOTAL_2="62" VAR="0.1515873015873016" WEIGHT="8.071359275375519"/>
<DICH_DATA CI_END="1.2697524036558048" CI_START="0.0492221946735862" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="48" LOG_CI_END="0.10371904362582872" LOG_CI_START="-1.3078390262817534" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="451" O_E="0.0" SE="0.82915619758885" STUDY_ID="STD-Van-Heusden-1990" TOTAL_1="49" TOTAL_2="50" VAR="0.6875" WEIGHT="3.16293051141236"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.5257277296295286" CI_START="1.1426502703278552" DF="0.0" EFFECT_SIZE="2.007155635062612" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="86" I2="0.0" ID="CMP-002.03.04" LOG_CI_END="0.5472487713538158" LOG_CI_START="0.05791332671362279" LOG_EFFECT_SIZE="0.3025810490337193" NO="4" P_CHI2="1.0" P_Z="0.015355201698839837" STUDIES="1" TAU2="0.0" TOTAL_1="128" TOTAL_2="130" WEIGHT="10.085532583851444" Z="2.4238912795148306">
<NAME>Fluconazole vs Econazole</NAME>
<DICH_DATA CI_END="3.5257277296295286" CI_START="1.1426502703278552" EFFECT_SIZE="2.007155635062612" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="86" LOG_CI_END="0.5472487713538158" LOG_CI_START="0.05791332671362279" LOG_EFFECT_SIZE="0.3025810490337193" ORDER="452" O_E="0.0" SE="0.2874380624311659" STUDY_ID="STD-Osser-1991" TOTAL_1="128" TOTAL_2="130" VAR="0.08262063973418282" WEIGHT="10.085532583851444"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.918051961642172" CI_START="1.353040108575226" DF="0.0" EFFECT_SIZE="3.473684210526316" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="19" I2="0.0" ID="CMP-002.03.05" LOG_CI_END="0.950269998467583" LOG_CI_START="0.1313106707104964" LOG_EFFECT_SIZE="0.5407903345890397" NO="5" P_CHI2="1.0" P_Z="0.009640077822176692" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="41" WEIGHT="6.555829981944707" Z="2.588479166321362">
<NAME>Itraconazole vs Econazole</NAME>
<DICH_DATA CI_END="8.918051961642172" CI_START="1.353040108575226" EFFECT_SIZE="3.473684210526316" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="19" LOG_CI_END="0.950269998467583" LOG_CI_START="0.1313106707104964" LOG_EFFECT_SIZE="0.5407903345890397" ORDER="453" O_E="0.0" SE="0.4810607630385658" STUDY_ID="STD-Timonen-_x0028_2_x0029_-1992" TOTAL_1="40" TOTAL_2="41" VAR="0.2314194577352472" WEIGHT="6.555829981944707"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="19.45221527660798" CI_END="1.9088241991894235" CI_START="0.9794954182201497" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.367364090977157" ESTIMABLE="YES" EVENTS_1="476" EVENTS_2="366" I2="48.59197341895873" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.28076593214553275" LOG_CI_START="-0.008997591161189903" LOG_EFFECT_SIZE="0.1358841704921714" METHOD="MH" NO="4" P_CHI2="0.03488091391533088" P_Q="0.0" P_Z="0.06602640683560583" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.1358924257661585" TOTALS="YES" TOTAL_1="766" TOTAL_2="687" WEIGHT="100.0" Z="1.838244353150281">
<NAME>Mycological cure (long term)</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intra-vaginal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intravaginal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="8.147410597332975" CI_END="2.244164408105036" CI_START="0.9453733603183794" DF="5.0" EFFECT_SIZE="1.45656213310561" ESTIMABLE="YES" EVENTS_1="270" EVENTS_2="200" I2="38.630808644445494" ID="CMP-002.04.01" LOG_CI_END="0.35105467028344883" LOG_CI_START="-0.024396639847505164" LOG_EFFECT_SIZE="0.16332901521797186" NO="1" P_CHI2="0.1482966303915535" P_Z="0.08814799297034713" STUDIES="6" TAU2="0.10118866186153214" TOTAL_1="436" TOTAL_2="381" WEIGHT="51.29271724363277" Z="1.7052490100299005">
<NAME>Fluconazole vs Clotrimazole</NAME>
<DICH_DATA CI_END="20.0706120799998" CI_START="0.9841795726517416" EFFECT_SIZE="4.444444444444445" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="12" LOG_CI_END="1.302560617077074" LOG_CI_START="-0.006925653299799112" LOG_EFFECT_SIZE="0.6478174818886375" ORDER="454" O_E="0.0" SE="0.769198717280955" STUDY_ID="STD-Adetoro-1990" TOTAL_1="23" TOTAL_2="20" VAR="0.5916666666666666" WEIGHT="3.981936764425524"/>
<DICH_DATA CI_END="2.408372922057888" CI_START="1.0534744098695386" EFFECT_SIZE="1.5928462709284628" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="90" LOG_CI_END="0.38172373568053913" LOG_CI_START="0.022623990549309945" LOG_EFFECT_SIZE="0.20217386311492452" ORDER="455" O_E="0.0" SE="0.21093696786249072" STUDY_ID="STD-Anonymous-1989" TOTAL_1="188" TOTAL_2="181" VAR="0.04449440441102145" WEIGHT="16.06045350209183"/>
<DICH_DATA CI_END="3.82516103230919" CI_START="0.12153110133959846" EFFECT_SIZE="0.6818181818181818" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5826497228807976" LOG_CI_START="-0.9153125664138475" LOG_EFFECT_SIZE="-0.16633142176652504" ORDER="456" O_E="0.0" SE="0.8799104637645947" STUDY_ID="STD-Goode-1992" TOTAL_1="14" TOTAL_2="14" VAR="0.7742424242424242" WEIGHT="3.183148407538744"/>
<DICH_DATA CI_END="4.241327456421064" CI_START="0.5705178652868271" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="15" LOG_CI_END="0.6275018039444425" LOG_CI_START="-0.24373075146661616" LOG_EFFECT_SIZE="0.19188552623891314" ORDER="457" O_E="0.0" SE="0.511766315719159" STUDY_ID="STD-Mikamo-_x0028_1_x0029_-1995" TOTAL_1="50" TOTAL_2="25" VAR="0.26190476190476186" WEIGHT="7.282842584716736"/>
<DICH_DATA CI_END="7.685464235589032" CI_START="0.9252676081923238" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="15" LOG_CI_END="0.8856701059106222" LOG_CI_START="-0.03373264136605994" LOG_EFFECT_SIZE="0.4259687322722811" ORDER="458" O_E="0.0" SE="0.5400617248673216" STUDY_ID="STD-Mikamo-_x0028_2_x0029_-1995" TOTAL_1="50" TOTAL_2="25" VAR="0.29166666666666663" WEIGHT="6.775892150873866"/>
<DICH_DATA CI_END="1.4453844025380058" CI_START="0.5088919338295039" EFFECT_SIZE="0.8576388888888888" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="64" LOG_CI_END="0.15998336383969775" LOG_CI_START="-0.29337443283882797" LOG_EFFECT_SIZE="-0.06669553449956515" ORDER="459" O_E="0.0" SE="0.2663046139262528" STUDY_ID="STD-Stein-1991" TOTAL_1="111" TOTAL_2="116" VAR="0.07091814739841056" WEIGHT="14.008443833986075"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.439169482659344" CI_START="0.31043570334892867" DF="0.0" EFFECT_SIZE="0.8701754385964913" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="15" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="0.3872419777743632" LOG_CI_START="-0.508028336138951" LOG_EFFECT_SIZE="-0.060393179182293914" NO="2" P_CHI2="1.0" P_Z="0.7914480957512225" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="23" WEIGHT="7.024131840662441" Z="0.2644306513231074">
<NAME>Itraconazole vs Clotrimazole</NAME>
<DICH_DATA CI_END="2.439169482659344" CI_START="0.31043570334892867" EFFECT_SIZE="0.8701754385964913" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="15" LOG_CI_END="0.3872419777743632" LOG_CI_START="-0.508028336138951" LOG_EFFECT_SIZE="-0.060393179182293914" ORDER="460" O_E="0.0" SE="0.5258862140522075" STUDY_ID="STD-Stein-1993" TOTAL_1="50" TOTAL_2="23" VAR="0.27655631013016413" WEIGHT="7.024131840662441"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.0351933695262385" CI_END="2.017135732524079" CI_START="0.26255836997710413" DF="1.0" EFFECT_SIZE="0.7277471195093073" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="77" I2="67.05316998777941" ID="CMP-002.04.03" LOG_CI_END="0.3047351227555934" LOG_CI_START="-0.5807741324828866" LOG_EFFECT_SIZE="-0.13801950486364664" NO="3" P_CHI2="0.08147706177255465" P_Z="0.5412142651942238" STUDIES="2" TAU2="0.36544124771449216" TOTAL_1="112" TOTAL_2="112" WEIGHT="18.767119360180267" Z="0.6109778234309821">
<NAME>Fluconazole vs Miconazole</NAME>
<DICH_DATA CI_END="2.4020830608427106" CI_START="0.5734035856529639" EFFECT_SIZE="1.1736111111111112" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="36" LOG_CI_END="0.38058802065305225" LOG_CI_START="-0.24153959561620444" LOG_EFFECT_SIZE="0.06952421251842389" ORDER="461" O_E="0.0" SE="0.3654408413779288" STUDY_ID="STD-Timonen-_x0028_1_x0029_-1992" TOTAL_1="63" TOTAL_2="62" VAR="0.13354700854700854" WEIGHT="10.752302482505463"/>
<DICH_DATA CI_END="1.0481791981116864" CI_START="0.16288604662904033" EFFECT_SIZE="0.4131994261119082" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="41" LOG_CI_END="0.02043553655818703" LOG_CI_START="-0.7881161172357443" LOG_EFFECT_SIZE="-0.3838402903387786" ORDER="462" O_E="0.0" SE="0.47494724383379133" STUDY_ID="STD-Van-Heusden-1990" TOTAL_1="49" TOTAL_2="50" VAR="0.22557488442531484" WEIGHT="8.014816877674802"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.3941957182492755" CI_START="1.2560911338815617" DF="0.0" EFFECT_SIZE="2.0648048693161476" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="57" I2="0.0" ID="CMP-002.04.04" LOG_CI_END="0.5307368812653864" LOG_CI_START="0.09902115015439818" LOG_EFFECT_SIZE="0.3148790157098923" NO="4" P_CHI2="1.0" P_Z="0.004248925699122614" STUDIES="1" TAU2="0.0" TOTAL_1="128" TOTAL_2="130" WEIGHT="14.470906043027579" Z="2.8590643602011787">
<NAME>Fluconazole vs Econazole</NAME>
<DICH_DATA CI_END="3.3941957182492755" CI_START="1.2560911338815617" EFFECT_SIZE="2.0648048693161476" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="57" LOG_CI_END="0.5307368812653864" LOG_CI_START="0.09902115015439818" LOG_EFFECT_SIZE="0.3148790157098923" ORDER="463" O_E="0.0" SE="0.25359195748192903" STUDY_ID="STD-Osser-1991" TOTAL_1="128" TOTAL_2="130" VAR="0.0643088808995165" WEIGHT="14.470906043027579"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.74157569888893" CI_START="0.9642531023325446" DF="0.0" EFFECT_SIZE="2.3529411764705888" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="17" I2="0.0" ID="CMP-002.04.05" LOG_CI_END="0.7590310950849297" LOG_CI_START="-0.01580895518555263" LOG_EFFECT_SIZE="0.37161106994968857" NO="5" P_CHI2="1.0" P_Z="0.060109954313831454" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="41" WEIGHT="8.445125512496935" Z="1.8799862322644083">
<NAME>Itraconazole vs Econazole</NAME>
<DICH_DATA CI_END="5.741575698888928" CI_START="0.9642531023325445" EFFECT_SIZE="2.3529411764705883" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="17" LOG_CI_END="0.7590310950849296" LOG_CI_START="-0.015808955185552677" LOG_EFFECT_SIZE="0.37161106994968846" ORDER="464" O_E="0.0" SE="0.45514488104898865" STUDY_ID="STD-Timonen-_x0028_2_x0029_-1992" TOTAL_1="40" TOTAL_2="41" VAR="0.207156862745098" WEIGHT="8.445125512496935"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Single dose oral anti-fungal therapy vs single dose intra-vaginal anti-fungal therapy</NAME>
<DICH_OUTCOME CHI2="4.5519995801405155" CI_END="1.0600078550778436" CI_START="0.5918151566194632" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.792040854230863" ESTIMABLE="YES" EVENTS_1="317" EVENTS_2="417" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.025309083570734744" LOG_CI_START="-0.22781391658007139" LOG_EFFECT_SIZE="-0.10125241650466833" METHOD="MH" NO="1" P_CHI2="0.4729564174132822" P_Q="0.0" P_Z="0.11687623191600983" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="456" TOTAL_2="588" WEIGHT="100.0" Z="1.5680209983175402">
<NAME>Clinical cure (short term)</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intra-vaginal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intravaginal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.302611684552798" CI_END="1.0612255443243783" CI_START="0.5189730060891377" DF="2.0" EFFECT_SIZE="0.7421235819434685" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="234" I2="13.142106703569947" ID="CMP-003.01.01" LOG_CI_END="0.02580769516027622" LOG_CI_START="-0.2848552309982007" LOG_EFFECT_SIZE="-0.12952376791896225" NO="1" P_CHI2="0.31622395936021275" P_Z="0.10219086092542061" STUDIES="3" TAU2="0.0" TOTAL_1="226" TOTAL_2="359" WEIGHT="68.48404016049349" Z="1.6343238853907482">
<NAME>Fluconazole vs Clotrimazole</NAME>
<DICH_DATA CI_END="1.347795770942692" CI_START="0.43982694795804905" EFFECT_SIZE="0.7699330493000609" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="106" LOG_CI_END="0.12962408932672523" LOG_CI_START="-0.3567181651731752" LOG_EFFECT_SIZE="-0.11354703792322499" ORDER="465" O_E="0.0" SE="0.2856798477262279" STUDY_ID="STD-Mendling-_x0028_1_x0029_-2004" TOTAL_1="77" TOTAL_2="161" VAR="0.08161297539688075" WEIGHT="27.262248593587447"/>
<DICH_DATA CI_END="1.598374914089661" CI_START="0.5269659868683796" EFFECT_SIZE="0.9177631578947368" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="95" LOG_CI_END="0.20367865484216283" LOG_CI_START="-0.2782174155124752" LOG_EFFECT_SIZE="-0.037269380335156185" ORDER="466" O_E="0.0" SE="0.28306813715033424" STUDY_ID="STD-Mendling-_x0028_2_x0029_-2004" TOTAL_1="77" TOTAL_2="157" VAR="0.08012757026976043" WEIGHT="25.65244692899739"/>
<DICH_DATA CI_END="1.0016332840973405" CI_START="0.1629824514510324" EFFECT_SIZE="0.40404040404040403" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="33" LOG_CI_END="7.087476351616267E-4" LOG_CI_START="-0.7878591541743367" LOG_EFFECT_SIZE="-0.3935752032695875" ORDER="467" O_E="0.0" SE="0.4632086889969677" STUDY_ID="STD-Woolley-_x0028_1_x0029_-1995" TOTAL_1="72" TOTAL_2="41" VAR="0.21456228956228957" WEIGHT="15.569344637908655"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3974533905840224E-31" CI_END="3.4174563347034663" CI_START="0.4455631819325953" DF="0.0" EFFECT_SIZE="1.2339743589743593" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="39" I2="99.99999999999999" ID="CMP-003.01.03" LOG_CI_END="0.5337029742366455" LOG_CI_START="-0.3510907032565296" LOG_EFFECT_SIZE="0.09130613549005799" NO="3" P_CHI2="0.0" P_Z="0.6858330870806608" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="50" WEIGHT="6.624341558404929" Z="0.40451631081965655">
<NAME>Fluconazole vs Miconazole</NAME>
<DICH_DATA CI_END="3.4174563347034654" CI_START="0.4455631819325952" EFFECT_SIZE="1.233974358974359" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="39" LOG_CI_END="0.5337029742366455" LOG_CI_START="-0.3510907032565297" LOG_EFFECT_SIZE="0.09130613549005791" ORDER="468" O_E="0.0" SE="0.5197321859588312" STUDY_ID="STD-Van-Heusden-1990" TOTAL_1="43" TOTAL_2="50" VAR="0.2701215451215451" WEIGHT="6.624341558404929"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.8933942205235725" CI_START="0.4638997681657373" DF="0.0" EFFECT_SIZE="1.5066666666666666" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="105" I2="0.0" ID="CMP-003.01.04" LOG_CI_END="0.6896102047036238" LOG_CI_START="-0.3335758445201845" LOG_EFFECT_SIZE="0.17801718009171966" NO="4" P_CHI2="1.0" P_Z="0.4952379433817329" STUDIES="1" TAU2="0.0" TOTAL_1="118" TOTAL_2="112" WEIGHT="4.507155470862885" Z="0.6820016005375235">
<NAME>Fluconazole vs Econazole</NAME>
<DICH_DATA CI_END="4.8933942205235725" CI_START="0.4638997681657373" EFFECT_SIZE="1.5066666666666666" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="105" LOG_CI_END="0.6896102047036238" LOG_CI_START="-0.3335758445201845" LOG_EFFECT_SIZE="0.17801718009171966" ORDER="469" O_E="0.0" SE="0.6010245501666935" STUDY_ID="STD-Osser-1991" TOTAL_1="118" TOTAL_2="112" VAR="0.36123050990307626" WEIGHT="4.507155470862885"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2956154731911895" CI_START="0.3342978633442281" DF="0.0" EFFECT_SIZE="0.6581196581196581" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="39" I2="0.0" ID="CMP-003.01.06" LOG_CI_END="0.11247612603266213" LOG_CI_START="-0.4758663991800216" LOG_EFFECT_SIZE="-0.18169513657367978" NO="6" P_CHI2="1.0" P_Z="0.2260589424693451" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="67" WEIGHT="20.384462810238695" Z="1.2105734621911415">
<NAME>Fluconazole vs Butoconazole</NAME>
<DICH_DATA CI_END="1.2956154731911895" CI_START="0.3342978633442281" EFFECT_SIZE="0.6581196581196581" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="39" LOG_CI_END="0.11247612603266213" LOG_CI_START="-0.4758663991800216" LOG_EFFECT_SIZE="-0.18169513657367978" ORDER="470" O_E="0.0" SE="0.34559531165239993" STUDY_ID="STD-Seidman-2005" TOTAL_1="69" TOTAL_2="67" VAR="0.11943611943611944" WEIGHT="20.384462810238695"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7989262794298174" CI_END="1.6668580852209485" CI_START="0.8043326607189478" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.157889631496308" ESTIMABLE="YES" EVENTS_1="232" EVENTS_2="332" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.22189862596534868" LOG_CI_START="-0.09456429598473266" LOG_EFFECT_SIZE="0.06366716499030801" METHOD="MH" NO="2" P_CHI2="0.8497238873682162" P_Q="0.0" P_Z="0.43033098349160104" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="292" TOTAL_2="450" WEIGHT="100.0" Z="0.7886254074242333">
<NAME>Clinical cure (long term)</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intra-vaginal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intravaginal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.48684759979388337" CI_END="1.726593633159903" CI_START="0.7416141690309506" DF="1.0" EFFECT_SIZE="1.1315769096751715" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="219" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.23719013511063086" LOG_CI_START="-0.12982198129995132" LOG_EFFECT_SIZE="0.053684076905339786" NO="1" P_CHI2="0.48533694248249215" P_Z="0.5663868650910037" STUDIES="2" TAU2="0.0" TOTAL_1="154" TOTAL_2="318" WEIGHT="75.26892104527582" Z="0.5733808371603433">
<NAME>Fluconazole vs Clotrimzole</NAME>
<DICH_DATA CI_END="1.7714644781700652" CI_START="0.530953659279415" EFFECT_SIZE="0.9698275862068966" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="116" LOG_CI_END="0.24833244817955502" LOG_CI_START="-0.2749433817386294" LOG_EFFECT_SIZE="-0.013305466779537178" ORDER="471" O_E="0.0" SE="0.30737481275107476" STUDY_ID="STD-Mendling-_x0028_1_x0029_-2004" TOTAL_1="77" TOTAL_2="161" VAR="0.09447927551375827" WEIGHT="39.55049736445404"/>
<DICH_DATA CI_END="2.3740361103134537" CI_START="0.723612011179328" EFFECT_SIZE="1.3106796116504855" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="103" LOG_CI_END="0.37548732051183387" LOG_CI_START="-0.140494232932166" LOG_EFFECT_SIZE="0.11749654378983393" ORDER="472" O_E="0.0" SE="0.3030901186428878" STUDY_ID="STD-Mendling-_x0028_2_x0029_-2004" TOTAL_1="77" TOTAL_2="157" VAR="0.09186362001895981" WEIGHT="35.71842368082177"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.661427859815934" CI_START="0.5098729793932629" DF="0.0" EFFECT_SIZE="1.5416666666666667" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="40" I2="0.0" ID="CMP-003.02.03" LOG_CI_END="0.668518967474315" LOG_CI_START="-0.2925380027635371" LOG_EFFECT_SIZE="0.18799048235538898" NO="3" P_CHI2="1.0" P_Z="0.44321859394441243" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="50" WEIGHT="9.51867567270711" Z="0.7667694762396574">
<NAME>Fluconazole vs Miconazole</NAME>
<DICH_DATA CI_END="4.661427859815934" CI_START="0.5098729793932629" EFFECT_SIZE="1.5416666666666667" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="40" LOG_CI_END="0.668518967474315" LOG_CI_START="-0.2925380027635371" LOG_EFFECT_SIZE="0.18799048235538898" ORDER="473" O_E="0.0" SE="0.5645296216264419" STUDY_ID="STD-Van-Heusden-1990" TOTAL_1="43" TOTAL_2="50" VAR="0.3186936936936937" WEIGHT="9.51867567270711"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.718653172644254" CI_START="0.40394602913590294" DF="0.0" EFFECT_SIZE="1.047945205479452" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="73" I2="0.0" ID="CMP-003.02.04" LOG_CI_END="0.4343538067731431" LOG_CI_START="-0.3936766567068197" LOG_EFFECT_SIZE="0.020338575033161693" NO="4" P_CHI2="1.0" P_Z="0.9232953404914563" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="82" WEIGHT="15.212403282017084" Z="0.09628359419128323">
<NAME>Fluconazole vs Econazole</NAME>
<DICH_DATA CI_END="2.718653172644254" CI_START="0.40394602913590294" EFFECT_SIZE="1.047945205479452" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="73" LOG_CI_END="0.4343538067731431" LOG_CI_START="-0.3936766567068197" LOG_EFFECT_SIZE="0.020338575033161693" ORDER="474" O_E="0.0" SE="0.4863891930650293" STUDY_ID="STD-Osser-1991" TOTAL_1="95" TOTAL_2="82" VAR="0.23657444713045034" WEIGHT="15.212403282017084"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.038732202951172" CI_END="1.5983748644918352" CI_START="0.8081274964567636" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1365257047868322" ESTIMABLE="YES" EVENTS_1="351" EVENTS_2="439" I2="33.619009112351144" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.20367864136593627" LOG_CI_START="-0.09252011615669442" LOG_EFFECT_SIZE="0.05557926260462097" METHOD="MH" NO="3" P_CHI2="0.17141156034284255" P_Q="0.0" P_Z="0.4620093132624402" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="421" TOTAL_2="550" WEIGHT="100.0" Z="0.7355422683299273">
<NAME>Mycological cure (short term)</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intra-vaginal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intravaginal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.962992187428742" CI_END="1.3915387357320088" CI_START="0.6240327348406168" DF="4.0" EFFECT_SIZE="0.9318614290201628" ESTIMABLE="YES" EVENTS_1="207" EVENTS_2="305" I2="32.9195834193301" ID="CMP-003.03.01" LOG_CI_END="0.14349530012785408" LOG_CI_START="-0.20479262796539527" LOG_EFFECT_SIZE="-0.030648663918770573" NO="1" P_CHI2="0.20192925294272146" P_Z="0.7301349093130819" STUDIES="5" TAU2="0.0" TOTAL_1="260" TOTAL_2="388" WEIGHT="79.14527781489278" Z="0.344946078286007">
<NAME>Fluconazole vs Clotrimazole</NAME>
<DICH_DATA CI_END="10.790662515787629" CI_START="0.45764304070423595" EFFECT_SIZE="2.2222222222222223" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="15" LOG_CI_END="1.0330481099394218" LOG_CI_START="-0.3394731374901092" LOG_EFFECT_SIZE="0.3467874862246563" ORDER="475" O_E="0.0" SE="0.8062257748298549" STUDY_ID="STD-Adetoro-1990" TOTAL_1="23" TOTAL_2="20" VAR="0.6499999999999999" WEIGHT="3.35829974638819"/>
<DICH_DATA CI_END="59.657390681735166" CI_START="0.4190595618466103" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="1.775664254099694" LOG_CI_START="-0.3777242454276566" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="476" O_E="0.0" SE="1.2649110640673518" STUDY_ID="STD-Boag-1991" TOTAL_1="11" TOTAL_2="9" VAR="1.6" WEIGHT="0.9627125939646144"/>
<DICH_DATA CI_END="1.5645094604074177" CI_START="0.42257262133705176" EFFECT_SIZE="0.8130921619293713" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="129" LOG_CI_END="0.19437819361855976" LOG_CI_START="-0.3740986444995695" LOG_EFFECT_SIZE="-0.08986022544050483" ORDER="477" O_E="0.0" SE="0.3339261087163215" STUDY_ID="STD-Mendling-_x0028_1_x0029_-2004" TOTAL_1="77" TOTAL_2="161" VAR="0.11150664608242455" WEIGHT="31.308384358345027"/>
<DICH_DATA CI_END="2.023147621169975" CI_START="0.5754040939185181" EFFECT_SIZE="1.0789473684210527" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="116" LOG_CI_END="0.3060275726969088" LOG_CI_START="-0.2400270524910581" LOG_EFFECT_SIZE="0.033000260102925345" ORDER="478" O_E="0.0" SE="0.3207551898494001" STUDY_ID="STD-Mendling-_x0028_2_x0029_-2004" TOTAL_1="77" TOTAL_2="157" VAR="0.1028838918153247" WEIGHT="30.225335571196727"/>
<DICH_DATA CI_END="1.2084099844096516" CI_START="0.05440721314835266" EFFECT_SIZE="0.2564102564102564" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="39" LOG_CI_END="0.08221430494624701" LOG_CI_START="-1.2643435189992456" LOG_EFFECT_SIZE="-0.5910646070264993" ORDER="479" O_E="0.0" SE="0.7909747313543117" STUDY_ID="STD-Woolley-_x0028_1_x0029_-1995" TOTAL_1="72" TOTAL_2="41" VAR="0.6256410256410256" WEIGHT="13.290545544998217"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="19.995970862538613" CI_START="0.15315585429949943" DF="0.0" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="48" I2="0.0" ID="CMP-003.03.03" LOG_CI_END="1.300942495241589" LOG_CI_START="-0.8148663978690002" LOG_EFFECT_SIZE="0.24303804868629442" NO="3" P_CHI2="1.0" P_Z="0.6525135971661437" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="50" WEIGHT="1.6562797315520248" Z="0.4502730126989136">
<NAME>Fluconazole vs Miconazole</NAME>
<DICH_DATA CI_END="19.995970862538606" CI_START="0.1531558542994995" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="48" LOG_CI_END="1.300942495241589" LOG_CI_START="-0.814866397869" LOG_EFFECT_SIZE="0.24303804868629442" ORDER="480" O_E="0.0" SE="1.2428366172360938" STUDY_ID="STD-Van-Heusden-1990" TOTAL_1="43" TOTAL_2="50" VAR="1.544642857142857" WEIGHT="1.6562797315520248"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0070767677616394E-31" CI_END="3.8260085108974082" CI_START="0.970877060550408" DF="0.0" EFFECT_SIZE="1.9273255813953487" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="86" I2="100.0" ID="CMP-003.03.04" LOG_CI_END="0.5827459317737834" LOG_CI_START="-0.012835760107297367" LOG_EFFECT_SIZE="0.28495508583324297" NO="4" P_CHI2="0.0" P_Z="0.06072628930446959" STUDIES="1" TAU2="0.0" TOTAL_1="118" TOTAL_2="112" WEIGHT="19.19844245355521" Z="1.8754831219902295">
<NAME>Fluconazole vs Econazole</NAME>
<DICH_DATA CI_END="3.8260085108974082" CI_START="0.9708770605504082" EFFECT_SIZE="1.927325581395349" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="86" LOG_CI_END="0.5827459317737834" LOG_CI_START="-0.012835760107297266" LOG_EFFECT_SIZE="0.284955085833243" ORDER="481" O_E="0.0" SE="0.34984763398786917" STUDY_ID="STD-Osser-1991" TOTAL_1="118" TOTAL_2="112" VAR="0.12239336700691009" WEIGHT="19.19844245355521"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Single dose oral therapy vs 3 day intra-vaginal therapy</NAME>
<DICH_OUTCOME CHI2="1.3225142964257213" CI_END="1.6541644120085468" CI_START="0.670172933418375" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0528894606519952" ESTIMABLE="YES" EVENTS_1="230" EVENTS_2="213" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.21857867310012521" LOG_CI_START="-0.17381311619697995" LOG_EFFECT_SIZE="0.022382778451572646" METHOD="MH" NO="3" P_CHI2="0.5162020208157796" P_Q="0.0" P_Z="0.8230684147153134" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="276" TOTAL_2="258" WEIGHT="100.0" Z="0.2236001916227926">
<NAME>Mycological cure (short term)</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intra-vaginal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intravaginal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2410155109922187" CI_START="0.7079138915028291" EFFECT_SIZE="1.2595419847328244" ESTIMABLE="YES" EVENTS_1="143" EVENTS_2="131" LOG_CI_END="0.3504448624766127" LOG_CI_START="-0.15001956536032862" LOG_EFFECT_SIZE="0.10021264855814202" ORDER="482" O_E="0.0" SE="0.2939752822502911" STUDY_ID="STD-Anonymous-1989" TOTAL_1="169" TOTAL_2="161" VAR="0.08642146657413832" WEIGHT="56.29046581136687"/>
<DICH_DATA CI_END="2.4920340812689235" CI_START="0.3656278345637371" EFFECT_SIZE="0.9545454545454546" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="40" LOG_CI_END="0.3965539774758227" LOG_CI_START="-0.4369607496523966" LOG_EFFECT_SIZE="-0.02020338608828695" ORDER="483" O_E="0.0" SE="0.48961067667955804" STUDY_ID="STD-O_x002d_Prasertsawat-1995" TOTAL_1="53" TOTAL_2="50" VAR="0.23971861471861472" WEIGHT="23.29805094325397"/>
<DICH_DATA CI_END="1.9203524182699245" CI_START="0.18450175428834964" EFFECT_SIZE="0.5952380952380952" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="42" LOG_CI_END="0.2833809366541281" LOG_CI_START="-0.7339995001058539" LOG_EFFECT_SIZE="-0.22530928172586287" ORDER="484" O_E="0.0" SE="0.5976143046671968" STUDY_ID="STD-Timonen-_x0028_1_x0029_-1992" TOTAL_1="54" TOTAL_2="47" VAR="0.35714285714285715" WEIGHT="20.411483245379163"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.0308918678895256" CI_END="1.7320727587537736" CI_START="0.8228008203316995" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1937968364746134" ESTIMABLE="YES" EVENTS_1="186" EVENTS_2="159" I2="34.012822391032955" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.23856613136584562" LOG_CI_START="-0.08470528398587844" LOG_EFFECT_SIZE="0.0769304236899836" METHOD="MH" NO="4" P_CHI2="0.21971026285516404" P_Q="0.0" P_Z="0.35090065950909544" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="267" TOTAL_2="242" WEIGHT="100.0" Z="0.9328437504053554">
<NAME>Mycological cure (long term)</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intra-vaginal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intravaginal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5262271800482416" CI_START="0.9654696138197303" EFFECT_SIZE="1.5617283950617284" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="90" LOG_CI_END="0.40247240346590846" LOG_CI_START="-0.015261390199534475" LOG_EFFECT_SIZE="0.19360550663318699" ORDER="485" O_E="0.0" SE="0.2453788982147091" STUDY_ID="STD-Anonymous-1989" TOTAL_1="160" TOTAL_2="145" VAR="0.06021080368906456" WEIGHT="52.3744341024822"/>
<DICH_DATA CI_END="1.7528708389658247" CI_START="0.3515453955833325" EFFECT_SIZE="0.784992784992785" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="33" LOG_CI_END="0.24374991609891708" LOG_CI_START="-0.45401858592617084" LOG_EFFECT_SIZE="-0.10513433491362682" ORDER="486" O_E="0.0" SE="0.4098726720993272" STUDY_ID="STD-O_x002d_Prasertsawat-1995" TOTAL_1="53" TOTAL_2="50" VAR="0.1679956073338426" WEIGHT="26.537509922260938"/>
<DICH_DATA CI_END="1.9545900213491074" CI_START="0.3229024851324125" EFFECT_SIZE="0.7944444444444444" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="36" LOG_CI_END="0.29105567726243425" LOG_CI_START="-0.4909286125389228" LOG_EFFECT_SIZE="-0.09993646763824428" ORDER="487" O_E="0.0" SE="0.4593414427139805" STUDY_ID="STD-Timonen-_x0028_1_x0029_-1992" TOTAL_1="54" TOTAL_2="47" VAR="0.210994560994561" WEIGHT="21.08805597525686"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Single dose oral therapy versus 6-7 day intra-vaginal therapy</NAME>
<DICH_OUTCOME CHI2="0.3884001767193641" CI_END="2.3672476445138395" CI_START="0.8036272527057922" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.3792696331881285" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="103" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.3742436930875316" LOG_CI_START="-0.09494534382640997" LOG_EFFECT_SIZE="0.13964917463056079" METHOD="MH" NO="1" P_CHI2="0.5331418965211889" P_Q="0.0" P_Z="0.2433213548782438" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="142" TOTAL_2="143" WEIGHT="99.99999999999999" Z="1.1667252694007302">
<NAME>Clinical cure (short term)</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intra-vaginal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intravaginal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<DICH_DATA CI_END="95.81881685682004" CI_START="0.1482704656325003" EFFECT_SIZE="3.769230769230769" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="1.9814508040119336" LOG_CI_START="-0.82894534856858" LOG_EFFECT_SIZE="0.5762527277216769" ORDER="488" O_E="0.0" SE="1.6508406117111138" STUDY_ID="STD-Goode-1992" TOTAL_1="3" TOTAL_2="9" VAR="2.725274725274725" WEIGHT="2.064080120506453"/>
<DICH_DATA CI_END="2.3041832040732846" CI_START="0.7664204712435674" EFFECT_SIZE="1.328899235118058" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="97" LOG_CI_END="0.3625170065892582" LOG_CI_START="-0.1155329036824037" LOG_EFFECT_SIZE="0.1234920514534272" ORDER="489" O_E="0.0" SE="0.2808088836787946" STUDY_ID="STD-Sobel-1995" TOTAL_1="139" TOTAL_2="134" VAR="0.07885362915293079" WEIGHT="97.93591987949354"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1153815877628683" CI_END="1.8270413215280874" CI_START="0.5350221147214558" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9886897953996696" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="107" I2="10.34458422379827" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.26174836974372273" LOG_CI_START="-0.2716282663843768" LOG_EFFECT_SIZE="-0.004939948320327055" METHOD="MH" NO="2" P_CHI2="0.29091513102591715" P_Q="0.0" P_Z="0.9710391589401486" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="134" TOTAL_2="132" WEIGHT="100.0" Z="0.036305005272127586">
<NAME>Clinical cure (long term)</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intra-vaginal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intravaginal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<DICH_DATA CI_END="144.10212194156446" CI_START="0.20570117156680215" EFFECT_SIZE="5.444444444444445" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="2.158670375961299" LOG_CI_START="-0.6867632347829211" LOG_EFFECT_SIZE="0.7359535705891889" ORDER="490" O_E="0.0" SE="1.6714217880746898" STUDY_ID="STD-Goode-1992" TOTAL_1="3" TOTAL_2="7" VAR="2.7936507936507935" WEIGHT="1.8299656881433473"/>
<DICH_DATA CI_END="1.7070358340487832" CI_START="0.4804630429527597" EFFECT_SIZE="0.9056310679611651" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="103" LOG_CI_END="0.23224263790811708" LOG_CI_START="-0.3183400124885836" LOG_EFFECT_SIZE="-0.04304868729023331" ORDER="491" O_E="0.0" SE="0.3234149742710966" STUDY_ID="STD-Sobel-1995" TOTAL_1="131" TOTAL_2="125" VAR="0.10459724558277407" WEIGHT="98.17003431185665"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0679210727184554" CI_END="2.0627508987605427" CI_START="0.7871085826092368" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.2742091414674988" ESTIMABLE="YES" EVENTS_1="153" EVENTS_2="146" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="0.31444678501354606" LOG_CI_START="-0.10396535204347541" LOG_EFFECT_SIZE="0.10524071648503534" METHOD="MH" NO="3" P_CHI2="0.5862784906961382" P_Q="0.0" P_Z="0.3241546344201871" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="192" TOTAL_2="193" WEIGHT="100.0" Z="0.9859561697645002">
<NAME>Mycological cure (short term)</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intra-vaginal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intravaginal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.984724040261197" CI_START="0.01044325512413639" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.7770441295870611" LOG_CI_START="-1.9811641122429862" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="492" O_E="0.0" SE="1.620185174601965" STUDY_ID="STD-Goode-1992" TOTAL_1="3" TOTAL_2="9" VAR="2.625" WEIGHT="4.534853589012698"/>
<DICH_DATA CI_END="3.016011672665945" CI_START="0.5028318202400397" EFFECT_SIZE="1.2314814814814814" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="36" LOG_CI_END="0.4794330180215425" LOG_CI_START="-0.2985772470612705" LOG_EFFECT_SIZE="0.09042788548013607" ORDER="493" O_E="0.0" SE="0.45700708092256814" STUDY_ID="STD-Mikamo-_x0028_1_x0029_-1995" TOTAL_1="50" TOTAL_2="50" VAR="0.20885547201336674" WEIGHT="29.385851256802287"/>
<DICH_DATA CI_END="2.4416602594469405" CI_START="0.7614205073152126" EFFECT_SIZE="1.363499245852187" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="102" LOG_CI_END="0.3876852346653287" LOG_CI_START="-0.11837543052414828" LOG_EFFECT_SIZE="0.1346549020705902" ORDER="494" O_E="0.0" SE="0.2972625397729923" STUDY_ID="STD-Sobel-1995" TOTAL_1="139" TOTAL_2="134" VAR="0.08836501755228982" WEIGHT="66.07929515418502"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9232218820382677" CI_END="2.1024735535815173" CI_START="0.8827700890839922" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.3623511904761907" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="114" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="0.3227305416372033" LOG_CI_START="-0.05415239046942316" LOG_EFFECT_SIZE="0.1342890755838901" METHOD="MH" NO="4" P_CHI2="0.6302675374388886" P_Q="0.0" P_Z="0.16249493439939192" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="184" TOTAL_2="182" WEIGHT="100.0" Z="1.3967294840889084">
<NAME>Mycological cure (long term)</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intra-vaginal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intravaginal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<DICH_DATA CI_END="144.10212194156446" CI_START="0.20570117156680215" EFFECT_SIZE="5.444444444444445" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="2.158670375961299" LOG_CI_START="-0.6867632347829211" LOG_EFFECT_SIZE="0.7359535705891889" ORDER="495" O_E="0.0" SE="1.6714217880746898" STUDY_ID="STD-Goode-1992" TOTAL_1="3" TOTAL_2="7" VAR="2.7936507936507935" WEIGHT="1.0714285714285714"/>
<DICH_DATA CI_END="3.5610972106006997" CI_START="0.6794964987803801" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="30" LOG_CI_END="0.5515838291786705" LOG_CI_START="-0.1678127767008442" LOG_EFFECT_SIZE="0.19188552623891314" ORDER="496" O_E="0.0" SE="0.4225771273642583" STUDY_ID="STD-Mikamo-_x0028_1_x0029_-1995" TOTAL_1="50" TOTAL_2="50" VAR="0.17857142857142855" WEIGHT="25.714285714285715"/>
<DICH_DATA CI_END="2.0756174032336396" CI_START="0.7345393318097904" EFFECT_SIZE="1.2347560975609757" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="80" LOG_CI_END="0.31714730342617103" LOG_CI_START="-0.133984944420192" LOG_EFFECT_SIZE="0.09158117950298951" ORDER="497" O_E="0.0" SE="0.2649973155255962" STUDY_ID="STD-Sobel-1995" TOTAL_1="131" TOTAL_2="125" VAR="0.07022357723577237" WEIGHT="73.21428571428572"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>Fluconazole vs Clotrimazole</NAME>
<DICH_OUTCOME CHI2="2.2508662383476796" CI_END="1.4095350024187079" CI_START="0.7498472540464667" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0280739034943198" ESTIMABLE="YES" EVENTS_1="287" EVENTS_2="397" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.14907586500262074" LOG_CI_START="-0.12502719458267425" LOG_EFFECT_SIZE="0.012024335209973262" METHOD="MH" NO="1" P_CHI2="0.6897283399734275" P_Q="0.0" P_Z="0.8634696477452933" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="374" TOTAL_2="536" WEIGHT="100.0" Z="0.17195914547791347">
<NAME>Long term clinical cure</NAME>
<GROUP_LABEL_1>Fluconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Clotrimazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clotrimazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours fluconazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="144.10212194156446" CI_START="0.20570117156680215" EFFECT_SIZE="5.444444444444445" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="2.158670375961299" LOG_CI_START="-0.6867632347829211" LOG_EFFECT_SIZE="0.7359535705891889" ORDER="498" O_E="0.0" SE="1.6714217880746898" STUDY_ID="STD-Goode-1992" TOTAL_1="3" TOTAL_2="7" VAR="2.7936507936507935" WEIGHT="0.49234856111202274"/>
<DICH_DATA CI_END="1.7714644781700652" CI_START="0.530953659279415" EFFECT_SIZE="0.9698275862068966" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="116" LOG_CI_END="0.24833244817955502" LOG_CI_START="-0.2749433817386294" LOG_EFFECT_SIZE="-0.013305466779537178" ORDER="499" O_E="0.0" SE="0.30737481275107476" STUDY_ID="STD-Mendling-_x0028_1_x0029_-2004" TOTAL_1="77" TOTAL_2="161" VAR="0.09447927551375827" WEIGHT="28.156269534070184"/>
<DICH_DATA CI_END="2.3740361103134537" CI_START="0.723612011179328" EFFECT_SIZE="1.3106796116504855" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="103" LOG_CI_END="0.37548732051183387" LOG_CI_START="-0.140494232932166" LOG_EFFECT_SIZE="0.11749654378983393" ORDER="500" O_E="0.0" SE="0.3030901186428878" STUDY_ID="STD-Mendling-_x0028_2_x0029_-2004" TOTAL_1="77" TOTAL_2="157" VAR="0.09186362001895981" WEIGHT="25.428190073614665"/>
<DICH_DATA CI_END="1.7070358340487832" CI_START="0.4804630429527597" EFFECT_SIZE="0.9056310679611651" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="103" LOG_CI_END="0.23224263790811708" LOG_CI_START="-0.3183400124885836" LOG_EFFECT_SIZE="-0.04304868729023331" ORDER="501" O_E="0.0" SE="0.3234149742710966" STUDY_ID="STD-Sobel-1995" TOTAL_1="131" TOTAL_2="125" VAR="0.10459724558277407" WEIGHT="26.41244885132205"/>
<DICH_DATA CI_END="1.7094214204110778" CI_START="0.37264001971396044" EFFECT_SIZE="0.7981220657276995" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="71" LOG_CI_END="0.23284914171276916" LOG_CI_START="-0.42871050583369674" LOG_EFFECT_SIZE="-0.0979306820604638" ORDER="502" O_E="0.0" SE="0.3886034117418643" STUDY_ID="STD-Stein-1991" TOTAL_1="86" TOTAL_2="86" VAR="0.15101261161741691" WEIGHT="19.510742979881087"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.592497615692817" CI_END="1.7125226543534988" CI_START="0.9993322816575616" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.3081969162038816" ESTIMABLE="YES" EVENTS_1="392" EVENTS_2="313" I2="39.61611869970051" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="0.23363632532979994" LOG_CI_START="-2.900832493211313E-4" LOG_EFFECT_SIZE="0.11667312104023941" METHOD="MH" NO="2" P_CHI2="0.11478165118569561" P_Q="0.0" P_Z="0.050570910614380855" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="544" TOTAL_2="471" WEIGHT="99.99999999999997" Z="1.955103030835501">
<NAME>Long term mycological cure</NAME>
<GROUP_LABEL_1>Fluconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Clotrimazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clotrimazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours fluconazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="20.0706120799998" CI_START="0.9841795726517416" EFFECT_SIZE="4.444444444444445" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="12" LOG_CI_END="1.302560617077074" LOG_CI_START="-0.006925653299799112" LOG_EFFECT_SIZE="0.6478174818886375" ORDER="503" O_E="0.0" SE="0.769198717280955" STUDY_ID="STD-Adetoro-1990" TOTAL_1="23" TOTAL_2="20" VAR="0.5916666666666666" WEIGHT="1.812321617398202"/>
<DICH_DATA CI_END="2.5262271800482416" CI_START="0.9654696138197303" EFFECT_SIZE="1.5617283950617284" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="90" LOG_CI_END="0.40247240346590846" LOG_CI_START="-0.015261390199534475" LOG_EFFECT_SIZE="0.19360550663318699" ORDER="504" O_E="0.0" SE="0.2453788982147091" STUDY_ID="STD-Anonymous-1989" TOTAL_1="160" TOTAL_2="145" VAR="0.06021080368906456" WEIGHT="28.74460925955345"/>
<DICH_DATA CI_END="144.10212194156446" CI_START="0.20570117156680215" EFFECT_SIZE="5.444444444444445" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="2.158670375961299" LOG_CI_START="-0.6867632347829211" LOG_EFFECT_SIZE="0.7359535705891889" ORDER="505" O_E="0.0" SE="1.6714217880746898" STUDY_ID="STD-Goode-1992" TOTAL_1="3" TOTAL_2="7" VAR="2.7936507936507935" WEIGHT="0.4058845288964723"/>
<DICH_DATA CI_END="4.241327456421064" CI_START="0.5705178652868271" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="15" LOG_CI_END="0.6275018039444425" LOG_CI_START="-0.24373075146661616" LOG_EFFECT_SIZE="0.19188552623891314" ORDER="506" O_E="0.0" SE="0.511766315719159" STUDY_ID="STD-Mikamo-_x0028_1_x0029_-1995" TOTAL_1="50" TOTAL_2="25" VAR="0.26190476190476186" WEIGHT="6.494152462343557"/>
<DICH_DATA CI_END="7.685464235589032" CI_START="0.9252676081923238" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="15" LOG_CI_END="0.8856701059106222" LOG_CI_START="-0.03373264136605994" LOG_EFFECT_SIZE="0.4259687322722811" ORDER="507" O_E="0.0" SE="0.5400617248673216" STUDY_ID="STD-Mikamo-_x0028_2_x0029_-1995" TOTAL_1="50" TOTAL_2="25" VAR="0.29166666666666663" WEIGHT="4.329434974895705"/>
<DICH_DATA CI_END="1.7528708389658247" CI_START="0.3515453955833325" EFFECT_SIZE="0.784992784992785" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="33" LOG_CI_END="0.24374991609891708" LOG_CI_START="-0.45401858592617084" LOG_EFFECT_SIZE="-0.10513433491362682" ORDER="508" O_E="0.0" SE="0.4098726720993272" STUDY_ID="STD-O_x002d_Prasertsawat-1995" TOTAL_1="53" TOTAL_2="50" VAR="0.1679956073338426" WEIGHT="14.564555522343317"/>
<DICH_DATA CI_END="2.0756174032336396" CI_START="0.7345393318097904" EFFECT_SIZE="1.2347560975609757" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="80" LOG_CI_END="0.31714730342617103" LOG_CI_START="-0.133984944420192" LOG_EFFECT_SIZE="0.09158117950298951" ORDER="509" O_E="0.0" SE="0.2649973155255962" STUDY_ID="STD-Sobel-1995" TOTAL_1="131" TOTAL_2="125" VAR="0.07022357723577237" WEIGHT="27.735442807925608"/>
<DICH_DATA CI_END="1.2365634247277955" CI_START="0.22196041283071535" EFFECT_SIZE="0.5238970588235294" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="64" LOG_CI_END="0.09221639672067108" LOG_CI_START="-0.6537244761000104" LOG_EFFECT_SIZE="-0.28075403968966967" ORDER="510" O_E="0.0" SE="0.43816936116174016" STUDY_ID="STD-Stein-1991" TOTAL_1="74" TOTAL_2="74" VAR="0.1919923890608875" WEIGHT="15.913598826643671"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>